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Abstract:
Many individual drug development com panies and independent parties have 
attempted the task of creating computational approaches to predict, and thus 
help explain, the metabolism of drugs. The cytochrome P450 family is 
responsible for >90% of the metabolism of all drugs, so the computational 
prediction of metabolism can help to design drugs and indicate possible drug 
interactions in the early phases of the drug discovery process. The generation 
of structures produced by the first step during drug metabolism w as 
investigated using experimental data and by identifying common structural 
trends, using and cross referencing the following properties: molecular m ass. 
Log P, pKa, cytochrome catalyst and the distance from the site of reaction to 
electronegative points in the structure. The creation of structural tem plates 
with the distances to the site of reaction offered guided predictions to the 
plausibility of a particular reaction occurring. By comparing the number of total 
possible reactions available to a molecule to the number of reactions which 
would occur according to template theory, the average reduction in reaction 
outcome is 36.1%; with structures expecting to have 15 or more reactions 
having a reaction reduction of 40.9%. These results show that tem plate theory 
has a positive effect on removing unlikely reactions and thus narrowing the 
number of predicted structures for first step metabolism and can aid in further 
clarifying the metabolic path of a  drug for the drug design process.
The software generated in this work utilized existing and created new specific 
functions for the template and produced a  reasonable platform for the 
template theory to be hosted and eventually expanded. This program has the 
ability to generate every structure that could possibly be generated from the 
original drug structure, but incorporates template theory to selectively remove 
those structures which are unlikely to occur.
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Chapter 1 : Introduction
CHAPTER 1 Introduction
1.1 Introduction
During our finite life span on this earth', we will com e into contact with, ingest, 
and be injected with many organic and inorganic substances". Those organic 
substances administered to treat a  d isease  in the patient are known 
generically a s  “drugs”. One definition penned by an anonymous source 
declared a  drug as, “A chemical substance administered to two or three 
animals to produce a scientific paper”. A more accurate definition might be 
that they are “powerful chemicals, very small quantities of which produce 
changes in other chemicals that are a part of living things”"'.
With these  substances influencing our lives constantly, the need to know how 
and why they act in our bodies is necessary  for the development of newer and 
more efficient drugs for treatm ent of disease'''. The science of drugs and their 
behaviour is known as  pharmacology'' and uses both biology and chemistry to 
understand the metabolism, or the biotransformation, of drugs. It is important 
to appreciate how drugs are metabolised for many purposes, thus scientific 
knowledge required for the development of a  new drug would encom pass 
whether the drug is acting a s  expected and whether at any point in the 
metabolism pathway the drug becom es toxic; such answ ers usually come 
from the study and comparison of existing drugs'''. Drug development is 
expensive a s  many materials and time are w asted in creating just a  single 
new drug and consequently for economic reasons, recently research into 
predictive drug structure and metabolism has greatly increased''".
1.2 Existing drug metabolism predictors
Many individual drug development com panies and independent parties have 
attempted the task of creating software and tools for the prediction of various 
unknown chemical aspects such a s  pKa, Log P (where pKg is the acid 
disassociation constant and LogP is the partition coefficient based on octanol
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and water) and metabolic fate. Previously, the values in question could only 
be generated by dedicated lab scientists after repeated experiments.
An online search generated the following available software designed for 
pharmacologists and chemists with interests in drug development and based 
on structural information rather than rate -based metabolism for adsorption;
• Pallas''"'
CompuDrug'^ creates software known as  “Pallas” for ADME and 
drug discovery. ADME is an acronym for absorption, distribution, 
metabolism, and excretion and all four phases are critical to the 
success  of the compound a s  a  drug.
This software is claimed to predict the following param eters for a 
given compound in the drug discovery process or during the 
research phase:
• the metabolic fate of the compound in question;
• the compound's toxicity a s  a  drug;
• pKa values for the compound in the aqueous phase
• logD values for the compound at the desired pH based on 
pKa and logP prediction;
• the ‘Rule of Five’ param eters for the compound;
• the toxicity of the selected organic compound, or 
compounds, based on toxic fragments.
This software is principally a rule-based system  with open 
architecture, allowing the user to modify library fragm ents as  
well a s  containing a “knowledge b ase” of existing drugs.
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METEOR*
Meteor is software which uses expert knowledge rules in 
metabolism to predict the metabolic fate of chemicals and 
he predictions are presented in metabolic trees.
Predicts the metabolic fate of chemicals.
Displays results a s  a metabolic tree.
Covers phase I and phase II biotransformations.
Links directly to MetaboLynx™ to speed up analysis of 
m ass spectrometry data from metabolism studies.
Pathw ay studio*^'
Ariadne Genomics^" creates software known as  Pathw ayS tudio  
used for metabolic pathway analysis and the interpretation of 
experimental results. Consequently, this software is mainly used 
for:
• the drawing and visualisation of metabolic pathways as  
well a s  the prediction of the effects of various biological 
entities;
• the simulation of dynamic behaviour of metabolic 
pathways.
• AGO LabsX III
Advanced Chemistry Development, Inc., (ACD Labs) is 
responsible for common computational chemistry freeware tools 
such a s  Chemsketch^’'', which w as designed for drawing and 
visualising chemical structures. ACD Labs has also created 
various software facilities, for industrial use, for which the 
following operations are claimed:^:
10
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• LogD - A prediction of the octanol-water distribution 
coefficient for ionizable compounds for the range pH 0 -  
14;
• LogP -  to enable the user to consult or predict the 
octanol-water partition coefficient for neutral compounds;
• PKa - to consult or predict the acid-base dissociation 
constant;
• Solubility - to determine the aqueous solubility for the 
range pH 0 -  14;
• A determination of the boiling point of a  given compound;
• Liquid properties - to enable the user to estim ate the 
refraction index, surface tension, density, molar volume.
Although not stated explicitly on the site, it is assum ed that the 
majority of software predictions are generated from a  large 
database, given that Log P predictions are derived from a 
da tabase  of over 5000 experimentally obtained log P values of 
over 3600^' different compounds.
• IDBS* "^ QSAR
IDBS is a  company providing software solutions for the 
pharmaceutical, biotechnology and agrochemical industries. The 
main chemistry software is ChemlQ2™, a  COM compliant dll 
(dynamic linked library) that is capable of displaying both 
reactions and stereochemical structures. IDBS also provides 
PredictionBase^'", software which utilizes mathematical QSAR 
(quantitative structural activity relationships, which will be 
discussed in a later chapter) to filter, screen, and validate 
potential models for a  new drug design.
This list is not exhaustive a s  much work is done in-house by com panies and is 
thus proprietary.
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1.3 Potential Research
As the current state of metabolic prediction research is heavily dependent 
upon libraries and rule-based system s, this allows for a  new approach to 
predictive solutions to be investigated.
Current predictions for both toxicity and metabolism tend to use the Hammett 
and T alf^  approach for predictions - breaking the structure down into 
fragments rather than considering it a s  a  whole. T hese programs generate 
every structure that could possibly be generated in silico, which, although 
useful for the toxicity aspect, is not so  useful when attempting to predict the 
most likely path of metabolism, as  the generation of all possible structures 
does not begin to narrow the scope for most likely metabolic pathways.
Recently, the industrial trend has been towards the use of high throughput 
screening^ and other rule-based system s which include every possible drug 
structure, rather than the most likely structures. Drug discovery by these  
m eans is in reality no better than attempting to generate blindly a  new drug in 
the laboratory. It does indeed save som e funding on materials, but is not 
using the information already obtained to guide the researcher towards 
specialist drugs and prediction of their structure.
This new approach will address the challenge of examining drug metabolism 
by investigating the chemical and structural properties of known drugs along 
with traditional m easurem ents of their metabolism. Rather than simply making 
a direct comparison of individual values known for a  given substance, the 
knowledge will used a s  a guide in developing software for metabolism 
prediction. Thus the focus is on creating a  piece of software which is able to 
predict the most likely pathway for the metabolism of drugs, based mainly on 
structure, but also supported by correlation with other relevant chemical 
properties such a s  LogP.
12
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The originality of this approach is that currently all known software, for which 
metabolism predictions are claimed, relies mainly on large industrial 
da tabases for predictions. Furthermore, all existing ideas are firmly rule based 
and do not appear to allow for the integration of new information to be applied 
to the algorithm.
By using solely chemical structure to predict the first step of metabolism, the 
most improbable reactions for the latter can be discarded and their resulting 
structures and pathways acknowledged but removed. Chemical based 
knowledge, using properties such a s  LogP and pKa, could then be predicted 
and applied to the information guidelines from original laboratory work to 
confirm the probability of the structure being created. The software could then 
be iterated to predict subsequent steps until the structure appears ready to be 
excreted. A final idea for this line of software might be to apply known 
toxicology results for fragments to se e  whether structures, arising from any of 
the metabolism stages, might prove toxic.
The whole idea for this attempt at predictive metabolism relies upon initial 
observation of drug metabolism in known structures. Following these  
observations, possible trends will be generated, according to the reactions 
and physical properties of the structure in question. The structural predictions 
would then be followed by the comparison of known LogP and pKa values. 
Given that drugs may access  the body by many different routes; structures 
whose metabolism m echanism s may be associated with particular LogP 
values will be attempted first due to the importance of LogP with respect to 
solubility and the importance of the drug becoming hydrophilic during the 
process.
By following this method, the need for continual reliance upon a  large 
database  of drug structures is removed, a s  the guidance would give an 
estimated range according to the structure/reaction. Additional information 
could be added to the software easily to improve future metabolism 
predictions, as  the new approach will have the intent to eventually incorporate 
all chemical properties with structural features.
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Furthermore, the approach of utilizing chemical knowledge for prediction 
should prove more valuable than the current use of QSAR, which predicts 
various properties via mathematical m eans after adjustment by the user. Each 
individual case  for prediction using this method has to have the QSAR 
equation manipulated in this fashion. Although som e of these QSAR 
expressions prove to be quite accurate once created, they cannot be applied 
universally.
1.4 Basic Drug Metabolism
In order for a drug to enter a  system, it has to pass  through various 
m em branes. Fat-soluble molecules can pass  through a  semi perm eable cell 
m em brane such a s  cell m em branes, w hereas water soluble, ions and ionized 
molecules may not. Using this knowledge a  drug may be rendered active or 
inactive with respect to cell entry, by making the drug more water-soluble.*®^'
Drugs may be transformed and metabolised by many routes and reactions in 
order to change their effectiveness. These reactions include oxidations, 
reduction, hydrolysis, hydration, conjugation and condensation. In 
understanding these  pathways, information about a  particular drug metabolic 
and toxicological behaviour can be derived and applied. Often the reactions 
are split into two different categories: phase 1 (functionalisation reactions) and 
phase 2 (conjugative reactions) and a  list of selected exam ples is given in 
Table 1 .1 J
P hase  1 and phase 2 reactions often, although not always, occur sequentially. 
The former are thought to prepare the drug by adding or revealing a 
chemically active functional group on which a phase 2 reaction may occur. A 
prime example of a phase 1 reaction is the hydrolysis of a drug, thus adjusting 
its solubility. P hase  2 reactions comprise conjugations between the drug 
metabolite and a  second molecule; these  are considered to be the 
detoxification pathways, as  the products are usually pharmacologically
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inactive and excreted (usually through urine or bile), due to their now 
increased polarity*®"'
Table 1.1: Selected Examples of Phase 1 and Phase 2 Reaction^:xiii
P h a se  1 P h ase  2
Oxidation Glucuronidation
Reduction Sulfation
Hydrolysis Méthylation
Hydration Acétylation
Dethioacetylation Amino acid conjugation
Isomérisation Glutathione, fatty acid conjugation 
Condensation
1.5 Drug M etabolism  P h a se  1 Reactions*^'''*“^
As mentioned, phase 1 reactions may “activate” a drug or prepare if for 
excretion. The following simplified metabolic exam ples of phase 1 reactions:
Monooxygenase Activity (oxidation)
Oxidative reactions include hydroxylation of carbon and nitrogen, nitrogen and 
oxygen de-alkylation, and oxidative deamination. The process of oxidation 
decreases the electron density on a  carbon by breaking a C-H bond or 
forming a  0 -0 , C-N or C-X (where X is a halogen).
• Aromatic oxidation, aliphatic oxidation and epoxidation
Aromatic oxidation is a  common reaction if the substance contains an 
aromatic ring. The addition of an -O H  onto the ring, the position of the 
additional -OH is dependant on the type and position of other functional 
group(s) attached to the ring:
15
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R
HO
OH
Aliphatic oxidation is another common reaction. The addition of an -OH 
onto the available saturated carbon:
HO ,OH
R CH3
Epoxidation is a less common reaction, but is known to occur in metabolic 
reactions. A simplified example of epoxidation:
,0
:CH,
Epoxides are normally considered to be unstable intermediates, but may 
be sufficiently stable if formed on fused polycyclic substances, e.g.
)(
Dealkylation and deamination
16
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Dealkylation, where the alkyl group is lost a s  an aldehyde, occurs readily with 
drugs containing a  secondary or tertiary amine, an alkoxy group or an alcohol- 
substituted thiol. W here X is NH, S or O;
X- -CHc
R X
V -OH ,XH
HoC  O
Deamination is the process of removal of a NH2 group from the original 
structure. This occurs via an unstable intermediate which produces a 
ketone and ammonia:
HoN
OH
-C H ,
NH, CH ,
N-Oxidative, S-Oxidative and Désulfuration
NH,
Groups that can be A/-hydroxylated are amines, imines, amides, 
hydrazines and heterocyclic compounds. An example of N hydroxylation, 
once again, this reaction occurs via an unstable intermediate:
H
.N.
R' R
H
\ .R
.N'
R'
O2-
OH
R N
R
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S-hydroxylation occurs in the sam e way:
R
H
4
6 '-
-OH
The désulfuration of phenothiazines may oxidize the structures into their 
S-oxides (S=0) and sulfones (0=S=0).
R- / o
Reductase Activity (Reduction)
Reductive reactions are less common than oxidative reactions, but do still 
occur and influence metabolic pathways. The process of reduction increases 
the electron density on a carbon by forming a C-H bond or breaking a C -0, C- 
N or C-X (where X is a  halogen).
• Azo Reduction and Nitro Reduction
The reduction of an azo-compound produces two amines:
R'
,NHo + .NH,
R;
Similarly, nitro reduction also produces an amine:
NH,
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Reductive Dehalogenation
The reduction of a halogenated compound replaces a halogen with a 
hydrogen.
Hz01
01-
01
01
-01 +  HOI
1.6 Drug M etabolism  P h ase  2 Reactions*"^'
P hase  2 reactions often involve conjugation of two molecules in order to make 
a compound ready for excretion in urine or bile. Table 1.2 shows som e 
examples;
Table 1.2 Selected Phase 2 Reactions along with the Necessary Enzymes 
and the Functional Groups Involved
R eaction Enzyme Functional g roup
Glucuronidation UDP Glucuronosyltranferase OH, COOH, NH2, SH
Glycosidation UDP Glycosyltransferase OH, COOH, SH
Sulfation Sulfotransferase NH2, S02NH2, OH
Méthylation methyltransferase OH, NH2
Acétylation acetyltransferase NH2, S02NH2, OH
Amino acid Conjugation COOH
Glutathione conjugation Glutathione-S-T ransferase Epoxide,organic halide
fatty acid coniugation OH
condensation Various
UDP -  Uridine diphosphate
The following show som e exam ples of the reactions described in table 1.2:
19
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• Glucuronidation
This is the most common of the conjugation reactions. W here UDPGA 
Uridine diphosphate glucuronic acid, an example of which is the 
glucuronidation of salicylic acid:
O.Gluc
UDPGA
• Sulfation
This is the major pathway of the conjugation reactions for phenols but also 
occurs for alcohols and amines. As with the sugar conjugation shown 
above, an energy rich donor is required, in this case  it is PAPS (3’- 
phosphoadenosine-5’-phosulphate). The sulphate conjugation occurs on 
the -OH much the sam e as  with the sugar conjugation. An example of 
sulphate conjugation of paracetamol:
CH,
H 0 / \
• Fatty acid conjugation
The fatty acid conjugation occurs on the -OH much the sam e as  with the 
glucuronidation conjugation. An exam ple of fatty acid conjugation of 11- 
hydroxy-9-tetrahydrocannabinol (A^-THC):
20
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R =
CO (CH2)ig CHg
Méthylation
The méthylation of a  structure involves the substitution of a hydrogen atom 
for a methyl group. This occurs, more than likely, via an S n2 substitution 
reaction. Example, the S-methylation of thiouracil
CHo
HS
HN CH.
CH.
HS
HN
HN 2H
• Acétylation
Acetyl reactions are common for aromatic am ines and sulfonamides and 
require acetyl-CoA. Example, N-Acetylation of Isoniazid. The acétylation of 
a structure involves the substitution of a hydrogen atom for an acetyl 
group. This occurs, more than likely, via an S n2 substitution reaction much 
like the méthylation:
21
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R
0 = 8 = 0  +  Acetyl-CoA
NHz
R
+  CoA-SH
HoC- \
W here CoA is coenzyme A is an organic non-protein molecule that carries 
small chemical groups between enzym es.
Amino Acid Conjugation
Mainly occurs in the removal of carboxylic acids through urine. An 
example is the glycine conjugation of benzoic acid, where ATP is 
Adenosine 5-triphosphate:
H O ^ . 0
+  ATP
AMP. / O CoA^
+  CoA-SfcL
Adenosyl-benzoic acid benzoyl-CoA
glycine
CoASH
22
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• Glutathione Conjugation
Glutathione, also known as  GSH, partakes in conjugation reactions in, an 
assum ed, similar substitution method a s  the reactions previously 
mentioned. An example Glutathione conjugation is of a) 2,4-dinitro-1- 
chlorobenzene and (b) esters of maleic acid:
a)
,CI
b)
W  V„/.
o
R
O-
,S-Glutathione 
+  H-CI
0  0  R
Glutathione
The structure of glutathione shows the reactive SH group which is used to 
attach to the structure in question:
HS.
OH
NH
HO NH
NH.
23
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1.7 Basic Drug Absorption
In order for a drug to enter a body, it may have to pass through various 
mem branes. Thus, fat-soluble (lipophilic) molecules can pass directly through 
the cell m em brane^", and as  previously established, water-soluble drugs, 
ions and ionized molecules may not. Drugs are usually designed to be as  lipid 
soluble as  possible^'". Drugs may be administered to the patient through a 
variety of means^'^: Sublingual (under the tongue). Oral, Rectal, Application 
to epithelial surfaces. Inhalation and Injection (Subcutaneous, Intramuscular, 
Intravenous, Intrathecal)
The routes of administration and excretion may be simplified a s  follows:
Gut
Skin
Liver
Muscle
Breast,
sweat
glands
PLASMA
Lung
Brain
Placenta
Kidney
CSF
Foetus
Figure 1.1 The main route of drug administration and excretion. Drug 
Administration: 1. Oral or rectal, 2. Intravenous, 3. Percutaneous, 4. 
Intramuscular, 5. Inhalation, 6. Intrathecal. Drug Excretion: 7. Urine, 8. 
Exhalation, 9. Milk, sweat, 10. Faeces.
24
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Despite the variety of administration m eans, it has been noted the majority of 
drugs are initialised/activated or inactivated by a phase 1 reaction involving 
Cytochrome P450 within the liver^', and then possibly followed by a phase  2 
reaction involving either a  conjugation or a  condensation. P hase  2 reactions 
have been found to occur with established drugs such as  thebaine, 
m edazepam , oxazepam, imiparmine, amphetamine, proanolol and 
lidocaine^", although these  are by no m eans the only drugs to which phase  2 
reactions occur.
Of the well-known drug reactions, common first phase reactions are 
déméthylation, hydroxylation or hydrolysis through P450, followed 
subsequently by oxidation to a  double bonded oxygen. Generally, the 
reactions investigated thus far show a  site preference for aromatics with the 
following trends with hydroxylation^'":
Aromatic rings with more than two bonds, where “A” is any atom. The site of 
preferred attack is highlighted:
no reaction
at sites 3, 4
25
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1.8 Simplified Basic Drug Reaction TreeX X X IV
2 rug
/ \
Hydrophilic
Nothing/excreted after use
Hydrophobic
P hase  1 reaction by P450'
/ \
Activated Less activated Inactivated
Effect before P hase  2 reaction Excretion Excretion
Excretion
"Reaction being oxidation, hydrolysis, hydroxylation, Dealkylation or 
deamination.
1.9 The Aims of the Project
The aims of this project are to investigate existing observed data on the drug 
interactions and reactions with cytochrome P450 with a view to identifying 
possible structural trends. The identification of these  trends should provide a 
starting point for further research into why and how specific metabolic 
reactions occur. Each property to be investigated, physical and chemical, will 
be analysed and cross referenced with each other the search for a pattern. 
The intention is to incorporate these  trends into novel software which it is 
hoped may predict the structural outcome of a potential drug once reacted 
with cytochrome P450. Ultimately such software could be integrated with the 
chemistry tools of ID Business Solutions, ChemlQ2™ due to the ability of 
ChemlQ2 to allow the user to analyze certain structural features of the drug 
such a s  stereochemistry.
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CHAPTER 2 Theory
2.1 Bioavailability and the Theory of the “Rule of 5”
Christopher A. Lipinski published a seminal paper in 1997 which put forth a 
theory which is now known as  “the rule of 5”'. This paper identifies features 
commonly found in orally active drugs and quantifies their structural properties 
with respect to their effectiveness and bioavailability a s  a drug.
Bioavailability has been defined in a  number of ways, which include:
1. the extent to which the active ingredient in a  drug product is taken up 
by the body in a  form which is physiologically active (National 
Formulary XVIII, 1970);
2. the availability of a  drug from a  dosage form, which involves both the 
rate and the com pleteness with which the drug product delivers the 
drug to an absorption site in the body in an absorbable form (J. Amer, 
Pharm. Ass., 1970)."
As mentioned in chapter 1, a drug may be administered through a  great 
variety of routes, the most common being oral, and the m ost common form of 
drug being in com pressed tablets or gelatinous capsules. Once again, it 
should be appreciated that the journey of the drug to the absorption site 
contains many extreme conditions that could alter the drug en route, for 
example gastric juice has a  pH of 3.0, where a s  plasm a is 7.4 and urine 8.0"'.
The term “bioavailability" is mainly a convenience to make generalized 
statem ents about the proportion of drug that p asses  into system ic circulation, 
usually following oral administration. However, bioavailability should not be 
assum ed a  quantifiable value'''.
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The majority of oral drugs are predominantly lipophilic in their structural 
behaviour and therefore the metabolism of the drug involves it becoming more 
hydrophilic and this is usually the m ost efficient m eans of the removal of the 
drug from the body''. This is in accordance with one of the ‘rule of five' rules 
which s ta tes  that the value of Log P m ust be less than 5. The greater the 
value of Log P, the more lipophilic or hydrophobic the drug is. However, Log P 
is not an accurate source for determining solubility alone, for example, when 
ionizable drugs in acidic form show poor transport through lipid membranes'".
As a  general rule, if a  drug adheres to these  rules it may be considered to be 
biologically active'"'. It can be assum ed that an orally active drug has the 
following:
• fewer than 5 hydrogen bond donors;
• fewer than 10 hydrogen bond acceptors;
• a molecular weight below than 500 gram s mole"\ and
• a Log P value lower than 5
2.2 Introduction to Cytochrome P450
Since the first report on Cytochrome P450 (published in 1962''"') there has 
been an explosion of interest in the subject due to the development of the 
pharmaceutical industry. P450 is so  called because of its reaction with carbon 
monoxide to give a  pink complex (P) with an absorption peak at 450 nm'^ in 
the visible light spectrum. Cytochrome P450 is not specifically one entity, but 
a  vastly populated family^ of haem-thiolate enzym e proteins capable of redox 
(mono-oxygenases) behaviour^'. These ubiquitous enzym es are found across 
almost all species of life, although those m ost scientifically investigated 
belong to hum ans and the other mammals^". The research behind 
Cytochrome P450 is inevitably twinned with that of drug metabolism as  many 
of the initial phase one reactions are catalysed by one form of Cytochrome 
P450^'". These enzym es are mainly located in the liver, but other forms have 
been proven to exist in the tissues of other organs such a s  the kidney.
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prostate, breast, lung, spleen, pancreas and the brain^"'. Often, drugs are 
removed from the patient efficiently by the liver and metabolized, known a s  
“first pass metabolism"^, thus greatly reducing the amount of the substance 
which is absorbed into the circulatory system. It is this first step  in drug 
reactions where the project begins.
The majority of phase one reactions are oxidation reactions^'. Most of the 
reactions involve nicotinamide adenine dinucleotide phosphate (NADPH), 
molecular oxygen, mixed function oxidase and a  member of the group of 
Cytochrome P450 haemoproteins^". The Cytochrome P450 family is one of 
the more powerful detoxifying enzym es, and there are around 60 forms 
known^'", with hundreds of genetic variations possible, producing a  wide 
variety of susceptibility to specific toxins. It is this great variance and 
adaptability of Cytochrome P450 which m akes the study of metabolism so 
intriguing for pharmaceutical biologists and chemists.
Figure 2.1. “Ribbon structure of the R. capsulatus Cytochrome P450, with the 
haem showing the thioether linkage (yellow)”
Given the shape and location of Cytochrome P450 it can be seen  that only 
relatively small drugs of a polar nature may be hydrolysed by the catalyst^. It 
is natural to assum e that the larger and more the bulky the drug molecule the 
greater the steric hindrance to binding with P450.
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2.3 Chemical Reactions of P450
Owing to the importance of the involvement of Cytochrome P450 in 
metabolism of drugs and steroids, the chemical m echanisms of these 
reactions are of great interest to toxicologists and pharmacologists. In many 
published books and papers, there is a standard accepted theoretical reaction 
cycle that takes place, which is shown in Figure 2.2. Although it is so widely 
accepted, it should also be noted that the intermediates are merely hopeful 
assum ptions that allow the reaction to appear chemically plausible.
1 0
R-H
ROM
RH
M e '  Q
RH
RHRH
F e
M e'M e 'M e'
H2
RHRH RH
M e ' M e '
- I  -1
0 —  0
RHH+ RH
M e ' M e'
H+
Figure 2.2 The accepted catalytic cycle of Cytochrome P450.
A. The cycle is initiated by the binding of the substrate (R-H ) to the P450.
B. This step allows the first electron transfer to occur, reducing Fe'" to Fe".
C. This step causes the attraction and binding of O2 to the Fe.
D. The second electron transfer takes place forming an iron-peroxo 
species.
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E. (Assumed intermediate, for which there is no direct evidence)
F. (Assumed intermediate, for which there is no direct evidence)
G. This oxyferryl intermediate reacts with the bound substrate and 
produces a hydroxyiated product.
The general reaction may be written a s  follows:
RH + 02 + 2H" + 2e +
A Simplified P450 cycle is provided below.
RH
RON
3+Fe
3+Fe
RH 1st e
2+Fe
RH
3+(Fe - O) 
RH Fe - O 2 
RH
^  2nd e
2H
Figure 2.3 A simplified cycle of the p450 hydrolysis reaction ™
This information is not directly required a s  a  part of the prediction of 
metabolites from any given reaction with Cytochrome P450, due to the great 
variation of reactions possible, but it is wise to understand and accept the 
potential m echanisms which may be involved in the process and which could 
aid in the establishm ent of trends and patterns.
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2.4.1 A P450 Substrate Example: Ibuprofen
One substrate for P450 is Ibuprofen. Ibuprofen is one of the propionic acids, 
an NSAID (non-steroidal anti-inflammatory drug) that p o ssesses  analgesic 
(pain reduction), antipyretic (temperature reduction) and anti-inflammatory 
properties.
Figure 2.4 Chemical structure of Ibuprofen
NSAIDs possess  strong oxygen radical ‘scavenging’ properties and are often 
highly hydrophobic. Given this, it has been suggested that Ibuprofen reacts 
according to the following scheme^'":
HoC
HoC
R-lbuprofen
HoC
R-2-hydroxyibuprofen
OH
R,S-3-hydroxyibuprofen R, R-3-hydroxyibuprofen
HoC
(A)
HO ^ O  
R,S-3-carboxyibuprofen
(B1)
R .R-3-carboxyibuprofen
(B2)
Figure 2.5 Assumed metabolism of Ibuprofeh^^'
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When introduced to Cytochrome P450, R-lbuprofen produces R-2-OHIbu (A) 
and two diastereomic forms of 3-OHIbu (B1 & B2) Ibuprofen is known to 
be a  rapid reversible competitor for inhibition of CYP450 enzym es. It may bind 
reversibly to the enzym e and com petes against the natural substrate 
arachidonic a c id ^ . It is believed that hydrophobic forces are of great 
importance in this reaction.
2.4.2 Another P450 Substrate Example: Acetaminophen (Paracetamol)
Another substrate of P450 is paracetamol. Paracetam ol is not an NSAID, but 
does possess  analgesic (pain reduction) p roperties^ . It is known to be a 
rapid reversible non-competitive inhibitor of CYP450 en zy m es^ '.
HO
V -CH,
NH
Figure 2.6 Chemical structure of Paracetamol
The metabolism for paracetamol is suggested to be a s  follows
O ^ C H  
NH
acetam inophen
UDPGA
HO
HO
U D P-glucuronosyltransferase ^  ^  
O HO
OH O
HO
m ercapturic acid
PA PS
m acrom oiecuies 
CH3
Suipho transferase  ^ * ^ 3
CH3  G lutathione
NH O
G lutathione
m acrom oiecuies
ceii d eath
Figure 2.7 Assumed metabolism of Paracetamol, where UDPGA (uridine- 
diphosphate glucuronic acid)
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Paracetam ol is usually metabolised in the liver to form small non-harmful 
metabolites, but can be also metabolised by P450 to form the toxic metabolite 
NAPQI (N-acetyl-para-benzoquinoneimine)^'". It is the reaction with the 
specific CYP450 family m em ber CYP2E1, which, on administration of toxic 
levels of paracetamol, leads to the depletion of enzym es and causes the 
formation of the toxic metabolites, NAPQI (b) below:
HO.
CH3
N' CHa
OH
(a) (b)
Figure 2.8 The toxic intermediates of Paracetamol: (a) Intermediate, (b) 
NAPQI
NAPQI may be detoxified by glutathione stored in the liver. W hen the supply 
of glutathione in the liver is depleted to less than 70% of normal levels, then 
the unbound NAPQI causes cell death^'^. The precise mechanism for cell 
death is unknown, but it is suggested that mitochondria dam age may be 
involved^.
The orientation of paracetamol when aligned on the enzym e affects the way 
NAPQI is produced and hence further ad d u c ts^ '. An example of these  
docking variations is shown below. It can be seen  that the docking for 
Paracetamol onto CYP2E1 has distances of 4.5Â and 3.8Â, w hereas the 
respective distances for the docking of Paracetam ol to CYP2A6 are 3.8Â and 
4.1Â. These data are useful for understanding how other drugs may situate 
them selves on to a  P450.
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CYP2E1 CPY2A6
COOH COOH
HOOC' HOOC'
'XXX//Figure 2.9 The docking of Paracetamol on CYP2E1 and CYP2A&
2.4.3 A Further P450 Substrate Example: Aflatoxin B1
The last example substrate of P450 to be considered in this chapter is 
Aflatoxin B1. Aflatoxin B1 is a fungal metabolite, which is usually found in 
contaminated peanut and corn crops^ '". As it is known to be highly 
carcinogenic in rodents, the possibility of the sam e effect on hum ans m ust be 
d e term ined^’''. Currently, Aflatoxin B1 is thought to be metabolised by 
CYP3A4, to produce the 8, 9 -e p o x id e ^  -  which is believed to have 
carcinogenic potential in humans, although such cases  are hard to identify 
and d ia g n o s e ^ \
O— CH
Figure 2.10 Chemical structure of Aflatoxin B1
The metabolism of Aflatoxin B1 has been suggested to be a s  shown in Figure 
2 . 11;
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OH
Glucoronide
O Aflatoxin
AFBi 8 , 9 - epoxide
OH
HO
Figure 2.11 Assumed metabolism of Aflatoxin B1XXVI
2.5 Cytochrome P450 Families
As established previously, Cytochrome P450 exists in many life forms across 
the biological kingdoms. The diversity of its forms and property of 
polymorphism m akes the task of investigating particular drug metabolism 
difficult^ '. Since the initial discovery of Cytochrome P450, there are now 
known to be more than 1500 known s e q u e n c e s ^ " . For classification 
purposes these  forms are grouped into families and subfamilies. Humans are 
known to have 18 families and 43 subfam ilies^ '"  of Cytochrome P450. The 
root of the nam e is CYP, with hum ans believed to currently p o ssess  57 forms 
of Cytochrome P450 (not including the 5 pseudogenes), although this is 
subject to c h a n g e ^ '\
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Cytochrome Family Family Members (Enzymes)
CYP1:
CYP2:
• CYP3:
• CYP4:
CYP5
CYP7
CYP8
CYP11
CYP17
CYP19
CYP20
CYP21
CYP24
CYP26
CYP27
CYP39
CYP46
CYP51
CYP1A1, CYP1A2, CYP1B1, CYP1A8P 
CYP2A6, CYP2A7, CYP2A13, CYP2B6, CYP2B7, 
CYP2C8,
CYP2C9, CYP2C11, CYP2C18, CYP2C19, CYP2D6, 
CYP2E1,
CYP2F1, CYP2G1P, CYP2G2P, CYP2J2, CYP2R1, 
CYP2S1, CYP2U1, CYP2W1 
CYP3A4, CYP3A5, CYP3A7, CYP3A43 
CYP4A11, CYP4A22, CYP4B1, CYP4F2, CYP4F3, 
CYP4F8,
CYP4F11, CYP4F12, CYP4V2, CYP4X1, CYP4Z1 
CYP5A1
CYP7A1, CYP7B1
CYP8A1, CYP8B1
CYP11A1, CYP11B1, CYP11B2
CYP17A1
CYP19A1
CYP20A1
CYP21A2
CYP24A1
CYP26A1, CYP26B1, CYP26C1
CYP27A1, CYP27B1, CYP27C1
CYP39A1
CYP46A1
CYP51A1
The First family is CYP1 (also represented a s  P450-1) and contains the two 
subfamilies of CYP1A1 and CYP1A2. P450-1 is som etim es known as  P448 
as  both CYP1A1 and CYP1A2 show peaks at 448nm in the uv/visible 
spectrum^'. The following information is for human Cytochrome only, and is 
limited owing to the difficulty of purifying the enzym e from human liver.
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Cytochrome Known Activity 
CYP1A1 n\a
CYP1A2 proven to metabolise Phenacetin and 7 ethoxyresorufin
and to activate pro-mutagensxli
The Largest Family of the Cytochrome P450 is CYP2 consisting of eight 
subfamilies (2A-2H). The CYP2 group is believed to be responsible for over 
54%^'" of drug and steroid phase 1 reactions.
Cytochrome Known Activity
CYP2A reported to catalyze hydroxylation of coumarin
CYP2B reported to catalyze O-deethylation of 7-
ethoxycoumarin x li
The remaining families from CYP3 to CYP51 vary in function from drug and 
steroid (including testosterone) metabolism to cholesterol biosynthesis and 
vitamin degradation^'". For the remainder of this thesis, the focus is upon the 
transformation of a drug through metabolism, usually induced by the CYP1 
and CYP2 families.
2.6 Example Drugs for P450 CYP2C
The particular Cytochrome for which Ibuprofen is a  substrate is known as  
CYP2C19. The chemical structures of other example substrates for this P450
are xliii.
Ibufenac Phenytoin
NH
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Tolbutamide Diclofenac
HO
Warfarin Caffeine
CH;OH
H,G.
CH;
CH,
Aspirin
H ,C ' 'O
Example inhibitors for CYP2C19 are:
S-Mephenytoin Omeprazole
H3C,
NH.
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Propranolol Diazepam
NH
Fluconazole Tranylcypromine
NH ,
Hexobarital
C H ,
Proguanil
H,C_ J
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2.7 Sites of P450 Interactions with Drugsxliv
Table 2.1 Selected reactions of Cytochrome P450 (varying family members) 
indicating the reaction site
Structure Name (S)ubstate or 
(l)nhibitor
Reaction (C^ aromatic carbon)
Ibuprofen S Hydroxylation C2, C3
Ibufenac S Hydroxylation C2, C3
Warfarin S Hydroxylation C4, C '^ , C*7, C*8
Diclofenac S Hydroxylation 0*4, C*5
S-mephenytoin 1 Déméthylation (N), Hydroxylation 
C4
Omeprazole 1 Hydroxylation C5, Déméthylation 
(S)
Aspirin 1 Hydroxylation C
Caffeine^"'' S Déméthylation, Hydroxylation C8
Nicotine S Hydroxylation C^2, C^5
Methadone S Déméthylation
A broader range of results involving drugs and their sites of reaction after 
interaction with Cytochrome P450 compiled from D. F. V. Lewis^''" is included 
in Section I in the appendix. To begin the investigation into drug metabolism 
and m ethods of metabolism prediction, Lewis' papers were examined and 
relevant QSAR information w as extracted. The aim of this w as to qualify and 
quantify data and to start the investigation into physical (numerical) properties 
exhibited by the drug molecules.
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2.8 Expansion to Test Set Structures
To narrow the field for investigative purposes, the spectrum of sam ple drugs 
and their paths were restricted to those used only in the above and related 
research papers by Lewis^’'"', other papers were reviewed for suitability but 
actually referenced these  original data. The selection covers a  wide range of 
primary paths and structure content as  well a s  a  selection of P450 catalysts.
17a-Ethylnyl oestradiol Amobarbital Clomipramine
17B-Oestradiol Aniline Clonazepam
2-AAF (N-hydroxy) A-naphthoflavone Clopazine
2-phenylimidazole Antipyrine Clotiazepam
3-hydroxy-paracetamol Arachidonic acid Cloxazolam
3-methoxy-paracetamol Aspirin Clozapine
4-aminobiphenyl Barbital Cocaine
4-methoxtamphetamine Benzo(a)pyrene Codeine
4-nitrophenol Benzo[a]pyrene 7,8-diol Cortisol
534u87 Benzphetamine Cotinine
58c80 Biperiden Coumarin
6-aminochysene Brofaromine Cyclophosamide
7-ethoxy-4-trifluro coumarin Bromazepam Cyclosporin
7-ethoxycoumarin Bromoperidol Dapsone
7-ethoxyresorufin Bromvalerylurea DDT
7-methoxyresorufin Bts8402 Debrisoquine
7-pentoxyresofurin Bufuralol Deildrin
Acetaminophen Bunitrolol A THC
Acetyipheneturide Bupropion DEN,DIVIN
Aflatoxin B1 Caffeine Desipramine
Aimaline Captopril Dextromethorphan
Aldrin Carbamazepine DHEA 3-sulphate
Alfentanil Carpipramine Diazepam
Allylisopropylacetamide Cerivastatin Diclofenac
Alprazolam Chlordane Dieldrin
Alprenolol Chlorpromazine Diltiazem
Amidarone Chlorzoxazone Encainide
Amiflamine Choramphenicol Erythromycin
Amitriptyline Citalopram Estazolam
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Ethanol Minaprine Retinoic acid
Ethenzamide Moclobemide Retinol
Ethyl-morphine Morpheine Rifampicin
Etizolam Mptp R-mephobarbital
Fadrozole N-acetylbenzoquinone-imine Rosiglitazone
Fenbufen Naproxen R-R-3-carboxyibuprofen
Fenoprofen Nicotine R-R-3-hyd roxyi bu profen
Feprazone Nifedipine R-S-3-carboxyibuprofen
FK-506 Nimetazepam R-S-3-hyd roxyi bu profen
Flecainide Nirvanol R-warfarin
Flubiprofen Nitrazepam Senicione
Fluconazole Norcordeine Skatole
Fludiazepam Normopheine S-mephenytoin
Flunitrazelpam Notriptyline S-naproxen
Fluoxetine Oestradiol Sparteine
Fluphenazine Omeprazole Sterigmatocystin
Glutethimide Ondanestron Stilbene epoxide
Guanoxan Oxazepam Sulfaphenazole
Haloperidol Oxazolam Sulfinpyrazone
Haloxazolam Oxprenolol Sulpiride
Hexobarbital Paracetamol S-warfarin
Hydroxyzine Paracetamol-cyteinate Tacrine
Ibufenac Paracetamol-glucuronide Tamoxifen
Ibuprofen Paracetamol-mercapturate Taxol
Ifosfamide Paracetamol-sulfate Terfenadine
Imipramine Parathion Testosterone
Indomethacine Paraxanthine-iii Thebaine
Indoramin Paroxetine Theobromine-iv
IQ Pentobarbital Theophylline
Ketoprofen Perhexiline Theophylline-ii
Levomepromazine Perphenazine Thioridazine
Lidocaine Phenacetin Tienilic acid
Lithocholic acid Phenformin Timiperone
Losigamone Phénobarbital Timolol
Lovastalin Phenylbutazone Tolbutamide
Maprotyline Phenylimidazole Tranylcypromine
MDMA Phenytoin T riacetyloleanomycin
Medazepam PhIP Triazolam
Mefenamic acid Pilocarpramine Trifluperidol
MelQ Pindolol Trihexphenidyl
Melatonin Piroxicam Trimethidone
Mephenytoin Primidone Trimethoprim
Mephobarbital Progesterone Trimipramine
Metharbital Proguanil Tr/s-(2,3-dibromopropyl)phosphate
Methoxyflurane Promethazine Tropisetron
Methoxyphenamine Propafenone Verapamil
Metoclopramide Propercyazine Warfarin
Metoprolol Propranolol Yohimbine
Mexiletine Ouinidine Zopiclone
Mianserin R-2-hydroxyibuprofen Zotepine
Midazolam Rapamycin Zoxazolamine
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For the complete adapted table of data, refer to Section IV in the appendix. 
Within the table the drugs may contain som e or all of the following information 
relating to that drug:
the Name of the drug, 
relatiye molecular m ass (RMM),
Log relatiye molecular m ass.
Log P (Log partition coefficient).
Log D7.4 (ionization corrected Log P),
Daylight^’'"" calculated Log P,
Number of hydrogen bonds.
Number of n-n  bonds.
Number of rotatable bonds.
Number of hydrogen bond acceptors.
Number of hydrogen bond donors.
Number of hydrogen bond acceptors and donors,
pKa,
Primary metabolic path.
Secondary metabolic path.
Km Michaelis constant,
AGsind Substrate Binding Affinity 
AGpart Free energy of partition,
A G hb Hydrogen bonding energy,
AGn-n H -n  stacking energy,
AGrot rotatable bond energy,
AGionic Ionic interaction energy.
Distance of substituent to haem,
• Second distance to haem.
It should be noted howeyer, that in the obtaining of these  data, 
discrepancies within the original papers were noted. Certain yalues for
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drugs yaried from each paper. To ayoid any loss of potentially correct 
data, extra columns were inserted into the table, e.g.
T o ta l L is t  m  lo g  P lo g  P  v a ry C L O G P
Where:
Log P (is first yalue recorded).
Log P yary (second yarying yalue of Log P recorded),
CLOGP is the yalue calculated by use of IDBS SMILES and from the Daylight 
website"^^'". This method w as used to obtain a  complete se t of Log P data 
from one source of calculation, which could then be related from one drug to 
another and compared with other structural data when distinguishing trends.
For yisual reference, the nam es and 3-dimensional wire-frame structures are 
located in Section V in the appendix. Also included are the known primary 
paths of reaction with Cytochrome P450 for som e of the drugs. Trends of 
reaction paths may be linked to the structure enyironment, electronic 
properties or combination of any of the giyen data.
2.9 Data and Theory problems
It w as discoyered that certain data gathered were not consistent for each  drug 
in the test-set or missing entirely. The missing data appear a s  blank a reas  in 
the collectiye table of data in Section IV in the appendix. Throughout the 
compilation of the papers, there appear to be som e yariety in property yalues 
for a few structures (such a s  pKa, LogP), possibly due to a  yariety of factors 
including human error (either typographical in nature or in the original 
experimentation). As there is currently no exact way of determining which of 
the yarying yalues are correct, all yalues haye been recorded until the correct 
yalues can be determined through either comparison or re-calculation. 
Extensiye research will be needed to establish a  full table which can be then 
analysed for trends and patterns according to reaction paths.
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In the course of completing the missing yalues from the incomplete test-set 
table, Log P and pKa were decided to be the m ost likely to be predicted 
through calculation. Howeyer, the only software ayailable for Log P and pKa 
prediction w as that of com panies who were not forthcoming with “free-ware” 
or calculation methods. Thus, Log P and p/Ca must be calculated or an 
alternatiye source of calculation must be found; calculating Log P and pKa 
w as unwise due to the considerable drain on time and resources. According 
to the Pallas^''^ (a commercially ayailable chemical prediction program) 
software site, predictions are m ade ayailable for pKa, log P, log D yalues and 
metabolites. Pallas relies on a system  of rule-based programming in order to 
gain eyery possible metabolite formed. In theory this is a good idea, but the 
formation of so many possible metabolites inyariably leads to a  saturation of 
choice dependent on the chemical enyironment, many of th ese  possibilities 
may neyer be formed. These results are presented in the form of a  tree (not 
dissimilar to a Windows Explorer tree).
2.10 Existing Ideas for Predictive Metabolism
As the pharmaceutical industry expands, the dem and for better, cheaper and 
more accurate drugs to tackle specific problems increases’. Without com puter 
modelling many costly materials, considerable funding and lost time, could be 
w asted on the preparation of a drug, which may proye ineffectiye or toxic. In 
order for com panies to ayoid such costly mistakes, many computational 
“predictiye” m ethods for drug discoyery haye been initialised in the past 
decade. The idea is a  simple yet effectiye one: minimizing experimental drug 
space  by identifying and comparing a  potential drug’s  properties to those of 
known structures with a  similar efficacy. By using this method, many useless 
prototypes can be eliminated in cyberspace without eyer haying to be m ade 
and subsequently disposed of in the laboratory. Combined with high 
throughput screening, many com panies are relying on such software a s  
Pallas’" and PredictionBase’" a s  well a s  the offerings on the web such as  
fragm ent-based Log P predictions from Daylight’"'.
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Many system s are “expert” based, where structural predictions are based on 
comparison to a huge da tabase  of existing drugs'"''. Although apparently the 
most reliable method to date, the rules are inflexible and often could bypass a 
better yet preyiously completely unknown structure.
Other system s are fragment based (like Daylight and PredictionBase) where 
certain properties are calculated according to the fragments from which the 
structure is composed. This incorporates the Hammett and Taft''' approach of 
fragment based prediction. It can be considered that yirtually all drugs are 
weak acids or b ases along the assumption that they contain at least one 
hydrogen donor (Rule of Fiye- m ust haye at least 5 hydrogen bond donors). 
This m eans that the drug is always in equilibrium between its acidic and basic 
form.
HA <=> H+ + A-
B ecause of this, the pKa or hydrogen dissociation constant can be calculated.
pKa = pH + log(HA/ A-)
Looking specifically at Aspirin a s  an example, the pKa of the carboxylic acid 
group is recorded a s  3.49'''". As the conditions in which aspirin is metabolised 
(the digestiye tract) ayerage conditions are of pH at around 2-3, this would 
mean that Aspirin most likely exists purely in a  basic (-H) form in the body. 
The pKa of a drug can be thought of a s  the pH at which the acidic and basic 
portions are equal. If the pH yalue is higher than the pKa, the sta te  of the drug 
is mostly acidic, and if the pH is lower than the pKa, the drug is mostly basic'''"". 
So knowing the p/Q of a drug is yery useful for the computer-aided predictiye 
metabolism approach. Values of pKa may be predicted by comparison of 
structures with unknown p/Cg to similar structures with known pKg.
More effectiye predictions of pKg are calculated by the Hammett equations. In 
1940, L.P. Hammett studied effects on the pKg yalues of meta- and para- 
substituted aromatic compounds (benzoic acids)"'".
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(
Figure 2.12 Dissociation of benzoic acids (R and R' both H) in water at 25'"C.
Using this equilibrium constant a s  Ko, new constants (K) are now determined 
based on the the sam e process but substituting the groups R and R’. These 
values were combined in the Hammett equation with Kq. This leads to the 
Hammett Equation for pKg:
pKa = pKa°-p*Z(Ô)
W here 6 is a  constant calculated for a  particular substituent, p  is a constant 
assigned to the particular acid or base  functional group and pKa° is the pKa of 
the unsubstituted acid or base. It can be appreciated that Hammett and Taft 
based pKa prediction is heavily dependant upon large databases, both for the 
substituent constants and for the acid/base functional group investigated.
W e can se e  a similar such approach to predictive problems in the 
PredictionBase software, where a  molecule is fragmented according to either 
the library settings or custom fragments defined by the user (creating a 
fragment da tabase  table). The molecule then undergoes “Mapping”, which is 
the process of counting the number of times each fragment in the Fragment 
D atabase Table fits on to each structure in the data source (contents of the 
*.sdffile)“ ".
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Figure 2.13 Three-dimensional graphical representation of Cytochrome P450, 
(C Y P 2 E lf
2.11 The Structure of the Thesis
Owing to the fragmented nature of the research, the remainder of the thesis 
has been segregated into chapters, each with its own short introduction, 
theory, results and consequential conclusions.
The first approach is described in Chapter 3 and exam ines the raw data 
extracted from the selected papers of drug interactions with Cytochrome P450 
and the possibility of physical and chemical trends within the data.
Chapter 4 introduces the idea behind the yet to be established template 
theory and the concluded results of that research. Template theory attem pts 
to relate a se t of two or more coordinates within the three dimensional 
structure of a drug which are common to several drugs partaking of similar 
reaction type.
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Chapter 5 investigates the existing predictive method of QSAR by direct 
comparison of industrial QSAR in the form of IDBS KBase'^ technology with 
the academ ic derived QSAR expressions from the sam e papers, from which 
the raw data w as extracted.
The software portion of the thesis is located in Chapter 6, which d iscusses the 
methodology and approach to incorporating the results of the previous 
chapters into the existing chemistry software of IDBS chemistry tool ChemlQ’^ '
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CHAPTER 3 Common Trends
3.1 Common Trends Introduction
Given the great possible variety in cytochrome P450 substrates, an attempt 
has been m ade to group the substrates according to trends, reactions or 
structural features. The problem can be compared to the initial inspiration for 
QSAR' (Quantitative Structure Activity Relationship), that a s  the physical 
properties of a  structure change, the relative chemical properties associated 
with it also change", and therefore a  link between physical properties and 
chemical structure must exist. By regressing back to the very basic properties 
of a structure, hopefully one or more of som e simplified trends should becom e 
visible, either singularly or by a combination of possibilities.
The following a reas were chosen for their accessibility from primarily its 
structural perspective and secondly from the e a se  of obtaining chemical 
knowledge from various sources. Structures from the chosen P450 data 
source papers'" were subsequently investigated for possible trends in 
associating reaction with cytochrome P450 structural and chemical properties;
• m ass and shape of structure, number of rings:
affecting the solubility and accessibility for docking to 
cytochrome P450;
• rule of 5 reference:
Lipinski's rule of five, based on m ass, hydrogen bond donors 
and acceptors. Log P, affects the solubility and indicates the 
potential drug candidate likeness to existing drugs- or in more 
simple terms, whether a  molecule is likely to be orally bio- 
available;
• positive and negative areas of electrostatic potential and the identified 
areas of HOMO or LUMO phases:
the possibility of indicating a preferential site for the structure to 
dock onto the cytochrome P450;
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• sites for hydroxylation preferences:
any obvious structural sites observed which could be reacted;
• log P to reactions:
possibly affect the solubility of the structure;
• pKa to reactions:
the acidity of a structure could imply a preference for a certain 
type of reaction;
• distances of site to specific areas:
relating to the template theory to be discussed at a later s tage of 
the document;
3.2 Common Trends Theory
3.2.1 Mass and shape of Structure- number of rings:
The possibility of reactions being linked to structure and m ass is completely 
feasible, and has been dem onstrated in docking research of Cytochrome 
P450'''. A potential drug which is relatively large in m ass and volume, has 
limited access  to the reaction site in the Cytochrome P450 and thus would be 
greatly hindered in its docking. This would then affect the reaction rate to such 
an extent that the desired reaction might not occur at all.
Figure 3.1 CYP2C8, showing the haem-group nestled in the surrounding 
protein
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Also, the overall three-dimensional properties of the structure have a role. If 
the current conformation of a large drug is very rigid, due to multiple or fused 
ring structures, or the possible reaction sites are only accessible via a  channel 
from the outside of the protein, then once again the accessibility to the 
suggested reaction site would be reduced and the rate of reaction greatly 
impaired.
3.2.2 Rule of 5:
It is also worth noting the “rule of 5” which Lipinski published in 1997''. As a 
general rule, if a  drug adheres to these  rules it may be considered to be 
biologically active'". It can be assum ed that an orally active drug has:
• fewer than 5 hydrogen bond donors;
• fewer than 10 hydrogen bond acceptors;
• a  molecular weight less than 500 g mol. ^
• a log P value lower than 5.
3.2.3 Positive and Negative Areas of Electrostatic Potential in the HOMO 
and LUMO:
According to the definitions of the HOMO (highest occupied molecular orbital), 
LUMO (lowest unoccupied molecular orbital), a reas of positive and negative 
phases may be established.
Certain areas in the structure of a substrate could also be a  major factor in the 
site selection of a reaction'"'. With respect to the identification and generation 
of a trend pattern, a certain value of positive or negative phase  could prove 
indicative for certain types of reaction. This theory could prove more useful for 
the great variety of hydroxylation possibilities than for obvious reaction 
candidates such a s  de-ethylation, given the greater variety of extremely 
different structures which undergo hydroxylation.
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aspirin UHF Alpha MO: 35
| 9 E  positive 
negative
Figure 3.2 the 3D structure of aspirin superimposed on the electrostatic 
potential contoured at the 0.05 probability level showing the HOMO
(1) aspirin UHF Alpha MO: 36
positive
negative
Figure 3.3 the 3 0  structure of aspirin superimposed on the electrostatic 
potential contoured at the 0.05 probability level showing LUMO areas
Also, to complement the HOMO and LUMO phases, the distribution of 
electrostatic potential (ESP) throughout the structure could also indicate 
possible site preference for a reaction. A se t of structures which each p o ssess  
a certain value of electrostatic potential at a certain atom in the structure could 
prove indicative for a trend for certain types of reaction.
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Esp mapped density [aspirin Esp: 0 aspirin EieDen: 0[
0.0500-> 0.0409 
0.0409-> 0.0318 
0.0318-> 0.0227 
0.0227-> 0.0136 
0.0136-> 0.0045 
0.0045-> -0.0045 
-0.0045-> -0.0136 
-0.0136-> -0.0227 
-0.0227-> -0.0318
-0-0318-> -0.0409
-0.0409 > -0.0500
Figure 3.4 the 3D structure of aspirin showing ESP mapped density areas 
contoured at 0.05
3.2.4 Relating the value of Log P to the likelihood of reactions:
Log P, the partition coefficient, is a constant for a given compound and may 
be defined as  the ratio of concentration of the compound in the aqueous 
phase to the concentration of the compound in an immiscible solvent, 
normally octanol.
Partition Coefficient, P = [Organic] / [Aqueous]
W here [ ] = concentration
Log P= logio (Partition Coefficient)
Log P = 1 m eans 10:1 Organic: Aqueous 
Log P = 0 m eans 1:1 Organic: Aqueous 
Log P = -1 m eans 1:10 Organic: Aqueous'""
The logP values of a drug could imply a preference for a certain type of 
reaction'^. Also, the difference in the log P of a specific drug before and after 
reaction with Cytochrome P450 could prove to be a direct link with the 
reaction involved.
60
Chapter 3: Common Trends
3.2.5 Relating pKa to reactions:
Referring to the Br0nsted definitions of acids and bases, where an acid is a 
proton (H^) donor and a  base  is a  proton acceptor. The equilibrium of proton 
donation and acceptance can be re-written to represent the acidity constant 
Ka"":
HA  +  H 2 O  —  A  + H 3 O"
Keq = [thQlm
[H A ][H 2 0 ]
Ka = Keq[H20] = [ H ^ lm  
[H A ]
The pKa values of a  drug could also imply a  preference for a certain type of 
reaction. Additionally, the changes in pKg before and after reaction of drug 
structures could prove a  direct link to the reaction involved.
3.2.6 Relating number of hydrogen bond acceptors/donors to the 
likelihood of reactions:
The number of hydrogen bond acceptors and/or donors of a  drug could also 
imply a  preference for a certain type of reaction. Certain reactions might only 
occur if a  certain number of hydrogen bond acceptors and/or donors are 
available to bond to the Cytochrome P450^'.
3.2.7 Relating distances of active site to relevant structural points on the 
drug molecule:
For drugs grouped by the sam e reactions, it is possible that certain atoms, 
which are considered electronegative, may exist within 3D sp ace  at similar 
points in each example. Results and more in-depth theory on this tem plate 
idea are explained in a  later chapter.
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3.3 Method for Elucidating Common Trends
3.3.1 Mass and shape of structure- number of rings:
Mass was calculated through the appropriate function on ChemlQ2^" via a 
quick Visual Basic 6 application (Figure 3.5) created for this project for filtering 
through the chosen drugs. The results were then listed according to 
alphabetical order, their associated Cytochrome P450 and known reaction.
EAfrom unMotal 3D stiuclure lbrarjj\aspirin.mol
reactions to be flagged?
r  0  d e  éthylation (DC2H5) [5 
r  0  d e  méthylation (QCH3) |Ô 
r  N de etiolation (NC2H5) [ô 
r  N de méthylation (NCH3) {ô 
r  N Hydroxylation (NH) [p 
r  Epoxidabon (C=C) [ô 
f5> Hydroxylation (C aroQ  [4 
Iv  Aromatic Hyrioxylatlon 
Iv Methyl hydroxylation
a s p i r i n
: PREV 1 NEXT > I ^"^2
E:\from uniMotal 3D structure library\aspitin mol
E:\from uniMotal 30 structure libray\aspirin.mol Load From array
IrëxtîT
Figure 3.5 Screen capture of the specifically created Visual Basic application 
for calculating the number of hydrogen bond donors and acceptors, mass and 
three-dimensional structure for a drug
3.3.2 Positive and negative areas of ESP in the HOMO and LUMO:
The charges of every atom in a structure were observed (in electrons) and 
recorded with use of Cerius^ using QEQ (Equalisation of orbital 
electronegativity)^'". The values were then displayed in chart and table form in 
Section Ilia in the appendix.
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3.3.3 Relating number of hydrogen bond acceptors/donors:
The values of the number of hydrogen bond donors, acceptors and basic 
nitrogen atom s for each structure were calculated through the appropriate 
function on ChemlQ2 via a  Visual Basic 6 application created for this project 
for filtering through the chosen drugs. The results were then listed first 
alphabetically, then by each value and finally by known reaction.
3.3.4 Relating Log P to reactions:
The values for log P of certain structures were extracted from the chosen data 
source papers'". As the majority of the data se t drugs did not have m easured 
log P values, the entire data se t had log P calculated via the Daylight ClogP 
website in order to have a  uniform source of values to investigate'"''. The 
results were then listed alphabetically, by log P value, then ClogP value and 
finally by their known reaction.
For the comparison of log P values for before and after a reaction, the ClogP 
values were used. By using a se t of values from purely one source, 
www.Daylight.com, the ClogP values could be compared against each  other 
within the table.
3.3.5 Relating PKa to reactions:
The values for pKg of certain structures were extracted from the chosen data 
source papers'". The results were then listed alphabetically and by pKg value 
and finally by their known reaction.
3.4 Results from the Study of Common Trends
The data tables displayed in this section are coloured according to reaction. 
Presenting the data in this way allows for “at a glance” identification of 
possible trends, where reactions of one type may group together in the list. 
The key is a s  follows:
Oxygen de-ethylation Nitrogen de-ethylation Methyl Hydroxylation
Oxygen de-methylation Nitrogen de-methylation Non Aromatic Hydroxylation
Epoxidation/Misc. reactions Nitrogen hydroxylation Aromatic Hydroxylation
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3.4.1 Mass and shape of structure- number of rings:
The following tables list the data; drug name, molecular m ass of the drug (Mr) 
in g/mol., the cytochrome used to catalyse the reaction and finally the 
identified reaction associated to that particular drug and cytochrome.
Table 3.1 Selected data arranged according to the molecular mass of the drug
D r u g  N a m e M r p450 Reaction
7 - e t h o x y c o u m a r i n 1 9 0 . 2 1 1b1 0-de-ethylation
I b u p r o f e n 2 0 6 . 2 8 2c9 isobutyl oxidation
N a p r o x e n 2 3 0 . 2 6 2c9 0-demethylation
C a r b a m a z e p i n e 2 3 6 . 2 7 2c8 10,11-epoxidation
M e f e n a m i c  a c i d 2 4 1 . 2 9 2c9 3'-methyl-hydroxyiation
P h e n y t o i n 2 5 2 . 2 7 2c9 4'-hydroxylation
B e n z o ( a ) p y r e n e 2 5 2 . 3 1b1 7,8-epoxidation
B u f u r a l o l 2 6 1 . 3 6 1b1 1 '-hydroxylation
T o l b u t a m i d e 2 7 0 . 3 5 2c9 4-methyl-hydroxylation
A - n a p h t h o f l a v o n e 2 7 2 . 3 1b1 inhibitor
1 7 B - e s t r a d i o l 2 7 2 . 4 1b1 4-hydroxylation
B e n z o [ a ] p y r e n e  7 , 8 - d i o l 2 8 6 . 3 1b1 9,10-epoxidation
R e t i n o l 2 8 6 . 5 2c8
T r i m e t h o p r i m 2 9 0 . 3 2 2c8 0-demethylation
D i c l o f e n a c 2 9 6 . 1 5 2c8 4'-hydroxylation
R e t i n o i c  a c i d 3 0 0 . 4 4 2c8 4-hydroxylation
A r a c h i d o n i c  a c i d 3 0 4 . 4 6 2c8
W a r f a r i n 3 1 2 . 3 6 2c9
T i e n i l i c  a c i d 3 3 1 . 1 7 2c9 s-oxidation
P i r o x i c a m 3 3 1 . 3 4 2c9 5'-hydroxylation
R o s i g l i t a z o n e 3 5 7 . 4 6 2c8 N-demethylation
Z o p i c l o n e 3 8 8 . 8 1 2c8 N-demethylation
C e r i v a s t a t i n 4 5 9 . 5 5 2c8
T a x o l 8 5 3 . 9 2 2c8 6a-hydroxylation
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Table 3.2 Selected data arranged according to the identified reaction
D r u g  N a m e M r p450 reaction
R e t i n o l 2 8 6 . 5 2c8
W a r f a r i n 3 1 2 . 3 6 2c9
C e r i v a s t a t i n 4 5 9 . 5 5 2c8
C a r b a m a z e p i n e 2 3 6 . 2 7 2c8 10,11-epoxidation
B u f u r a l o l 2 6 1 . 3 6 1b1 1'-hydroxylation
M e f e n a m i c  a c i d 2 4 1 . 2 9 2c9 3'-methyl-hydroxylation
P h e n y t o i n 2 5 2 . 2 7 2c9 4'-hydroxylation
D i c l o f e n a c 2 9 6 . 1 5 2c8 4'-hydroxylation
1 7 B - e s t r a d i o l 2 7 2 . 4 1b1 4-hydroxylation
R e t i n o i c  a c i d 3 0 0 . 4 4 2c8 4-hydroxylation
T o l b u t a m i d e 2 7 0 . 3 5 2c9 4-methyl-hydroxylation
P i r o x i c a m 3 3 1 . 3 4 2c9 5'-hydroxylation
T a x o l 8 5 3 . 9 2 2c8 6a-hydroxylation
B e n z o ( a ) p y r e n e 2 5 2 . 3 1b1 7,8-epoxidation
B e n z o [ a ] p y r e n e  7 , 8 - d i o l 2 8 6 . 3 1b1 9,10-epoxidation
A - n a p h t h o f l a v o n e 2 7 2 . 3 1b1 inhibitor
I b u p r o f e n 2 0 6 . 2 8 2c9 isobutyl oxidation
R o s i g l i t a z o n e 3 5 7 . 4 6 2c8 N-demethylation
Z o p i c l o n e 3 8 8 . 8 1 2c8 N-demethylation
7 - e t h o x y c o u m a r i n 1 9 0 . 2 1 1b1 0-de-ethylation
N a p r o x e n 2 3 0 . 2 6 2c9 O-demethylation
T r i m e t h o p r i m 2 9 0 . 3 2 2c8 0-demethylation
T i e n i l i c  a c i d 3 3 1 . 1 7 2c9 s-oxidation
A r a c h i d o n i c  a c i d 3 0 4 . 4 6 2c8
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Table 3.3 Selected data arranged according to the cytochrome catalyst
D r u g  N a m e M r p450 reaction
7 - e t h o x y c o u m a r i n 1 9 0 . 2 1 1b1 0-de-ethylation
B e n z o ( a ) p y r e n e 2 5 2 . 3 1b1 7,8-epoxidation
B u f u r a l o l 2 6 1 . 3 6 1b1 1'-hydroxylation
A - n a p h t h o f l a v o n e 2 7 2 . 3 1b1 inhibitor
1 7 B - e s t r a d i o l 2 7 2 . 4 1b1 4-hydroxylation
B e n z o [ a ] p y r e n e  7 , 8 - d i o l 2 8 6 . 3 1b1 9,10-epoxidation
C a r b a m a z e p i n e 2 3 6 . 2 7 2c8 10,11-epoxidation
R e t i n o l 2 8 6 . 5 2c8
T r i m e t h o p r i m 2 9 0 . 3 2 2c8 O-demethylation
D i c l o f e n a c 2 9 6 . 1 5 2c8 4'-hydroxylation
R e t i n o i c  a c i d 3 0 0 . 4 4 2c8 4-hydroxylation
A r a c h i d o n i c  a c i d 3 0 4 . 4 6 2c8
R o s i g l i t a z o n e 3 5 7 . 4 6 2c8 N-demethylation
Z o p i c l o n e 3 8 8 . 8 1 2c8 N-demethylation
C e r i v a s t a t i n 4 5 9 . 5 5 2c8
T a x o l 8 5 3 . 9 2 2c8 6a-hydroxylation
I b u p r o f e n 2 0 6 . 2 8 2c9 isobutyl oxidation
N a p r o x e n 2 3 0 . 2 6 2c9 O-demethylation
M e f e n a m i c  a c i d 2 4 1 . 2 9 2c9 3'-methyl-hydroxylation
P h e n y t o i n 2 5 2 . 2 7 2c9 4'-hydroxylation
T o l b u t a m i d e 2 7 0 . 3 5 2c9 4-methyl-hydroxylation
W a r f a r i n 3 1 2 . 3 6 2c9
T i e n i l i c  a c i d 3 3 1 . 1 7 2c9 s-oxidation
P i r o x i c a m 3 3 1 . 3 4 2c9 5'-hydroxylation
3.4.2 Positive and negative areas of ESP in the HOMO and LUMO:
For the results of specific charges of atom s of selected drug substrates refer 
to the tables and graphs of these results in Section Ilia in the appendix. Within 
the section the following tables list the data; drug name, the atom number, the 
atom type, the type of bond (e.g., single, double, aromatic and single on 
aromatic -  for hydrogens) and finally the charge -  m easured in partial 
electrons.
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3.4.3 Relating Log P to reactions:
The following table lists the data: drug Name, molecular m ass of the drug (Mr) 
in g/mol., the cytochrome used to catalyse the reaction, the identified reaction 
associated to that particular drug and cytochrome, the recorded log P, log P 
variation (noted as  som e drug log P values varied in several papers) and 
finally the Clog P calculated from Daylight.com.
Table 3.4 Selected data including drug name, reaction, mass, cytochrome. 
Log P and CLog P arranged according to the reaction
T o t a l  L i s t M r p450 reaction l o g  P l o g  P  v a r y C L O G P
R e t i n o l 2 8 6 . 5 2c8 6 . 3 3 5 . 6 8 8 . 4 7 3
W a r f a r i n 3 1 2 . 3 6 2c9 1 . 6 2 8
C e r i v a s t a t i n 4 5 9 . 5 5 2c8 4 . 5 4 1 . 2 6 6
C a r b a m a z e p i n e 2 3 6 . 2 7 2c8 10,11-epoxidation 2 . 2 8 2 . 7 6 3
B e n z o ( a ) p y r e n e 2 5 2 . 3 1b1 7,8-epoxidation 6 . 3 5 6 . 1 1 8
B e n z o [ a ] p y r e n e  7 , 8 - d i o l 2 8 6 . 3 1b1 9,10-epoxidation 3 . 8 7 4 . 8 5 4
B u f u r a l o l 2 6 1 . 3 6 1b1 1'-hydroxylation 3 . 5 1 . 5 1 8
m e f e n a m i c  a c i d 2 4 1 . 2 9 2c9 3'-methyl-hydroxylation 5 . 1 2 2 . 7 4 9
D i c l o f e n a c 2 9 6 . 1 5 2c8 4'-hydroxylation 4 . 4 3 . 6 6 6
P h e n y t o i n 2 5 2 . 2 7 2c9 4'-hydroxylation 2 . 3 7 2 . 4 7 1 . 3 4 2
1 7 B - e s t r a d i o l 2 7 2 . 4 1b1 4-hydroxylation 3 . 8 6 3 . 7 8 4
R e t i n o i c  a c i d 3 0 0 . 4 4 2c8 4-hydroxylation 6 . 5 8 7 . 6 4 4
T o l b u t a m i d e 2 7 0 . 3 5 2c9 4-methyl-hydroxylation 2 . 3 4 2 . 0 4 6
P i r o x i c a m 3 3 1 . 3 4 2c9 5'-hydroxylation 1 . 5 8 0 . 1 3 3
T a x o l 8 5 3 . 9 2 2c8 6a-hydroxylation 2 . 2 8 0 , 7 3 9
A - n a p h t h o f l a v o n e 2 7 2 . 3 1b1 inhibitor 4 . 8 1 3 . 9
R o s i g l i t a z o n e 3 5 7 . 4 6 2c8 N-demethylation 2 . 4 3 0 . 9 1
Z o p i c l o n e 3 8 8 . 8 1 2c8 N-demethylation - 0 . 3 6
T r i m e t h o p r i m 2 9 0 . 3 2 2c8 O-demethylation 0 . 6 7 0 . 9 1 * 0 . 9 8 1
N a p r o x e n 2 3 0 . 2 6 2c9 O-demethylation 3 . 1 8 1 . 8 4 6
7 - e t h o x y c o u m a r i n 1 9 0 . 2 1 1b1 O-de-ethylation 2 . 3 1 . 9 6 9
T i e n i l i c  a c i d 3 3 1 . 1 7 2c9 s-oxidation 3 . 1 5 1 . 5 7 7
I b u p r o f e n 2 0 6 . 2 8 2c9 isobutyl oxidation 3 . 5 1 2 . 7 0 9
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Table 3.5 Selected data including dmg name, reaction, mass, cytochrome, 
Log P and CLog P arranged according to log P
T o t a l  L i s t M r p450 reaction l o g  P l o g  P  v a r y C L O G P
Z o p i c l o n e 3 8 8 . 8 1 2c8 N-demethylation - 0 . 3 6
T r i m e t h o p r i m 2 9 0 . 3 2 2c8 O-demethylation 0 . 6 7 0 . 9 1 * 0 . 9 8 1
P i r o x i c a m 3 3 1 . 3 4 2c9 5'-hydroxylation 1 . 5 8 0 . 1 3 3
C a r b a m a z e p i n e 2 3 6 . 2 7 2c8 10,11-epoxidation 2 . 2 8 2 . 7 6 3
T a x o l 8 5 3 . 9 2 2c8 6a-hydroxylation 2 . 2 8 0 , 7 3 9
7 - e t h o x y c o u m a r i n 1 9 0 . 2 1 1b1 O-de-ethylation 2 . 3 1 . 9 6 9
T o l b u t a m i d e 2 7 0 . 3 5 2c9 4-methyl-hydroxylation 2 . 3 4 2 . 0 4 6
P h e n y t o i n 2 5 2 . 2 7 2c9 4-hydroxylation 2 . 3 7 2 . 4 7 1 . 3 4 2
R o s i g l i t a z o n e 3 5 7 . 4 6 2c8 N-demethylation 2 . 4 3 0 . 9 1
T i e n i l i c  a c i d 3 3 1 . 1 7 2c9 s-oxidation 3 . 1 5 1 . 5 7 7
N a p r o x e n 2 3 0 . 2 6 2c9 O-demethylation 3 . 1 8 1 . 8 4 6
B u f u r a l o l 2 6 1 . 3 6 1b1 1'-hydroxylation 3 . 5 1 . 5 1 8
I b u p r o f e n 2 0 6 . 2 8 2c9 isobutyl oxidation 3 . 5 1 2 . 7 0 9
1 7 B - e s t r a d i o l 2 7 2 . 4 1b1 4-hydroxylation 3 . 8 6 3 . 7 8 4
B e n z o [ a ] p y r e n e  7 , 8 - d i o l 2 8 6 . 3 1b1 9,10-epoxidation 3 . 8 7 4 . 8 5 4
D i c l o f e n a c 2 9 6 . 1 5 2c8 4'-hydroxylation 4 . 4 3 . 6 6 6
C e r i v a s t a t i n 4 5 9 . 5 5 2c8 4 . 5 4 1 . 2 6 6
A - n a p h t h o f l a v o n e 2 7 2 . 3 1b1 inhibitor 4 . 8 1 3 . 9
M e f e n a m i c  a c i d 2 4 1 . 2 9 2c9 3'-methyl-hydroxylation 5 . 1 2 2 . 7 4 9
R e t i n o l 2 8 6 . 5 2c8 6 . 3 3 5 . 6 8 8 . 4 7 3
B e n z o ( a ) p y r e n e 2 5 2 . 3 1b1 7,8-epoxidation 6 . 3 5 6 . 1 1 8
R e t i n o i c  a c i d 3 0 0 . 4 4 2c8 4-hydroxylation 6 . 5 8 7 . 6 4 4
W a r f a r i n 3 1 2 . 3 6 2c9 1 . 6 2 8
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Table 3.6 Selected data including drug name, reaction, mass, cytochrome, log 
P and CLog P arranged according to CLog P
T o t a l  L i s t M r p450 reaction l o g  P l o g  P  v a r y C L O G P
P i r o x i c a m 3 3 1 . 3 4 2c9 5'-hydroxylation 1 . 5 8 0 . 1 3 3
R o s i g l i t a z o n e 3 5 7 . 4 6 2c8 N-demethylation 2 . 4 3 0 . 9 1
T r i m e t h o p r i m 2 9 0 . 3 2 2c8 O-demethylation 0 . 6 7 0 . 9 1 * 0 . 9 8 1
C e r i v a s t a t i n 4 5 9 . 5 5 2c8 4 . 5 4 1 . 2 6 6
P h e n y t o i n 2 5 2 . 2 7 2c9 4-hydroxylation 2 . 3 7 2 . 4 7 1 . 3 4 2
B u f u r a l o l 2 6 1 . 3 6 1b1 T-hydroxylation 3 . 5 1 . 5 1 8
T i e n i l i c  a c i d 3 3 1 . 1 7 2c9 s-oxidation 3 . 1 5 1 . 5 7 7
W a r f a r i n 3 1 2 . 3 6 2c9 1 . 6 2 8
N a p r o x e n 2 3 0 . 2 6 2c9 O-demethylation 3 . 1 8 1 . 8 4 6
7 - e t h o x y c o u m a r i n 1 9 0 . 2 1 1b1 O-de-ethylation 2 . 3 1 . 9 6 9
T o l b u t a m i d e 2 7 0 . 3 5 2c9 4-methyl-hydroxylation 2 . 3 4 2 . 0 4 6
I b u p r o f e n 2 0 6 . 2 8 2c9 isobutyl oxidation 3 . 5 1 2 . 7 0 9
M e f e n a m i c  a c i d 2 4 1 . 2 9 2c9 3'-methyl-hydroxylation 5 . 1 2 2 . 7 4 9
C a r b a m a z e p i n e 2 3 6 . 2 7 2c8 10,11-epoxidation 2 . 2 8 2 . 7 6 3
D i c l o f e n a c 2 9 6 . 1 5 2c8 4-hydroxylation 4 . 4 3 . 6 6 6
1 7 B - e s t r a d i o l 2 7 2 . 4 1b1 4-hydroxylation 3 . 8 6 3 . 7 8 4
A - n a p h t h o f l a v o n e 2 7 2 . 3 1b1 inhibitor 4 . 8 1 3 . 9
B e n z o [ a ] p y r e n e  7 , 8 - d i o l 2 8 6 . 3 1b1 9,10-epoxidation 3 . 8 7 4 . 8 5 4
B e n z o ( a ) p y r e n e 2 5 2 . 3 1b1 7,8-epoxidation 6 . 3 5 6 . 1 1 8
R e t i n o i c  a c i d 3 0 0 . 4 4 2c8 4-hydroxylation 6 . 5 8 7 . 6 4 4
R e t i n o l 2 8 6 . 5 2c8 6 . 3 3 5 . 6 8 8 . 4 7 3
T a x o l 8 5 3 . 9 2 2c8 6a-hydroxylation 2 . 2 8 0 . 7 3 9
69
Chapter 3: Common Trends
Table 3.7 Selected data including drug name, reaction, mass, cytochrome, log 
P and CLog P arranged according to mass
T o t a l  L i s t M r p450 reaction l o g  P l o g  P  v a r y C L O G P
7 - e t h o x y c o u m a r i n 1 9 0 . 2 1 1b1 O-de-ethylation 2 . 3 1 . 9 6 9
I b u p r o f e n 2 0 6 . 2 8 2c9 isobutyl oxidation 3 . 5 1 2 . 7 0 9
N a p r o x e n 2 3 0 . 2 6 2c9 O-dennethylation 3 . 1 8 1 . 8 4 6
C a r b a m a z e p i n e 2 3 6 . 2 7 2c8 10,11-epoxidation 2 . 2 8 2 . 7 6 3
M e f e n a m i c  a c i d 2 4 1 . 2 9 2c9 3'-methyl-hydroxylation 5 . 1 2 2 . 7 4 9
P h e n y t o i n 2 5 2 . 2 7 2c9 4'-hydroxylation 2 . 3 7 2 . 4 7 1 . 3 4 2
B e n z o ( a ) p y r e n e 2 5 2 . 3 1b1 7,8-epoxidation 6 . 3 5 6 . 1 1 8
B u f u r a l o l 2 6 1 . 3 6 1b1 1'-hydroxylation 3 . 5 1 . 5 1 8
T o l b u t a m i d e 2 7 0 . 3 5 2c9 4-methyl-hydroxylation 2 . 3 4 2 . 0 4 6
A - n a p h t h o f l a v o n e 2 7 2 . 3 1b1 inhibitor 4 . 8 1 3 . 9
1 7 B - e s t r a d i o l 2 7 2 . 4 1b1 4-hydroxylation 3 . 8 6 3 . 7 8 4
B e n z o [ a ] p y r e n e  7 , 8 - d i o l 2 8 6 . 3 1b1 9,10-epoxidation 3 . 8 7 4 . 8 5 4
R e t i n o l 2 8 6 . 5 2c8 6 . 3 3 5 . 6 8 8 . 4 7 3
T r i m e t h o p r i m 2 9 0 . 3 2 2c8 O-demethylation 0 . 6 7 0 . 9 1 * 0 . 9 8 1
D i c l o f e n a c 2 9 6 . 1 5 2c8 4'-hydroxylation 4 . 4 3 . 6 6 6
R e t i n o i c  a c i d 3 0 0 . 4 4 2c8 4-hydroxylation 6 . 5 8 7 . 6 4 4
W a r f a r i n 3 1 2 . 3 6 2c9 1 . 6 2 8
T i e n i l i c  a c i d 3 3 1 . 1 7 2c9 s-oxidation 3 . 1 5 1 . 5 7 7
P i r o x i c a m 3 3 1 . 3 4 2c9 5'-hydroxylation 1 . 5 8 0 . 1 3 3
R o s i g l i t a z o n e 3 5 7 . 4 6 2c8 N-demethylation 2 . 4 3 0 . 9 1
C e r i v a s t a t i n 4 5 9 . 5 5 2c8 4 . 5 4 1 . 2 6 6
T a x o l 8 5 3 . 9 2 2c8 6a-hydroxylation 2 . 2 8 0 . 7 3 9
70
Chapter 3: Common Trends
3.4.4 Relating pKg to reactions:
Table 3.8 Selected data including drug name, reaction, pKg, arranged 
according to pKa
T o t a l  L i s t p K a p a t h
D i a z e p a m 3 . 7 N - d e m e t h y l a t i o n
N a p r o x e n 4 . 1 5 O - d e m e t h y l a t i o n
M e f e n a m i c  a c i d 4 . 2 3 ' - m e t h y l - h y d r o x y l a t i o n
D i c l o f e n a c 4 . 2 2 4 ' - h y d r o x y l a t i o n
C e r i v a s t a t i n 4 . 3 2 O - d e m e t h y l a t i o n
C o t i n i n e 4 . 4 4 3 ’- h y d r o x y l a t i o n
A n i l i n e 4 . 7 4 - h y d r o x y l a t i o n
T i e n i l i c  a c i d 4 . 8 s - o x i d a t i o n
5 8 c 8 0 5 t e r t i a r y  b u t y l  o x i d a t i o n
S - w a r f a r i n 5 . 1 7 - h y d r o x y l a t i o n
R e t i n o i c  a c i d 5 . 1 2 4 - h y d r o x y l a t i o n
I b u p r o f e n 5 . 2 i s o b u t y l  o x i d a t i o n
R - i b u p r o f e n 5 . 2 i s o b u t y l  o x i d a t i o n
S - i b u p r o f e n 5 . 2 i s o b u t y l  o x i d a t i o n
L Y 3 0 7 6 4 0 5 . 4 O - d e m e t h y l a t i o n
T o l b u t a m i d e 5 . 4 3 4 - m e t h y l - h y d r o x y l a t i o n
F a d r o z o l e 6 . 1 6 8 - h y d r o x y l a t i o n
T r i m e t h o p r i m 6 . 2 O - d e m e t h y l a t i o n
P i r o x i c a m 6 . 3 5 ' - h y d r o x y l a t i o n
R o s i g l i t a z o n e 6 . 4 N - d e m e t h y l a t i o n
B e n z p h e t a m i n e 6 . 6 N - d e m e t h y l a t i o n
M o c l o b e m i d e 7 . 0 9 m o r p h o l i n e  r i n g  o x i d
O n d a n e s t r o n 7 . 7 7 - h y d r o x y l a t i o n
N i c o t i n e 8 5 ' - o x i d a t i o n
P h e n y t o i n 8 . 1 4 ' - h y d r o x y l a t i o n
S - m e p h e n y t o i n 8 . 1 N - d e m e t h y l a t i o n
H e x o b a r b i t a l 8 . 2 3 ' - h y d r o x y l a t i o n
C o d e i n e 8 . 2 O - d e m e t h y l a t i o n
C h l o r z o x a z o n e 8 . 3 6 - h y d r o x y l a t i o n
B u p r o p i o n 8 . 3 5 t - b u t y l  o x i d a t i o n
P h I P 8 . 6 9 N - h y d r o x y l a t i o n
O m e p r a z o l e 8 . 7 5 - m e t h l y  h y d r o x y l a t i o n
B u f u r a l o l 9 1 ' - h y d r o x y l a t i o n
I Q 9 . 1 8 N - h y d r o x y l a t i o n
A m i t r i p t y l i n e 9 . 4 1 0 - h y d r o x y l a t i o n
Z o p i c l o n e 9 . 4 1 N - d e m e t h y l a t i o n
I m i p r a m i n e 9 . 5 2 - h y d r o x y l a t i o n
P r o p r a n o l o l 9 . 5 4 - h y d r o x y l a t i o n
M e t o p r o l o l 9 . 6 8 O - d e m e t h y l a t i o n
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N o t r i p t y l i n e 9 . 7 3 1 0 - h y d r o x y l a t i o n
M e l Q 9 . 7 7 N - h y d r o x y l a t i o n
T a c r i n e 9 . 8 7 - h y d r o x y l a t i o n
7 - e t h o x y r e s o r u f i n 9 . 8 5 O - d e - e t h y l a t i o n
D e s i p r a m i n e 1 0 2 - h y d r o x y l a t i o n
M D M A 1 0 . 0 4 O - d e m e t h y l a t i o n
P r o g u a n i l 1 0 . 6 i s o p r o p y l  o x i d a t i o n
D e b r i s o q u i n e 1 3 . 0 1 4 - h y d r o x y l a t i o n
C a r b a m a z e p i n e n e u t r a l 1 0 , 1 1 - e p o x i d a t i o n
T e s t o s t e r o n e n e u t r a l 1 6 b - h y d r o x y l a t i o n
4 - n i t r o p h e n o l n e u t r a l 2 - h y d r o x y l a t i o n
O e s t r a d i o i n e u t r a l 2 - h y d r o x y l a t i o n
L o s i g a m o n e n e u t r a l 3 ,  4 - h y d r o x y l a t i o n
P a r a c e t a m o l n e u t r a l 3 - h y d r o x y l a t i o n
T a x o l n e u t r a l 6 a - h y d r o x y l a t i o n
M e l a t o n i n n e u t r a l 6 - h y d r o x y l a t i o n
C o u m a r i n n e u t r a l 7 - h y d r o x y l a t i o n
A f l a t o x i n  B 1 n e u t r a l 8 , 9 - e p o x i d a t i o n
M e t h o x y f l u r a n e n e u t r a l d e c h l o r i n a t i o n
C a f f e i n e n e u t r a l N - d e m e t h y l a t i o n
7 - e t h o x y - 4 - t r i f l u r o  c o u m a r i n n e u t r a l O - d e - e t h y l a t i o n
7 - e t h o x y c o u m a r i n n e u t r a l O - d e - e t h y l a t i o n
P h e n a c e t i n n e u t r a l O - d e - e t h y l a t i o n
7 - m e t h o x y r e s o r u f i n n e u t r a l O - d e m e t h y l a t i o n
1 7 B - e s t r a d i o l 4 - h y d r o x y l a t i o n
M e p h o b a r b i t a l 4 - h y d r o x y l a t i o n
M e t h a r b i t a l 4 - h y d r o x y l a t i o n
B e n z o ( a ) p y r e n e 7 , 8 - e p o x i d a t i o n
B e n z o [ a ] p y r e n e  7 , 8 - d i o l 9 , 1 0 - e p o x i d a t i o n
Q u i n i d i n e i n h i b i t i o n
A - n a p h t h o f l a v o n e i n h i b i t o r
A m i d a r o n e N - d e - e t h y l a t i o n
D i m e t h y l n i t r o s a m i n e N - d e m e t h y l a t i o n
M p t p N - d e m e t h y l a t i o n
3.4.5 Relating number of hydrogen acceptors/donors:
The following tables list the data: drug Name, the number of hydrogen bond 
acceptors, the number of hydrogen bond donors, the sum of both hydrogen 
bond donors and acceptors, the number of basic nitrogen atom s in the 
molecule and finally the reaction associated to that particular drug.
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Table 3.9 Data including drug name, reaction, number of hydrogen bond 
donors, hydrogen bond acceptors, the sum of both hydrogen bond donors and 
acceptors, the number of basic nitrogen atoms. Data arranged according to 
hydrogen bond acceptors
T o t a l  L i s t N o  H B  A C N o  H B  D N  H B  A / D N o  b a s i c  N p a t h
N o t r i p t y l i n e 0 0 1 1 0 - h y d r o x y l a t i o n
I m i p r a m i n e 0 0 2 2 - h y d r o x y l a t i o n
O e s t r a d i o i 0 2 0 2 - h y d r o x y l a t i o n
D e b r i s o q u i n e 0 3 3 4 - h y d r o x y l a t i o n
1 7 B - e s t r a d i o l 0 2 2 0 4 - h y d r o x y l a t i o n
A n a l i n e 0 2 2 1 4 - h y d r o x y l a t i o n
B e n z o ( a ) p y r e n e 0 0 0 7 , 8 - e p o x i d a t i o n
B e n z o [ a ] p y r e n e  7 , 8 - d i o l 0 2 0 9 , 1 0 - e p o x i d a t i o n
M p t p 0 0 1 N - d e m ^ y l a t i o n
T e s t o s t e r o n e 2 / 1 0 1 6 b - h y d r o x y l a t i o n
B u f u r a l o l 2 1 1 ' - h y d r o x y l a t i o n
P a r a c e t a m o l 2 1 3 - h y d r o x y l a t i o n
M e f e n a m i c  a c i d 2 1 3 ' - m e t h y l - h y d r o x y l a t i o n
R e t i n o i c  a c i d 1 0 4 - h y d r o x y l a t i o n
T a c r i n e 2 2 7 - h y d r o x y l a t i o n
I b u p r o f e n 1 0 i s o b u t y l  o x i d a t i o n
R - i b u p r o f e n 1 0 i s o b u t y l  o x i d a t i o n
B e n z p h e t a m i n e 1 / 0 1 N - d e m e t h y l a t i o n
M e l O 2 3 N - h y d r o x y l a t i o n
M e t o p r o l o l 1 0 O - d e m e t h y l a t i o n
B u p r o p i o n 2 1 t - b u t y l  o x i d a t i o n
L o s i g a m o n e 2 1 0 3 ,  4 - h y d r o x y l a t i o n
C o t i n i n e 2 0 2 3 ' - h y d r o x y l a t i o n
P h e n y t o i n 2 2 2 4 ' - h y d r o x y l a t i o n
C o u m a r i n 2 0 0 7 - h y d r o x y l a t i o n
F a d r o z o l e 2 0 3 8 - h y d r o x y l a t i o n
A - n a p h t h o f l a v o n e 2 0 0 i n h i b i t o r
S - i b u p r o f e n 2 1 1 i s o b u t y l  o x i d a t i o n
M o c l o b e m i d e 2 1 2 m o r p h o l i n e  r i n g  o x i d
S - m e p h e n y t o i n 2 1 2 N - d e m e t h y l a t i o n
I Q 2 2 4 N - h y d r o x y l a t i o n
P h e n a c e t i n 2 1 1 O - d e - e t h y l a t i o n
C e r i v a s t a t i n 2 1 O - d e m e t h y l a t i o n
C o d e i n e 2 1 1 O - d e m e t h y l a t i o n
M D M A 2 1 1 O - d e m e t h y l a t i o n
N a p r o x e n 2 1 0 O - d e m e t h y l a t i o n
5 8 c 8 0 2 1 0 t e r t i a r y  b u t y l  o x i d a t i o n
C a r b a m a z e p i n e 3 2 1 0 , 1 1 - e p o x i d a t i o n
4 - n i t r o p h e n o l 3 1 4 1 2 - h y d r o x y l a t i o n
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H e x o b a r b i t a l 3 1 2 3 - h y d r o x y l a t i o n
D i c l o f e n a c 3 2 1 4 - h y d r o x y l a t i o n
M e p h o b a r b i t a l 3 1 2 4 - h y d r o x y l a t i o n
M e t h a r b i t a l 3 1 2 4 - h y d r o x y l a t i o n
C h l o r z o x a z o n e 3 1 1 6 - h y d r o x y l a t i o n
M e l a t o n i n 3 1 2 6 - h y d r o x y l a t i o n
O n d a n e s t r o n 3 0 3 7 - h y d r o x y l a t i o n
C a f f e i n e 3 4 N - d e m e t h y l a t i o n
7 - e t h o x y c o u m a r i n 3 0 0 O - d e - e t h y l a t i o n
T o l b u t a m i d e 4 2 2 4 - m e t h y l - h y d r o x y l a t i o n
M e t h o x y f l u r a n e 4 0 0 d e c h l o r i n a t i o n
7 - m e t h o x y r e s o r u f i n 4 0 1 O - d e m e t h y l a t i o n
P i r o x i c a m 5 3 3 5 ' - h y d r o x y l a t i o n
A m i d a r o n e 5 0 1 N - d e - e t h y l a t i o n
R o s i g l i t a z o n e 5 1 3 N - d e m e t h y l a t i o n
L Y 3 0 7 6 4 0 5 1 O - d e m e t h y l a t i o n
T r i m e t h o p r i m 5 4 4 O - d e m e t h y l a t i o n
A f l a t o x i n  B 1 6 0 2 8 , 9 - e p o x i d a t i o n
7 - e t h o x y - 4 - t r i f l u r o  c o u m a r i n 6 0 0 O - d e - e t h y l a t i o n
T i e n i l i c  a c i d 6 1 0 s - o x i d a t i o n
Z o p i c l o n e 8 0 6 N - d e m e t h y l a t i o n
A m i t r i p t y l i n e 0 / 1 0 1 1 0 - h y d r o x y l a t i o n
P r o g u a n i l 0 / 1 5 5 i s o p r o p y l  o x i d a t i o n
N i c o t i n e 1 * 0 1 2 5 ' - o x i d a t i o n
D e s i p r a m i n e 1 / 0 1 1 / 2 2 - h y d r o x y l a t i o n
P r o p r a n o l o l 2 / 1 2 1 4 - h y d r o x y l a t i o n
D i a z e p a m 2 / 3 0 2 N - d e m e t h y l a t i o n
O u i n i d i n e 3 ' 2 1 2 i n h i b i t i o n
O m e p r a z o l e 5 / 6 1 3 5 - m e t h y l  h y d r o x y l a t i o n
T a x o l 6 a - h y d r o x y l a t i o n
S - w a r f a r i n 1 7 - h y d r o x y l a t i o n
D i m e t h y l n i t r o s a m i n e N - d e m e t h y l a t i o n
P h I P N - h y d r o x y l a t i o n
7 - e t h o x y r e s o r u f i n O - d e - e t h y l a t i o n
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Table 3.10 Data including drug name, reaction, number of hydrogen bond 
donors, hydrogen bond acceptors, the sum of both hydrogen bond donors and 
acceptors, the number of basic nitrogen atoms. Data arranged according to 
hydrogen bond donors
T o t a l  L i s t N o  H B  A C N o  H B D N  H B  A / D N o  b a s i c  N p a t h
N o t r i p t y l i n e 0 0 1 1 0 - h y d r o x y l a t i o n
I m i p r a m i n e 0 0 2 2 - h y d r o x y l a t i o n
B e n z o ( a ) p y r e n e 0 0 0 7 , 8 - e p o x i d a t i o n
M p t p 0 0 1 ^ J - d e m e t h y l a t i o n
C o t i n i n e 2 0 2 3 ' - h y d r o x y l a t i o n
C o u m a r i n 2 0 0 7 - h y d r o x y l a t i o n
F a d r o z o l e 2 0 3 8 - h y d r o x y l a t i o n
A - n a p h t h o f i a v o n e 2 0 0 i n h i b i t o r
O n d a n e s t r o n 3 0 3 7 - h y d r o x y l a t i o n
7 - e t h o x y c o u m a r i n 3 0 0 O - d e - e t h y l a t i o n
M e t h o x y f i u r a n e 4 0 0 d e c h l o r i n a t i o n
7 - m e t h o x y  r e s o  r u f i  n 4 0 1 0 - d e m e t h y l a t i o n
A m i d a r o n e 5 0 1 N - d e - e t h y l a t i o n
A f l a t o x i n  B 1 6 0 2 8 , 9 - e p o x i d a t i o n
7 - e t h o x y - 4 - t r i f l u r o  c o u m a r i n 6 0 0 O - d e - e t h y l a t i o n
Z o p i c l o n e 8 0 6 N - d e m e t h y i a t i o n
A m i t r i p t y l i n e 0 / 1 0 1 1 0 - h y d r o x y l a t i o n
N i c o t i n e 1 * 0 1 2 5 ' - o x i d a t i o n
D i a z e p a m 2 / 3 0 2 N - d e m e t h y l a t i o n
R e t i n o i c  a c i d 1 0 4 - h y d r o x y l a t i o n
I b u p r o f e n 1 0 i s o b u t y l  o x i d a t i o n
R - i b u p r o f e n 1 0 i s o b u t y l  o x i d a t i o n
M e t o p r o l o l 1 0 0 - d e m e t h y l a t i o n
L o s i g a m o n e 2 0 3 ,  4 - h y d r o x y l a t i o n
S - i b u p r o f e n 2 1 i s o b u t y l  o x i d a t i o n
M o c l o b e m i d e 2 2 m o r p h o l i n e  r i n g  o x i d
S - m e p h e n y t o i n 2 2 N - d e m e t h y l a t i o n
P h e n a c e t i n 2 1 O - d e - e t h y l a t i o n
C o d e i n e 2 1 0 - d e m e t h y l a t i o n
M D M A 2 1 0 - d e m e t h y l a t i o n
N a p r o x e n 2 0 O - d e m e t h y l a t i o n
5 8 c 8 0 2 0 t e r t i a r y  b u t y l  o x i d a t i o n
4 - n i t r o p h e n o ! 3 4 1 2 - h y d r o x y l a t i o n
H e x o b a r b i t a l 3 2 3 ' - h y d r o x y l a t i o n
M e p h o b a r b i t a l 3 2 4 - h y d r o x y l a t i o n
M e t h a r b i t a i 3 2 4 - h y d r o x y l a t i o n
C h l o r z o x a z o n e 3 1 6 - h y d r o x y l a t i o n
M e l a t o n i n 3 2 6 - h y d r o x y l a t i o n
R o s i g l i t a z o n e 5 3 N - d e m e t h y l a t i o n
L Y 3 0 7 6 4 0 5 O - d e m e t h y l a t i o n
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T i e n i l i c  a c i d 6 1 0 s - o x i d a t i o n
D e s i p r a m i n e 1 / 0 1 1 / 2 2 - h y d r o x y l a t i o n
Q u i n i d i n e 3 ’2 1 2 i n h i b i t i o n
O m e p r a z o l e 5 / 6 1 3 5 - m e t h y l  h y d r o x y l a t i o n
S - w a r f a r i n 1 7 - h y d r o x y l a t i o n
O e s t r a d i o l 0 2 0 2 - h y d r o x y l a t i o n
1 7 B - e s t r a d i o l 0 2 2 0 4 - h y d r o x y l a t i o n
A n a l i n e 0 2 2 1 4 - h y d r o x y l a t i o n
B e n z o [ a ] p y r e n e  7 , 8 - d i o l 0 2 0 9 , 1 0 - e p o x i d a t i o n
B u f u r a l o l 1 2 1 T - h y d r o x y l a t i o n
P a r a c e t a m o l 1 2 1 3 - h y d r o x y l a t i o n
M e f e n a m i c  a c i d 1 2 1 3 ' - m e t h y l - h y d r o x y t a t i o n
T a c r i n e 1 2 2 7 - h y d r o x y l a t i o n
M e l O 1 2 3 N - h y d r o x y l a t i o n
B u p r o p i o n 1 2 1 t - b u t y l  o x i d a t i o n
P h e n y t o i n 2 2 2 4 ' - h y d r o x y l a t i o n
I Q 2 2 4 N - h y d r o x y l a t i o n
D i c l o f e n a c 3 2 1 4 - h y d r o x y l a t i o n
T o l b u t a m i d e 4 2 2 4 - m e t h y l - h y d r o x y l a t i o n
P r o p r a n o l o l 2 / 1 2 1 4 - h y d r o x y l a t i o n
D e b r i s o q u i n e 0 3 3 4 - h y d r o x y l a t i o n
P i r o x i c a m 5 3 3 5 ' - h y d r o x y l a t i o n
T r i m e t h o p r i m 5 4 4 O - d e m e t h y l a t i o n
P r o g u a n i l 0 / 1 5 5 i s o p r o p y l  o x i d a t i o n
B e n z p h e t a m i n e 1 1 / 0 1 N - d e m e t h y l a t i o n
T e s t o s t e r o n e 1 2 / 1 0 1 6 b - h y d r o x y l a t i o n
C e r i v a s t a t i n 2 1 O - d e m e t h y l a t i o n
C a r b a m a z e p i n e 3 2 1 0 , 1 1 - e p o x i d a t i o n
C a f f e i n e 3 4 N - d e m e t h y l a t i o n
T a x o l 6 a - h y d r o x y l a t i o n
D i m e t h y l n i t r o s a m i n e N - d e m e t h y l a t i o n
P h I P N - h y d r o x y l a t i o n
7 - e t h o x y r e s o r u f i n O - d e - e t h y l a t i o n
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Table 3.11 Data including drug name, reaction, number of hydrogen bond 
donors, hydrogen bond acceptors, the sum of both hydrogen bond donors and 
acceptors, the number of basic nitrogen atoms. Data arranged according to 
number of basic nitrogen atoms
T o t a l  L i s t N o  H B  A C N o  H B D N  H B  A / D N o  b a s i c  N p a t h
B e n z o ( a ) p y r e n e 0 0 0 7 , 8 - e p o x i d a t i o n
C o u m a r i n 2 0 0 7 - h y d r o x y l a t i o n
A - n a p h t h o f i a v o n e 2 0 0 n h i b i t o r
7 - e t h o x y c o u m a r i n 3 0 0 O - d e - e t h y l a t i o n
M e t h o x y f i u r a n e 4 0 0 d e c h l o r i n a t i o n
7 - e t h o x y - 4 - t r i f I u r o  c o u m a r i n 6 0 0 O - d e - e t h y l a t i o n
R e t i n o i c  a c i d 1 0 4 - h y d r o x y l a t i o n
i b u p r o f e n 1 0 i s o b u t y l  o x i d a t i o n
R - i b u p r o f e n 1 0 i s o b u t y l  o x i d a t i o n
M e t o p r o l o l 1 0 O - d e m e t h y l a t i o n
L o s i g a m o n e 2 0 3 ,  4 - h y d r o x y l a t i o n
N a p r o x e n 2 0 O - d e m e t h y l a t i o n
5 8 c 8 0 2 0 t e r t i a r y  b u t y l  o x i d a t i o n
T i e n i l i c  a c i d 6 0 s - o x i d a t i o n
O e s t r a d i o l 0 2 0 2 - h y d r o x y l a t i o n
1 7 B - e s t r a d i o l 0 2 2 0 4 - h y d r o x y l a t i o n
B e n z o [ a ] p y r e n e  7 , 8 - d i o l 0 2 0 9 , 1 0 - e p o x i d a t i o n
T e s t o s t e r o n e 1 2 / 1 0 1 6 b - h y d r o x y l a t i o n
N o t r i p t y l i n e 0 0 1 0 - h y d r o x y l a t i o n
M p t p 0 0 N - d e m e t h y l a t i o n
7 - m e t h o x y r e s o r u f i n 4 0 O - d e m e t h y l a t i o n
A m i d a r o n e 5 0 N - d e - e t h y l a t i o n
A m i t r i p t y l i n e 0 / 1 0 1 0 - h y d r o x y l a t i o n
S - i b u p r o f e n 2 i s o b u t y l  o x i d a t i o n
P h e n a c e t i n 2 O - d e - e t h y l a t i o n
C o d e i n e 2 O - d e m e t h y l a t i o n
M D M A 2 O - d e m e t h y l a t i o n
4 - n i t r o p h e n o l 3 4 2 - h y d r o x y l a t i o n
C h l o r z o x a z o n e 3 6 - h y d r o x y l a t i o n
A n a l i n e 0 2 2 4 - h y d r o x y l a t i o n
B u f u r a l o l 1 2 1 ' - h y d r o x y l a t i o n
P a r a c e t a m o l 1 2 3 - h y d r o x y l a t i o n
M e f e n a m i c  a c i d 1 2 3 ’- m e t h y l - h y d r o x y l a t i o n
B u p r o p i o n 1 2 t - b u t y l  o x i d a t i o n
D i c l o f e n a c 3 2 4 ' - h y d r o x y l a t i o n
P r o p r a n o l o l 2 / 1 2 4 - h y d r o x y l a t i o n
B e n z p h e t a m i n e 1 1 / 0 N - d e m e t h y l a t i o n
C e r i v a s t a t i n 2 O - d e m e t h y l a t i o n
I m i p r a m i n e 0 0 2 2 - h y d r o x y l a t i o n
C o t i n i n e 2 0 2 3 ' - h y d r o x y l a t i o n
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A f l a t o x i n  B 1 6 0 2 8 , 9 - e p o x i d a t i o n
N i c o t i n e 1 * 0 1 2 5 ' - o x i d a t i o n
D i a z e p a m 2 / 3 0 2 N - d e m e t h y l a t i o n
M o c l o b e m i d e 2 2 m o r p h o l i n e  r i n g  o x i d
S - m e p h e n y t o i n 2 2 N - d e m e t h y l a t i o n
H e x o b a r b i t a l 3 2 3 - h y d r o x y l a t i o n
M e p h o b a r b i t a l 3 2 4 - h y d r o x y l a t i o n
M e t h a r b i t a i 3 2 4 - h y d r o x y l a t i o n
M e l a t o n i n 3 2 6 - h y d r o x y l a t i o n
Q u i n i d i n e 3 '2 2 i n h i b i t i o n
T a c r i n e 1 2 2 7 - h y d r o x y l a t i o n
P h e n y t o i n 2 2 2 4 - h y d r o x y l a t i o n
T o l b u t a m i d e 4 2 2 4 - m e t h y l - h y d r o x y l a t i o n
C a r b a m a z e p i n e 3 2 1 0 , 1 1 - e p o x i d a t i o n
F a d r o z o l e 2 0 3 8 - h y d r o x y l a t i o n
O n d a n e s t r o n 3 0 3 7 - h y d r o x y l a t i o n
R o s i g l i t a z o n e 5 1 3 N - d e m e t h y l a t i o n
O m e p r a z o l e 5 / 6 1 3 5 - m e t h y l  h y d r o x y l a t i o n
M e l O 1 2 3 N - h y d r o x y l a t i o n
D e b r i s o q u i n e 0 3 3 4 ' - h y d r o x y l a t i o n
P i r o x i c a m 5 3 3 5 ' - h y d r o x y l a t i o n
1 0 2 2 4 N - h y d r o x y l a t i o n
T r i m e t h o p r i m 5 4 4 O - d e m e t h y l a t i o n
C a f f e i n e 3 4 N - d e m e t h y l a t i o n
P r o g u a n i l 0 / 1 5 5 i s o p r o p y l  o x i d a t i o n
Z o p i c l o n e 8 0 6 N - d e m e t h y l a t i o n
D e s i p r a m i n e 1 / 0 1 1 / 2 2 - h y d r o x y l a t i o n
L Y 3 0 7 6 4 0 5 1 O - d e m e t h y l a t i o n
S - w a r f a r i n 1 7 - h y d r o x y l a t i o n
T a x o l 6 a - h y d r o x y l a t i o n
D i m e t h y l n i t r o s a m i n e N - d e m e t h y l a t i o n
P h I P N - h y d r o x y l a t i o n
7 - e t h o x y r e s o r u f i n O - d e - e t h y l a t i o n
3.4.6 Identifying differences in CiogP values for structures before and 
after a reaction:
The following tables list the data: Drug Name, the value of Clog P, the 
reaction involved. The final fourth column shows the difference between the 
two values for ClogP given by the before (e.g. “aspirin”) and after (e.g. 
“aspirin+1”) reaction structures.
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E p o x id a t io n
C a r b a m a z e p i n e 2 . 7 6 3 1 0 , 1 1 - e p o x i d a t i o n
C a r b a m a z e p i n e + 1 0 . 1 8 5 1 0 , 1 1 - e p o x i d a t i o n 2 . 5 7 8
B e n z o ( a ) p y r e n e 6 . 1 1 8 7 , 8 - e p o x i d a t i o n
B e n z o [ a ] p y r e n e  7 , 8 - d i o l 4 . 8 5 4 9 , 1 0 - e p o x i d a t i o n 1 . 2 6 4
B e n z o [ a ] p y r e n e  7 , 8 - d i o l + 1 3 . 5 9 6 9 , 1 0 - e p o x i d a t i o n 1 . 2 5 8
A f l a t o x i n  B 1 - 0 . 4 3 8 8 , 9 - e p o x i d a t i o n
A f l a t o x i n  B 1 + 1 - 2 . 3 9 2 8 , 9 - e p o x i d a t i o n 1 . 9 5 4
O x id a tio n
N i c o t i n e 0 . 8 8 3 5 ' - o x i d a t i o n
N i c o t i n e + 1 0 . 2 1 7 5 ' - o x i d a t i o n 0 . 6 6 6
I b u p r o f e n 2 . 7 0 9 i s o b u t y l  o x i d a t i o n
l b u p r o f e n + 1 a 1 . 6 9 2 i s o b u t y l  o x i d a t i o n 1 . 0 1 7
l b u p r o f e n + 1 b 1 . 6 9 2 i s o b u t y l  o x i d a t i o n 1 . 0 1 7
P r o g u a n i l 0 . 5 5 4 i s o p r o p y l  o x i d a t i o n
P r o g u a n i l + 1 a - 0 . 4 4 8 i s o p r o p y l  o x i d a t i o n 1 . 0 0 2
P r o g u a n i l + 1 b - 0 . 4 4 8 i s o p r o p y l  o x i d a t i o n 1 . 0 0 2
T i e n i l i c  a c i d 1 . 5 7 7 s - o x i d a t i o n
T i e n i l i c  a c i d + 1 0 . 0 5 8 s - o x i d a t i o n 1 . 5 1 9
B u p r o p i o n 3 . 0 5 8 t - b u t y l  o x i d a t i o n
B u p r o p i o n + 1 a 1 . 8 2 9 t - b u t y l  o x i d a t i o n 1 . 2 2 9
B u p r o p i o n + 1 b 1 . 8 2 9 t - b u t y l  o x i d a t i o n 1 . 2 2 9
N - D e - e t h / m e t h y l a t i o n
A m i d a r o n e 7 . 9 9 9 N - d e - e t h y l a t i o n
A m i d a r o n e + 1 a 6 . 8 7 7 N - d e - e t h y l a t i o n 1 . 1 2 2
A m i d a r o n e + 1 b 6 . 8 7 7 N - d e - e t h y l a t i o n 1 . 1 2 2
B e n z p h e t a m i n e 4 . 3 8 2 N - d e m e t h y l a t i o n
B e n z p h e t a m i n e + 1 3 . 9 1 6 N - d e m e t h y l a t i o n 0 . 4 6 6
C a f f e i n e - 0 . 2 6 2 N - d e m e t h y l a t i o n
C a f f e i n e + 1 - 1 . 2 7 6 N - d e m e t h y l a t i o n 1 . 0 1 4
D i a z e p a m 1 . 6 8 8 N - d e m e t h y l a t i o n
D i a z e p a m + 1 0 . 8 5 6 N - d e m e t h y l a t i o n 0 . 8 3 2
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M p t p 2 . 7 8 9 N - d e m e t h y l a t i o n
M p t p + 1 2 . 3 4 3 N - d e m e t h y l a t i o n 0 . 4 4 6
R o s i g l i t a z o n e 0 , 9 1 N - d e m e t h y l a t i o n
R o s i g l i t a z o n e + 1 0 . 6 6 7 N - d e m e t h y l a t i o n 0 . 2 4 3
S - m e p h e n y t o i n 1 . 6 6 N - d e m e t h y l a t i o n
S - m e p h e n y t o i n + 1 0 . 8 3 2 N - d e m e t h y l a t i o n 0 . 8 2 8
Z o p i c l o n e 2 . 1 3 3 N - d e m e t h y l a t i o n
Z o p i c l o n e + 1 1 . 1 7 2 N - d e m e t h y l a t i o n 0 . 9 6 1
M D M A 1 . 8 5 3 N - d e m e t h y l a t i o n
M D M A + 1 - 1 . 5 3 5 N - d e m e t h y l a t i o n 3 . 3 8 8
I Q - 0 . 7 4 3 N - h y d r o x y l a t i o n
I Q + 1 - 5 . 4 9 ‘? N - h y d r o x y l a t i o n 4 . 7 5 6
M e l Q 2 . 2 4 3 N - h y d r o x y l a t i o n
M e l Q + 1 2  3 9 N - h y d r o x y l a t i o n - 0 . 1 4 7
P h I P 2 . 4 : ' ' " N - h y d r o x y l a t i o n
P h l P + 1 2 6 2 9 N - h y d r o x y l a t i o n - 0 . 1 4 7
O - d e - e t h y l a t i o n
7 - e t h o x y - 4 - t r i f l u r o  c o u m a r i n 2 . 1 1 2 O - d e - e t h y l a t i o n
7 - e t h o x y - 4 - t r i f l u r o  c o u m a r i n + 1 1 . 0 0 7 O - d e - e t h y l a t i o n 1 . 1 0 5
7 - e t h o x y c o u m a r i n 1 . 9 6 9 O - d e - e t h y l a t i o n
7 - e t h o x y c o u m a r i n + 1 0 . 8 6 4 O - d e - e t h y l a t i o n 1 . 1 0 5
7 - e t h o x y r e s o r u f i n 2 . 1 6 1 O - d e - e t h y l a t i o n
7 - e t h o x y r e s o r u f i n + 1 0 . 5 2 4 O - d e - e t h y l a t i o n 1 . 6 3 7
P h e n a c e t i n 1 . 7 1 6 O - d e - e t h y l a t i o n
P h e n a c e t i n + 1 0 . 4 1 7 O - d e - e t h y l a t i o n 1 . 2 9 9
O - d e m e t h y l a t i o n
7 - m e t h o x y r e s o r u f i n 1 . 0 3 9 O - d e m e t h y l a t i o n
7 - m e t h o x y r e s o r u f i n + 1 0 . 3 9 2 O - d e m e t h y l a t i o n 0 . 6 4 7
C o d e i n e 1 . 2 6 2 O - d e m e t h y l a t i o n
C o d e i n e + 1 0 . 8 5 6 O - d e m e t h y l a t i o n 0 . 4 0 6
M e t o p r o l o l 1 . 4 8 6 O - d e m e t h y l a t i o n
M e t o p r o l o l + 1 0 . 7 7 O - d e m e t h y l a t i o n 0 . 7 1 6
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N a p r o x e n 1 . 8 4 6 O - d e m e t h y l a t i o n
N a p r o x e n + 1 1 . 2 6 O - d e m e t h y l a t i o n 0 . 5 8 6
T r i m e t h o p r i m 0 . 9 8 1 O - d e m e t h y l a t i o n
T r i m e t h o p r i m + 1 a 0 . 5 4 6 O - d e m e t h y l a t i o n 0 . 4 3 5
T r i m e t h o p r i m + 1 b 0 . 6 4 6 O - d e m e t h y l a t i o n 0 . 3 3 5
T r i m e t h o p r i m + 1 c 0 . 5 4 6 O - d e m e t h y l a t i o n 0 . 4 3 5
3.5 Common Trends Identified so Far
As mentioned, drugs may be introduced into a patient in a great variety of 
ways, such as  oral, intravenous, inhalation etc. Because of this extremely 
diverse se t of points of origin for the drug transformation and to the sheer 
volume of numbers of drugs available the spectrum w as reduced to those 
noted in the OSAR papers of Lewis which concentrate on those drugs which 
are taken orally and activated in the liver by the cytochrome P450. This also 
leads us to a selection of data which can be referred to without the problems 
of contradicting evidence between sources such as  research papers and 
company files. The data retrieved so far is continually being examined and 
applied as  more potential ideas and more fields of data are added for 
crossover trends occur.
On first examining the data, the most common reaction for substrates 
involving cytochrome P450 is hydroxylation. This is probably because 
hydroxylation seem s the least difficult change for a structure to undertake as  
very little or nothing needs to be cleaved from the structure. Although 
hydroxylation is the most common reaction, the great variety of substrates 
which undergo hydroxylation do not provide much indication as  to the reason 
why the reaction occurs. Less common reactions such as  oxygen based dé­
éthylation (O-de-ethylation) and nitrogen based déméthylation (N- 
demethylation) although appearing much less in the sampled data than 
hydroxylation reactions, provide a narrower and more exclusive field of data to
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examine and a  greater possibility of finding a trend from the gathered data 
and results.
Currently the reasons for a certain selectivity for each reaction are still elusive 
which indicates that there is more scope for continued research. Subsequent 
trends will hopefully em erge through more example structures and reactions 
discovered through further examination of individual and multiple se ts  of 
information.
Examining the results for reactions linked to molecular m ass and identified 
CYP450 yields no obvious immediate trend. By m ass alone the reaction 
selection appears to be random. This is not entirely unexpected given the 
diversity of drug structures. On closer examination of the identified 
cytochrome of a  reaction, it w as noted that:
Both of the methyl hydroxylation reactions are catalysed by cyp2c9 
Both of the noted epoxidation reactions are catalysed by cyp1b1 
Two of the nitrogen based déméthylation reactions and one of the 
oxygen based déméthylation are catalysed by c28 
The remaining oxygen déméthylation is 2c9
Given that these  are only a  few exam ples per reaction, and the fact that the 
Cytochromes are well known for their ability to exhibit polymorphism, 
assigning reactions according to cytochrome alone is unwise.
When comparing m ass with cytochrome identification the following w as 
observed:
• Those reactions catalysed by cyp1b1 act on structures with weights 
between -1 9 0  to 287 g/mol. These include epoxidation, O de-ethylation 
and hydroxylation
• Those reactions catalysed by cyp2c8 act on the structures with weights 
between -236  to 854 g/mol. These include epoxidation, O 
déméthylation, N déméthylation and hydroxylation
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• Those reactions catalysed by cyp2c9 act on the structures with weights 
between -206  to 332 g/mol. These include O déméthylation, methyl 
hydroxylation, hydroxylation and oxidation
• Structures w hose reaction is Methyl hydroxylation ; m ass -  241 -  271 
g/mol
• Structures w hose reaction O déméthylation; m ass -230-291 g/mol
• Structures w hose reaction N déméthylation; m ass -357-389 g/mol
• Structures w hose reaction hydroxylation; m ass -261 -  854 g/mol
• Structures w hose reaction epoxidation; m ass -236-287 g/mol
Examining the results for reactions linked to HOMO/LUMO and possible site 
of reaction identification due to specific atomic charge, the following five drugs 
had every atom numbered, identified and charge recorded, with the identified 
site atom of reaction highlighted. These five structures were selected because  
of their frequency in drug metabolism literature and their variety of three 
dimensional structure with respect to each  other.
/  \
OH
A spirin
\
N
CH.
N
/
Caffeine
-OH
NH
HgC
OH
Warfarin
Diclofenac
OH
Ibuprofen
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Charges on site atom (m easured a s  partial electrons):
• Ibuprofen -0.4220,-3.959 oxidation
• Aspirin -0.0174, -0.0183 aromatic hydroxylation/oxidation
• Caffeine -0.4062, -0 .3903, -0.3960 N déméthylation
• Diclofenac -0.1093, -0.1040 aromatic hydroxylation
• Warfarin -0.1324, -0.1547, -0.665 and on far ring -0 .1072
Aromatic hydroxylation
The charges on the identified carbon atom s for oxidation in Ibuprofen do 
stand apart from the rest of the other potential reaction sites. Their partial 
charge value appears to be approximately -0 .4 0  electrons (e). Unfortunately, 
no other oxidation substrates were m easured at the time for comparison.
On considering the charges on the selected nitrogen atom for nitrogen 
déméthylation in caffeine one site does not stand apart from the rest of the 
other potential reaction sites. The charge value appears to be approximately -  
0.40e, similar to the other methyl bearing nitrogen atom s which each have a 
charge of -0.39e. Unfortunately, no other nitrogen déméthylation substrates 
were m easured at the time for comparison.
The charges on the identified carbons for aromatic hydroxylation of aspirin do 
stand apart from the rest of the other potential reaction sites. Their charge 
value appears to be approximately -0 .0 1 8e.
The charges on the identified carbons for aromatic hydroxylation of Diclofenac 
also appear somew hat individual from the other immediate surrounding 
potential reaction sites, but when applied to the entire molecule, three other 
potential sites are identified, with the carbons of the sam e type (e.g. aromatic) 
and in similar surroundings. Their charge value appears to be approximately -  
O .lle .
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The charges on the identified carbons for aromatic hydroxylation of Warfarin 
do not stand out at all from the rest of the potential reaction sites. W hen the 
specific charge theory is applied to the entire molecule, at least five other 
potential sites are identified, with the carbons of the sam e type (e.g. aromatic) 
and in similar surroundings. Their charge value appears to be approximately 
-0.13e.
On comparison of the three aromatic hydroxylation substrates, none of the 
identified charges can be used on another molecule. The site charges are 
obviously drug structure, and not reaction type, specific.
Examining the results for reactions linked to Log P, ClogP and identified 
cytochrome yields no obvious trend. By Log P alone, there is no evidence of 
any trend. Nor is there evidence of any trend when examining the ClogP 
results. However on closer inspection of the change in ClogP values of before 
and after reaction structures, the following observations were recorded:
R eaction Min C logP Max ClogP ACIogP (m ax -  min)
Epoxidation 1.26 - 2.58 1.32
Oxidation 0.66 - 1.52 0.85
N déméthylation 0.24 - 3.39 3.15
N hydroxylation -0.15 - 4.76 4.90
0  de-ethylation 1.11 - 1.64 0.53
0  déméthylation 0.34 - 0.72 0.38
Table 3.12 Recorded ClogP values for reactions, stating the maxima recorded 
ClogP from both before and after metabolism structures, minima recorded 
ClogP from both before and after metabolism structures and range between 
the maxima and minima values
It can be seen  that for the few structures per reaction example in our test set, 
the change in ClogP values have kept to fairly similar values. Epoxidation 
reactions show that a drop in ClogP of approximately 1 .3 -  2.5 is expected.
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As well as  O de-ethylation reactions might be expected to show a drop of 
approximately 1 .1 -1 .6 5 . Although these  results exhibit slight trends, it must 
be noticed that this pattern does not apply to N hydroxylation or N 
déméthylation reactions as  the range in ClogP differences are just too great.
In order to try to clarify the slight em ergence of a possible trend, the change in 
ClogP (A ClogP) w as plotted against the original m ass of the structure (Figure 
3.6). There appears to be som e clustering by O déméthylation substrates and 
by the oxidation substrates. However no obvious trend can be established 
from this chart alone.
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♦  N hydroxy lation  
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♦  0 -D e m e th y la t io n
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d e l t a  C L o g P
Figure 3.6 Plot of A ClogP against molecular mass
Examining the results for reactions linked to pKa, yields no obvious immediate 
trend. By pKa alone the reaction selection appears to be random, though this 
is not entirely unexpected given the diversity of drug structures. Cross- 
referencing of data of reaction, ClogP, pKa and molecular weight still proves 
no trend. However, future studies may be able to manipulate the data by 
applying other mathematical tools such as  exponentials, or alternative
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methods like OSAR to produce more distinct trends. Suggested courses of 
action could be to incorporate more information into the database  as  bigger 
populations may show previously hidden trends.
Examining the results for reactions linked to the quantities of hydrogen bond 
acceptors, hydrogen bond donors and basic nitrogen atom s in the structure, 
yields no obvious immediate trend. By each  quantity alone the reaction 
selection appears to be random, again this is not entirely unexpected given 
the diversity of drug structures.
Although all these  individual trend attem pts appear to be resulting in null 
results, they are all part of Lipinski’s  rule of 5. That rule proves that united, all 
these  individual components may indicate the potential for a  particular 
structure to becom e a successful drug. With that in mind, it is not 
unreasonable to expect the information gained from physical and chemical 
changes in a structure upon reaction to contain the reasoning a s  to why that 
specific reaction occurred.
3. 6 Common Trend Conclusion
In conclusion, the m ost common reactions for inhibitors involving cytochrome 
P450 are hydroxylation of a methyl group or benzene ring and déméthylation. 
The reasons for this selectivity are still being researched and hopefully a trend 
will em erge through examination of more example structures.
Factors which may affect the preference for the site of attack on the drug 
structure with interaction to P450 may include the nucleophilicity of the site, 
potential charge, and the electron distribution around the structure and steric 
factors. The increasing importance of Log P and pKa of th ese  molecules in 
reactions to cytochrome P450 shows definite potential for use  for evolving a 
trend for predictive metabolism methods. The fundamental principle of 
hydrophilicity must not be forgotten for the accessibility of the drug to the 
patient, nor the possibility of size, hindering access  to the cytochrome P450.
87
Chapter 3: Common Trends
The possibility of association of three-dimensional structure to specific 
reactions through structural tem plates is a factor about to be explored.
Continued research is to be undertaken quantitatively with recent acquisitions 
of cytochrome P450 papers obtained though Lewis (Molecular toxicology 
group, School of Biomedical and Molecular Science) and trends relating to 
structure and various numerical data, QSAR and more recently with the 
discovery of structural templates^’''.
* http://www.netsci.org/Science/Compchem/feature 19.html Accessed Sept 2006
“ K K Chohan, S. W. Paine, N. J. Waters, Current topics in Medicinal Chemistry, Vol. 6 (15), 1569-
78, “Quantitative structure activity relationships in drug metabolism”
“ D. Lewis Paper list:
D. F. V. Lewis, Archives of Biochemistry and Biophysics, Vol. 409 (1), 32-44,2003, “Essential 
requirements for substrate binding affinity and selectivity toward human cyp2 family enzymes”
D. F, V, Lewis, B. G. Lake, M. Dickens, P. S. Goldfarb, Toxicology in Vitro, Vol. 17,179-190,2003, 
“Homology modelling o f CYP2A6 based on CYP2C5 crystallographic template: enzyme-substrate 
interactions and QSARs for binding affinity and inhibition”
D. F. V. Lewis, Elizabeth M. J. Gillam, Steven A. Everett, Tsutomu Shimada, Chemico-Biological 
Interactions, Vol. 145,281-295,2003, “Molecular modelling of human CYPIBI substrate interactions 
and investigation o f allelic variant effects on metabolism”
D. F. V. Lewis, B. G. Lake, M. G. Bird, G. D. Loizou, M. Dickens, P. S. Goldfarb, Toxicology in 
Vitro, Vol. 17,93-105,2003, “Homology modelling of human CYP2E1 based on CYP2C5 crystal 
structure: investigation of enzyme-substrate and enzyme inhibitor interactions”
D. F. V. Lewis, Brian G. Lake, Maurice Dickens, Peter S. Goldfarb, Drug Metabolism and Drug 
Interactions, Vol. 19 (2), 115-135,2002, “Molecular modelling of CYP2B6 based on homology with 
the CYP2C5 Crystal structure: analysis of enzyme-substrate interactions”
D. F. V. Lewis, Maurice Dickens, Brian G. Lake, Peter S. Goldfarb, Drug Metabolism and Drug 
Interactions, Vol. 19 (4), 257-285,2003, “Investigation of enzyme selectivity in the human CYP2C 
subfamily: homology modelling of CYP2C8, CYP2C9 and CYP2C19 fi*om the CYP2C5 
crystallographic template”
D. F. V. Lewis, Maurice Dickens, Brian G. Lake, Peter S. Goldfarb, Drug Metabolism and Drug 
Interactions, Vol. 19 (3), 189-210,2003,“A molecular model o f CYP2D6 constructed by the 
homology with the CYP2C5 crystallographic template: investigation of enzyme-substrate interactions”
D. F. V. Lewis, B. G. Lake, M. Dickens, Y. -F. Ueng, P. S. Goldfarb, Xenobiotica, Vol. 33 (3), 239- 
254,2003, “Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template 
structure”
D. F. V. Lewis, “Toxicology in Vitro”, Vol. 18,89-97,2004, “Quantative structure-activity 
relationships (QSARs) for substrates of human Cytochromes P450 CYP2 family enzymes”
D. F. V. Lewis, Current Drug Metabolism, Vol. 4,331-340,2003, “On the estimation of binding 
affinity (AGbind) for Human P450 substrates (based on K^and Kd Values)
88
Chapter 3: Common Trends
s. s. Ericksen, G. D. Szklarz, Journal of biomolecular Structure and dynamics, Vol. 23 (3), 243-
56, “Regiospecificity of human cytochrome p450 lA l mediated oxidations: the role of steric effects”
 ^C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, Advanced Drug Delivery Reviews, Vol. 
23,3-25,1997, “Experimental and computational approaches to estimate solubility and permeability in 
drug discovery and development settings”
^ http://www.acdlabs.com/products/phys_chem_lab/logp/ruleof5.html Accessed May 2006
^  K. K. Chohan, S. W. Paine, J. Mistry, P. Barton, A. M. Davis, Journal of medicinal chemistry. 
Vol. 48 (16), 5151-61,2005, “A rapid computational filter for cytochrome P450 1A2 inhibition 
potential of compound libraries”
http://www.raell.demon.co.uk/chem/logp/logppka.html Accessed Nov 2005
^  D. F. Lewis, M. N. Jacobs, M. Dickins, Drug Discovery Today, Vol. 9 (12), 530-7,2004, 
“Compound lipophilicity for substrate binding to human P450s in drug metabolism”
* http://enzyme.ucd.ie/Science/pKa/pKa_introduction Accessed May 2006
^ S. Ekins, G. Bravi, J. H. Wikel, S. A. Wrighton, The Journal of Pharmacology and experimental 
therapeutics. Vol. 291 (1), 424-33,1999, “Three-dimensional-quantitative structure activity 
relationship analysis o f cytochrome P-450 3a4 substrates”
^  http://www.idbs.com/chemiq/ Accessed May 2006
Cerius2, Simulation tools. User’s reference, 116-117
J. Rodrigo, M. Barbany, H. Gutiérrez-de-Teran, N. B. Centeno, M. de-Caceres,
C. Dezi, F. Fontaine, J. J. Lozano, M. Pastor, J. Villa and F. Sanz, Journal Brazilian Chemistry 
Soceity, Vol. 13 (6), 795-799,2002, “Comparison of biomolecules on the basis o f molecular 
interaction potentials”
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CHAPTER 4 Template Theory 
4.1 Template Introduction
In the previous chapter an attempt has been m ade to explain the reaction 
behaviour of a drug by reference to its physical structure and chemical 
properties. Following on from the common trends explained in Chapter 3, this 
next chapter will endeavour to find the similar features between se ts  of 
structures, grouped by reaction, which cause  that reaction to occur. To 
simplify the situation, in order for a  drug to be catalysed by an enzyme, the 
drug m ust “fit” into an active site on the enzym e before a  reaction may occur. 
Therefore, it is logical to assum e that drugs that have similar reactions would 
show som e form of structural similarity.
Recent research' has suggested that reactions may be linked to specific atom 
locations in 3D space {i.e. similar to a  reaction template). This w as concluded 
after several biologically similar cyp1a2 substrates were modelled and their 
molecular interaction properties (MIR) were calculated. These molecules 
possessed  highly attractive molecular electrostatic potentials (MEP) a reas  at 
distances approximately 2.2-3.1Â and 6.7-7.5Â from the group to be oxidized'. 
It has also been suggested in specific cytochrome CYP3A4 research", that the 
reaction drug p o ssesses  one or more hydrophobic regions which could be key 
to linking the overall structure of a drug to the reaction in which it participates.
4.2 Template Theory
The preliminary idea behind template theory w as extracted from the paper 
“Comparison of Biomolecules on the Basis of Molecular Interaction Potentials” 
submitted by the Research Group on Biomedical Informatics from the 
University of Pompeu (Barcelona)'. In this paper, a  few selected molecules 
were submitted to investigation by their molecular interaction potential (MIP). 
The MIP for each structure w as generated by specific software known as  
“GRID”. The conclusion of this investigation of th ese  several biologically
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similar cyp1a2 substrates after being modelled and their MIP calculated, was 
that these  molecules possessed  highly attractive MEP areas at distances of 
approximately 2.2-3.1Â and 6.7-7.5Â from the group to be oxidized. By 
calculating the MIP distribution, or the location of highly electronegative areas 
within the molecule, the necessary  “tem plate” em erges, which a  structure 
m ust possess  in order to be catalysed by an enzym e in a certain reaction.
From Figure 4.1, we can see  that the “tem plate” points of interest are located 
at electronegative atom s that lie in the structure a t certain points. The 
molecules in Figure 4.1 are not grouped by any particular reaction other than 
each m em ber being cyp1a2 substrates. For example, caffeine undergoes 
nitrogen de-methylation, MelQ undergoes nitrogen hydroxylation and 7- 
ethoxyresorufin and Phenacetin undergoes oxygen de-ethylation.
As discussed in the common trends chapter, there w as no definite trend for 
reactions linked to a specific cytochrome P450 member. Hence, for the 
selected molecules in Figure 4.1, the likelihood that this template alone can 
predict whether or not all structures with similar situated electronegative 
atom s will react with cyp1a2 is small.
The initiative to associate specific reactions to the cytochromes is still 
relatively new research, and the cytochrome specific template is hinted at in 
the paper “Pharmacophore and Three Dimensional Quantitative Structure 
Activity Relationship Methods for Modelling Cytochrome P450 Active S ites” 
submitted by Etkins et a/.'". This paper sum m arises the findings of several 
other papers that have approached the possibility of structural distances of 
site to MIP areas for each cytochrome.
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HoC-
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H3C
Phenacetin
HoC
7-ethoxyresorufin
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HlC- -N :0
Caffeine
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/  V / /
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Enoxacin
<
P
OH
Figure 4.1 The structures used in the preliminary template extracted from 
Rodrigo et at. The Red areas indicate the sites of reaction; the green areas 
indicate the MIP minima that define a common template
In fact the approach of pharm acophore mapping has been examined in a 
number of studies and several computer algorithms e.g GASP"', DISCO'' and 
GALAHAD''" have been developed. All adopt a  similar approach in that each 
takes a se t of molecules with som e observed activity and tries to identify 
common geometric features in them. The following summary table 
sum m arises the relevant and applicable information from the Etkins'" paper:
92
Chapter 4: Template Theory
CYP Key features of Pharmacophore Reference
1A2 • 2 positive potentials and 2 negative 
potentials are required for quinoline inhibitors
• Planar molecules with small volume to 
surface area are potent inhibitors.
Fuhr et al. 1993 
Lee et al. 1998 
Lozano et al. 2000
2B6 • Substrates posses at least 3 hydrophobes 
and 1 hydrogen bond acceptor.
Etkins et al. 1999
2C9 • Hydrogen bond donor 7Â from site of 
metabolism.
• Distance between hydroxylation site and 
anionic site is 7.8Â. There is a  hydrophobic 
zone between the hydroxylation site and the 
cationic site on the protein.
• Favourable interactions occur when 
substrate has a partial negative charge 10Â 
from the oxidation site with a second position 
of favoured negative charge on the substrate 
6Â from the oxidation site.
Jones et al. 1996 
Mancy et al. 1995 
Rao et al. 2000
2D6 • Substrates possess  a basic nitrogen at either 
5Â or 7Â from the site of oxidation.
• Substrates posses a carboxylate group 
within the protein responsible for 5Â or 7Â 
between the basic nitrogen atom and the site 
of oxidation.
Wolff ef a/. 1985 
Meyer et al. 1986 
Islam et al. 1991 
Koymans et al. 
1992
3A4 • Substrate model includes hydrogen bond 
acceptor atom 5.5Â to 7.8Â from the site of 
metabolism and 3Â from the oxygen 
molecule associated with the haem.
• Inhibitor pharm acophores include 3 
hydrophobes at distances of 5.2Â to 8.8Â 
from a hydrogen bond acceptor, 3 
hydrophobes at distances of 4.2Â to 7.1Â
Lewis et al. 1996 
Ekins etal. 1999
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from a hydrogen bond acceptor and an 
additional 5.2Â from another hydrogen bond 
acceptor, or one hydrophobe at distances 
from 8.1Â to 16.3Â from the 2 furthest of 3 
hydrogen bond acceptors.
Substrate pharm acophore possessed  2 
hydrogen bond acceptors, one hydrogen 
bond donor and one hydrophobic region.
It can be seen  from this information that attem pts to quantify the reactions of 
cytochromes are still selectively enzym e based, a s  opposed to reaction 
based. In order for a  specific reaction to occur, it is obvious that the structure 
must first possess  the key reaction atom s for that reaction, it is useless to try 
to predict the occurrence of a  nitrogen de-methylation reaction if the drug 
does not possess  nitrogen with a methyl group in the first place.
By approaching the problem from grouping the structures by known reactions 
rather than according to the known cytochrome catalyst, and by identifying the 
functional groups of a  molecule, a  reaction specific template might be 
discovered and potentially refined alongside other chemical properties.
4.3 Template Experimental
The range of molecules used in the test se t are those which appear in the 
Cytochrome P450 Papers by Lewis'"' from which the previous data were 
accumulated and used. The aim w as to correlate any structural findings with 
other numerical properties, a s  well a s  using a  generic molecule se t that is 
composed of structures which were not specifically chosen in order to 
conform to the theory. The test se t com prises 232 files, 52 of which have 
identified reactions and data associated to a cytochrome P450 m em ber and 
can be divided a s  such:
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By reaction: 
Epoxidation 
Methyl Hydroxylation 
Oxidation 
N De Ethylation 
N De Méthylation 
N Hydroxylation 
O De Ethylation 
O De Méthylation 
Hydroxylation
3
3
7 
1
8 
3 
3 
5
19 (aromatic and non-aromatic)
Bv Cytochrome:
CYP1A2
CYP1B1
CYP2C19
CYP2C8
CYP2C9
14
6
12
10
10
All the structure models were created and minimised in ArgusLab'"" using the 
Hamiltonian UFF method. The distance between atom s w as m easured using 
IDBS ChemlQ'^ software. ChemlQ w as integrated and used through a  C++ 
program written specifically for this work to m easure from the site of reaction 
(entered manually by the user) and electronegative atom s (namely any atom s 
which w as not carbon or hydrogen). The program returned 2 text files: first 
recording all distances between all atom s in the molecule, the second 
recording all distances between the site atom and all other atom s in the 
molecule, exam ples of the distances returned are in Table 4.1.
Conformational analysis at this stage w as not considered because  of the large 
amount of extra data it would generate.
Using these  distances from each  molecule and grouping them by reaction, 
common distances were drawn up, an example of the results of which are 
recorded in Table 4.2. The maximum and minimum m easured distances were 
recorded and a  “central” value established (a rough m ean value) to be sought
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when looking for the likelihood of reaction in 'unknown' molecules. This 
distance w as found to vary by ca. +1Â within the data set. The maximum and 
minimum values were then subjected to a reasonable variation (e.g. if the 
maximum recorded distance w as 5.75Â, then the programmed distance would 
be 6Â) either side of the recorded distances to ensure proper distance 
“capturing” for the program prediction method.
The program prediction method involved using these  raw “tem plates” for each 
reaction alongside fragment recognition. The software was programmed to 
first identify the reaction being searched for by fragment identification, e.g. If 
the search w as to be for an N déméthylation reaction, the software would first 
search and map any occurrences of “NCH3”. Then, once found, the potential 
site for reaction w as m easured against all non-carbon and non-hydrogen 
atom s in the molecule. If the correct distances for a specific template are 
m easured, then it is noted that the searched reaction is applicable. This is 
explained in more depth in chapter 6, which deals with the software. In order 
to calculate the number of possible reactions available to the molecule 
regardless of the template, an application w as created in Visual Basic to 
recognise the reactions by the fragments (as before) and then display the 
number of times a certain reaction could occur.
^Xj
reactions to be f l^ e d ?
r  0  de ethyWon (0C2H5] [Ô 
r  0  de metiTylation (0CH3) [5 
r  N dBelMationO^C2H5] fÔ 
I?  N de méthylation (NCH3) -1 '
(ï? N H ydroj^ion PJH) 
r  Epoxidation (C»Q 
(v Hydroxjtetion (C ar^) 
fi? Aromatic Hydio)54^ion 
p  MetlylhytkorqiWiæ
M elQ
LçjhskTs fute of 5
P  Less than 5 H doncxs 
[? Less tha ï 10 H acceptors 
Iv Weight under 9X)
E.Shom m \to td  X  structure ftxarySMelQ.mot <PREV I NEXT>I jY if
|E;\hom uniVotaJ 30 structure übtatySMelQ.mof
E Vrom uniMolal 30 structure ftxaryVileiQ.mol
Figure 4.2 Screenshot of the Visual basic application for cycling through the 
set of structures
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4.4 Template Results
Table 4.1 Example output distances tabulated in excel for ease of reference, 
the highlighted electronegative atoms oxygen (red) and nitrogen (blue)
7-ethoxycoumarin Atoms = 24
SiteAtom 
= 1
Atom1 Atom2 Distance
C13 01 1.42
C2 01 1.46
H16 01 2.09
H15 01 2.16
C14 01 2.45
C12 01 2.45
C3 01 2.45
H19 01 2.67
H24 01 2.67
H23 01 2.67
H17 01 2.78
H18 01 3.41
C11 01 3.72
C9 01 3.73
C10 01 4.22
H22 01 4.60
07 01 4.89
C4 01 5.70
C6 01 5.90
H20 01 6.35
C5 01 6.39
08 01 6.65
H21 01 7.45
7-ethoxy 4 
triflourocoumarin Atoms =27 SiteAtom = 1
Atomi Atom2 Distance
016 01 1.42
02 01 1.46
H20 01 2.09
H19 01 2.16
013 01 2.44
017 01 2.45
03 oi 2.45
H23 01 2.67
H25 OI 2.67
H26 01 2.67
H22 01 2.78
H21 01 3.41
014 01 3.72
018 01 3.73
015 01 4.24
H27 01 4.58
07 01 4.89
04 01 5.72
06 01 5.87
05 01 6.38
012 01 6.58
F9 OI 6.64
08 01 6.70
F11 01 6.82
H24 01 7.44
F10 01 8.06
Phenacetin Atoms = 26
SiteAtom 
= 1
Atomi Atom2 Distance 013 OI 3.72
C11 01 1.42 09 OI 3.73
02 01 1.46O10 01 4.23
H15 01 2.09 H24 01 4.59
H14 01 2.16 H26 01 4.59
012 01 2.44 N4 5.69
08 01 2.45 H19 01 6.06
03 01 2.45 05 01 6.22
H18 01 2.66 07 01 6.33
H25 01 2.67 H22 OI 6.90
H23 01 2.68 06 OI 7.10
H16 OI 2.78 H20 01 7.21
H17 01 3.41 H21 01 8.13
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The highlighted distances in Table 4.1 (non-carbon and non-hydrogen atom to 
site distances were assem bled into tables similar to Table 4.2, where the 
presence of Nitrogen and Oxygen atoms are recorded along with their 
distance to the assum ed site atom. In subsequent template development it 
w as decided to try and incorporate the possible electronegative areas of the 
electron dense centre of aromatic rings, those rings that were directly bonded 
to the identified reaction site atom were ignored.
Table 4.2 Identified highlighted distances tabulated for ease of comparison, 
the electronegative atoms oxygen and nitrogen, highlighted in red and blue 
respectively
DRUG f  N 1^0 2nd Q nearest edge of ring
7 ethoxycoumarln 6.654121 4.894080 one bond away
7 ethoxycoumarln 4 triflouro. 4.886690 6.579024 one bond away
Phenacetin 5.686648 6.334100 one bond away
The distances in Table 4.2 were analysed and certain “trend” distances 
grouped. Tables such as table 4.3 show the groups of accumulated maximum 
and minimum distances of notable atom s to the site atom and the difference 
between the maximum and minimum.
W here “Centre NAR” is the distance from the site to the centre of the nearest 
aromatic ring, and NARC is the distance from the site to the nearest aromatic 
ring carbon
L
Figure 4.3 A benzene ring indicating the highlighted atoms for calculating the 
ring centre
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Table 4.3 Raw data for template stating maximum and minimum distances per 
reaction
Reaction 0 De éthylation
Trend Dist 1 6.5
TD 1 min 6.33
TD 1 max 6.65
TD 1 range 0.32
Trend Dist 2 5.25
TD 2 min 4.89
TD 2 max 5.69
TD 2 range 0.8
Ring distance X
RD 1 max X
RD 1 min X
RD 1 range X
AIM points 2 out 2
The discounted distances in the following tables such as  “fused rings” and 
“one bond away” are discarded as  potential points for a template distance as  
the point in question is either directly attached to the site atom, or part of a 
multi ringed system to which it would prove difficult to associate an 
electronegative centre.
Table 4.4 Raw data for template stating the distances for occurring oxygen 
and nitrogen atoms in structures which undergo O déméthylation
DRUG 1 N 2N 3N 4N 1 0 2 0 NARC Centre NAR
Trimethoprim 7.31 6.37 7.46 8.38 4.90 2.84 5.54 6.93
Trimethoprim 1 8.59 7.28 8.74 9.58 2.83 2.84 5.12 6.51
Trimethoprim ii 7.84 6.78 8.13 9.11 2.83 4.90 5.84 7.23
Naproxen 9.48 8.41 4.30 5.62
7-methoxyresorufin 5.64 9.16 4.89 fuse rings
Codeine 7.32 6.58 2.99 one bond away
Metoprolol 9.96 8.84 6.36 2.95 4.35
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Table 4.5 Raw data for template stating the distances for occurring oxygen 
and nitrogen atoms in structures which undergo O dééthylation
DRUG 1 N 1 O 2 0 NARC
7 ethoxy 6.65 4.89 one bond aw ay
7 ethoxy 4 trif 4.89 6.58 one bond aw ay
Phenacetin 5.69 6.33 one  bond aw ay
Table 4.6 Raw data for template stating the distances for occurring oxygen 
and nitrogen atoms in structures which undergo N déméthylation
DRUG 1N 2N 3N 4N 5N 1 0 2 0 3 0 IS NARC
C entre
MAR
diazepam 2 3 9 1 bond aw ay
mptp 4.21 5.60
caffeine 4.27 3.90 2.63 2.36 2.36 1 bond aw ay
benzphetam ine 3.78 5.17
zopiclone 6.66 6.37 7.15 2.85 9.34 4.99 5.19 9.72 5.21 6.61
s-m ephenytoin 2.49 2.35 2.35 3.63 5.02
rosiglitazone 9.62 2.48 10.44 2.40 8.83 8.38 3.64 5.03
MDMA 6.89 7.85 3.81 5.20
Table 4.6a Raw data for template stating the distances for occurring oxygen 
and nitrogen atoms in structures which undergo N dééthylation
DRUG IN 2N 3N 4N 5N 1 0 2 0 3 0 4 0 11 21
C entre
NAR NARC
am idarone 3.76 9.47 9.79 5.46 5.63 6.03 4.81
alfentanil 7.41 3.75 2.42 2.23 1.39 8.53 7.87 2.39 8.52 7.79
lidocaine 3.57 3.00 5.75 4.57
m etoclopram ide 9.08 3.79 5.25 5.40 9.17 6.75 5.68
sulpuride 3.80 8.55 6 3 6 6.98 6.92 6.82 6.23 5.22
Additional structures were used alongside the original known N dééthylation 
structure, amidarone, in order to generate template distances due to their 
possession of an N-ethyl group.
Table 4.7 Raw data for template stating the distances for occurring oxygen 
and nitrogen atoms in structures which undergo N Hydroxylation
DRUG 1N 2N 3N 10 20 30 IS NARC
Meiq 2.47 2.43 7.06 fused  ring
iq 7.22 2.40 2.55 fused  ring
PhIP 4.81 2.40 2.57 3.54
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Table 4.8 Raw data for template stating the distances for occurring oxygen 
and nitrogen atoms in structures which undergo Methyl Hydroxylation
DRUG 1N 2N 3N 10 20 30 IS NARC
M efenam ic 4.99 8.47 7.30 one  bond aw ay
tolbutam ide 7.02 6.90 8.46 6.93 6.96 6.11 one  bond aw ay
om eprazole 5.04 6.19 3.80 10.61 2.89 4.81 3.69 one bond aw ay
Template based on Mefenamic acid and Omeprazole as  Tolbutamide has a 
long flexible structure with more chance of conformational change.
Table 4.9 Raw data for template stating the distances for occurring oxygen 
and nitrogen atoms in structures which undergo Epoxidation
DRUG IN 2N 10 20 30 40 50 60 NARC
carbam azep ine 4 .45 2.80 4.19 fused  rings
carb am azep in e  1 4.75 3.09 5.04 fused  rings
aflatoxin 3.46 4.49 7.30 3.33 2.31 5.32 fused  rings
aflatoxin 1 4 .7â 5.68 8.45 3.26 1.42 5.45 fused  rings
b enzoapyrene 4.21 3.70 fused  rings
benzoapyrene  1 3.71 2.42 fused  rings
Table 4.10 Raw data for template stating the distances for occurring oxygen 
and nitrogen atoms in structures which undergo oxidation
DRUG IN 2N 3N 4N N5 10 20 30 40 ICI C2I NARC
nicotine 1.48 5.52 3.65
proguanil 4.28 6.21 4.82 2.45 4.29 4.81
proguanil 1 3.52 6.49 4 .67 2.45 5.34 6.16
tienilic acid 8.04 3.11 10.44 10.98 3.71 6.79 4.00
bupropion 2.51 3.18 4.66
Bupropion 1 2.43 4.86 3.56
bupropion II 2.47 3.21 5.32
Ibu profen 7.68 7.04 3.10
ibuprofen 1 7.3S 7.14 3.12
ibuprofen II 7.44 6.47 2.56
101
Chapter 4: Template Theory
Table 4.11 Raw data for template stating the distances for occurring oxygen 
and nitrogen atoms in structures which undergo aromatic hydroxylation
Possible Site (Simplistic structure 
terms) DRUG 1N 2N 10 20 30 40
on end b en zen e  ring oestradiol 8.99 2.43
on ring position 3 / 5 4-nitrophenol 2.50 3.71 2.69 3.51
on ring position 3 / 6 4-nitrophenol 1 2.50 3.71 3.51 2.69
on ring position 3 75 paracetam ol 3.78 4.25 2 . m
on ring position 3/ 5 paracetam ol 1 3.75 4.90 2.43
on ring position 4 phenytoin 5.08 5.89 5.13 6.78
on ring position 4 phenytoin 1 5.03 6.18 5.36 6.96
on ring with Cl, position 4 diclofenac 4 .m 8.31 7.42
on ring position 4 analine 4.251
on ring position 4 m ephobarbital 5.98 6.34 5.06 6.62 4 . ^
on end  b en zen e  ring 17b estradiol 8.80 2.43
on mid ring opposite  big chain (position 4) propranolol 6.21 5.94 4.21
on b en zen e  ring next to OH m elatonin 7.17 3.69 6.90 2.45
on ring (possib le Epoxidation) benzo(a)pyrene
on ring position 3 coum arin 4.78 3.73
on ring warfarin 5.65 4.30 4.22 8.48
Table 4.12 Raw data for template stating the distances for occurring oxygen 
and nitrogen atoms in structures which undergo non-aromatic hydroxylation
Where (Simplistic structure terms) DRUG N1 2N 10 20 30
on bridging ring betw een  2 b en zen es nortriptyline 5.072
on bridging ring betw een  2 b en zen es nortriptyline 1 5.914
on bridging ring betw een  2 b en zen es amitriptyline 8.003
on bridging ring betw een  2 b en zen es amitriptyline 1 7.117
on end  5 m em bered  ring testo ste ro n e 2.462 10.401
On a  methyl on end N-C(CH3)3 bufuralol 2 .553 7.102 5.283
On a  methyl on end N-C(CH3)4 bufuralol 1 2.515 6.737 4.505
On a  methyl on end N-C(CH3)5 bufuralol ii 2 .447 8.220 5.090
on 5 m em bered  ring cotinine 2.486 5.390 2.503
on ethyl chain m etharbital 3 .738 3.264 3.532 5.341 3.203
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All these  distances were accumulated and examined for common distances 
for all the mem bers of each reaction group to build up a “tem plate”. These 
base  distances were then given a degree of variation for a reasonable range 
of approximately 1A (central m ean distance + 0.5À) of applicable distances for 
potential new drugs. These template distances are displayed in Table 4.13 
and 4.14.
Table 4.13 The accumulated distances for template creation derived from 
Tables 4.4, 4.5, 4.9 and 4.10
Reaction Epoxidation 0  De éthylation 0  d e  Méthylation Oxidation
Trend Dist 1 4.4 6.5 9 5.1
ID  1 min 4.19 6.33 8.84 4.82
TD 1 m ax 4.75 6.65 9.57 5.87
ID  1 range 0.56 0.32 0.73 1.05
Trend Dist 2 3.3 5.25 6.5 6.5
TD 2 min 3.09 4.89 6.36 6.21
TD 2 m ax 3.7 5.69 6.78 6.79
TD 2 range 0.62 0.8 0.42 0.58
Trend Dist 3 2.5
TD 3 min 2.31
TD 3 m ax 2.8
TD 3 range 0.49
Ring d istance X X 5.25
RD 1 m ax X X 7.25
RD 1 min X X 4.25
RD 1 range X X 3
AIM 2 out 3 TWICE 2 out 2 1 of 2 1 out 2
R equirem ent Double or arom atic bond O with ethyl group O with methyl group
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Table 4.14 The accumulated distances for template creation derived from 
Tables 4.6, 4.6a, 4.7 and 4.8
R eaction N hydroxylation N d e  Ethyl N de  méthylation methyl hydroxylation
Trend Dist 1 2.5 3.65 2.5 5
TD 1 min 2.39 3.45 2.34 4.81
TD 1 m ax 2.56 4 2.85 5.03
TD 1 range 0.17 0.55 0.51 0.22
Trend Dist 2 6.75
TD 2 min 6.11
TD 2 m ax 7.3
TD 2 range 1.19
Trend Dist 3 9
TD 3 min 8.47
TD 3 m ax 10.61
TD 3 range 2.14
Ring d istance X 6.25 5.75 one bond aw ay
RD 1 m ax X 5.5 6.606 one bond aw ay
RD 1 min X 7 5.022 o ne  bond aw ay
RD 1 range X 1.5 1.584 one bond aw ay
AIM 2 out 1 2 of 2 1 of 1 2 of 3
R equirem ent NH N with ethyl N with methyl methyl group
An example of the above distances as  a guide in the software, an output file 
for MelQ is shown which should flag two distances at approximately 2.5Â 
each. The title of the output file indicates the structure, the site atom and the 
reaction involved:
OutSiteNonC_MeIQ_4_N_Hydroxylation.txt
NewFile Total Atoms 
MolSiteAtom = 4
2 9
H Acceptors = 3,
H Donors = 1 ,
Weight = 212.25,
CLogP = Not Calculated Yet 666
Atoml
Atoml
N1 Atom2 = N4 Distance
N2 Atom2 = N4 Distance
2 . 4 2 7 6 1 8
2 . 4 6 9 8 7 9
The output file states the following information: the count of atom s in the 
molecule, the numeric label of the site atom, the count of hydrogen acceptors
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and donors, the m ass and ClogP (not yet calculated nor able to be input by 
the user). After that is a list of all the acceptable template distances m easured 
by the software that apply to the template distances. By fragment recognition 
and the raw template distances, the results cam e out a s  shown in Table 4.15 
and the columns are a s  follows, where “expected” is the number of possible 
occurrences of that specific reaction can occur based on the structure and 
“predicted” is the number of possible occurrences of that specific reaction can 
occur based on the template distances.
Drug nam e (Total List!
expected 0  dééthylation reactions |ODE 1
predicted 0  dééthylation reactions Iprecil
expected 0  déméthylation reactions |ODM 1
predicted 0  déméthylation reactions Ip re d 1
expected N dééthylation reactions |NDE 1
predicted N dééthylation reactions Ipred 1
expected N déméthylation reactions [ndSTI
predicted N déméthylation reactions [prëdl
expected N hydroxylation reactions NH
predicted N hydroxylation reactions Ipred 1
expected Epoxidation reactions lEpox 1
predicted Epoxidation reactions Ipred 1
expected Non aromatic hydroxylation reactions |NAH
predicted Non aromatic hydroxylation reactions Ip red 1
expected Aromatic hydroxylation reactions |AH 1
predicted Aromatic hydroxylation reactions Ipred 1
expected Methyl hydroxylation reactions |MH 1
predicted Methyl hydroxylation reactions jp re ll
Total number of expected reactions Itotal 1
Total number of predicted reactions lE ta l pr |
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Chapter 4: Template Theory
Table 4.16 shows the results of the number of reactions predicted without 
using the software compared to the number of reactions possible according to 
the software and the consequential (if applicable) percentage reduction.
Columns are:
• Drug Name |Total List
• Total number of reactions expected (without software) 1^
• Total number of reactions predicted (with software)
• The percentage of predicted reactions from
expected reactions |% po ss  pred |
• The percentage of reaction reduction ! % rxn reduced
• The experimentally obtained path from literature
• Finally if the recorded reaction in question w as
caught in the predicted reactions [caught rxn?
Table 4.16 Table showing the results of the number of reactions predicted 
without using the software compared to the number of reactions possible 
according to the software and the consequential (if applicable) percentage 
reduction- Table situated on following pages.
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Total List Z ex I  pred % poss pred % rxn reduced p a t h caught rxn?
17a-Ethylnyl estradiol 22 14 63.64 36.36
17B-estradiol 23 14 60.87 39.13 4 - h y d r o x y l a t i o n y
2-AAF (N-hydroxy) 14 10 71.43 28.57
2-phenyjimldazole 9 6 66.67 33.33
3-hydroxy-paracetamol 8 5 62.5 37.5
3-methoxy-paracetamoi 13 7 53.85 46.15
4-aminobiphenyl 11 9 81.82 18.18
4-methoxtamphetamine 30 13 43.33 56.67
4-nitrophenol 4 4 100 0 2 - h y d r o x y  l a t i o n y
58c80 27 13 48.15 51.85 t e r t i a r y  b u t y l  o x i d a t i o n y
6-aminochysene 12 10 83.33 16.67
7-ethoxy-4-trifluro coumarin 11 8 72.73 27.27 0 - d e - e t h y i a t i o n y
7-ethoxycoumarin 11 6 54.55 45.45 0 - d e - e t h y l a t i o n y
7-ethoxyresorufin 13 8 61.54 38.46 0 - d e - e t h y i a t i o n y
7-methoxyresorufin 10 8 80 20 0 - d e m e t h y i a t i o n y
7-pentoxyresofurin 17 11 64.71 35.29
Acetaminophen 9 6 66.67 33.33
Acetylpheneturide 18 11 61.11 38.89
Aflatoxin B1 12 9 75 25 8 , 9 - e p o x i d a t i o n y
Ajmaline 27 17 62.96 37.04
Aldrin 6 5 83.33 16.67
Alfentanil 37 22 59.46 40.54
Allylisopropylacetamide 16 5 31.25 68.75
Alprazolam 14 10 71.43 28.57
Alprenolol 20 11 55 45
Amidarone 35 20 57.14 42.86 N - d e - e t h y l a t i o n y
Amiflamine 26 9 34.62 65.38
Amitriptyline 26 12 46.15 53.85 1 0 - h y d r o x y i a t i o n y
Amobarbital 21 12 57.14 42.86
Analine 7 5 71.43 28.57 4 - h y d r o x y l a t i o n y
A-naphthoflavone 12 11 91.67 8.33 I n h i b i t o r
Antipyrine 15 8 53.33 46.67
Arachidonic acid 12 12 100 0
Aspirin 9 6 66.67 33.33
Barbital 14 8 57.14 42.86
Benzo(a)pyrene 5 0 0 100 7 , 8 - e p o x i d a t i o n y
Benzo[a]pyrene 7,8-diol 5 5 100 0 9 , 1 0 - e p o x i d a t i o n y (Arom H)
Benzphetamine 24 13 54.17 45.83 N - d e m e t h y l a t i o n y
Biperiden 25 16 64 36
Brofaromine 17 10 58.82 41.18
Bromazepam 8 8 100 0
Bromoperidol 22 15 68.18 31.82
Bromvalerylurea 13 7 53.85 46.15
Bts8402 18 12 66.67 33.33
Bufuralol 21 10 47.62 52.38 1 ' - h y d r o x y l a t i o n y
Bunitrolol 22 13 59.09 40.91
Bupropion 22 11 50 50 t - b u t y l  o x i d a t i o n
Caffeine 17 7 41.18 58.82 N - d e m e t h y l a t i o n y
Captopril 14 7 50 50
Carbamazepine 11 10 90.91 9.09 1 0 , 1 1 - e p o x i d a t i o n y
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Total List I  ex Z pred % poss pred % rxn reduced path caught rxn?
Carpipramine 37 22 59.46 40.54
Cerivastatin 33 20 60.61 39.39
Chlordane 8 6 75 25
Chlorpromazine 23 15 65.22 34.78
Chlorzoxazone 3 3 100 0 6 - h y d r o x y  l a t i o n y
Choramphenicoi 10 9 90 10
Citalopram 25 15 60 40
Clomipramine 28 16 57.14 42.86
Clonazepam 12 11 91.67 8.33
Clotiazepam 19 12 63.16 36.84
Cloxazolam 15 12 80 20
Clozapine 21 14 66.67 33.33
Cocaine 25 16 64 36
Codeine 26 14 53.85 46.15 O - d e m e t h y l a t i o n y
Cortisol 28 15 53.57 46.43
Cotinine 14 9 64.29 35.71 3 ' - h y d r o x y l a t i o n y
Coumarin 5 4 80 20 7 - h y d r o x y l a t i o n y
Cyclophosamide 15 8 53.33 46.67
Cyclosporin 127 77 60.63 39.37
Dapsone 13 8 61.54 38.46
DDT 9 9 100 0
Debrisoquine 13 9 69.23 30.77 4 ' - h y d r o x y i a t i o n y
Deildrin 9 8 88.89 11.11
A  THC 33 16 48.48 51.52
Desipramine 24 15 62.5 37.5 2 - h y d r o x y  l a t i o n y
Dextromethorphan 25 14 56 44
DHEA 3-sulphate 35 15 42.86 57.14
Diazepam 11 7 63.64 36.36 N - d e m e t h y l a t i o n y
Diclofenac 10 8 80 20 4 ' - h y d r o x y l a t i o n y
Diltiazem 33 20 60.61 39.39
Encainide 31 20 64.52 35.48
Erythromycin 78 47 60.26 39.74
Estazolam 11 10 90.91 9.09
Ethenzamide 13 8 61.54 38.46
Ethyl-morphine 24 14 58.33 41.67
Etizolam 17 10 58.82 41.18
Fadrozole 13 9 69.23 30.77 8 - h y d r o x y l a t i o n y
Fenbufen 13 10 76.92 23.08
Fenoprofen 14 11 78.57 21.43
Feprazone 21 15 71.43 28.57
FK-506 62 37 59.68 40.32
Flecainide 20 13 65 35
Flubiprofen 16 12 75 25
Fluconazole 11 9 81.82 18.18
Fludiazepam 14 10 71.43 28.57
Fluoxetine 24 16 66.67 33.33
Fluphenazine 39 23 58.97 41.03
Glutethimide 16 10 62.5 37.5
Guanoxan 12 10 83.33 16.67
Haloperidol 26 17 65.38 34.62
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Total List £ ex £ pred % poss pred % rxn reduced path caught rxn?
Haloxazolam 17 12 70.59 29.41
Hexobarbital 18 8 44.44 55.56 3 ' - h y d r o x y l a t i o n
Hydroxyzine 26 18 69.23 30.77
Ibufenac 18 9 50 50
Ibuprofen 20 10 50 50 i s o b u t y l  o x i d a t i o n y (As Hydox)
Ifosfamide 15 8 53.33 46.67
Imipramine 28 16 57.14 42.86 2 - h y d r o x y l a t i o n y
Indomethacine 18 13 72.22 27.78
Indoramin 24 17 70.83 29.17
IQ 11 7 63.64 36.36 N - h y d r o x y i a t i o n y
Ketoprofen 14 11 78.57 21.43
Levomepromazine 31 17 54.84 45.16
Lidocaine 28 12 42.86 57.14
Lithocholic acid 38 20 52.63 47.37
Losigamone 11 9 81.82 18.18 3 ,  4 - h y d r o x y l a t i o n y
Lovastalin 38 23 60.53 39.47
Maprotyline 25 14 56 44
MDMA 18 10 55.56 44.44 N - d e m e t h y l a t i o n y
Medazepam 15 12 80 20
Mefenamic acid 16 11 68.75 31.25 3 ' - m e t h y l - h y d r o x y l a t i o n y
MelQ 16 9 56.25 43.75 N - h y d r o x y l a t i o n y
Melatonin 18 10 55.56 44.44 6 - h y d r o x y l a t i o n y
Mephenytoin 12 12 100 0
Mephobarbital 17 11 64.71 35.29 4 - h y d r o x y l a t i o n y
Metharbital 18 8 44.44 55.56 4 - h y d r o x y l a t i o n y
Methoxyflurane 6 2 33.33 66.67 d e c h l o r i n a t i o n n
Methoxyphenamine 22 9 40.91 59.09
Metoclopramide 28 15 53.57 46.43
Metoprolol 28 16 57.14 42.86 o - d e m e t h y l a t i o n y
Mexiletine 20 8 40 60
Mianserin 22 15 68.18 31.82
Midazolam 15 11 73.33 26.67
Minaprine 20 14 70 30
Moclobemide 17 11 64.71 35.29 m o r p h o l i n e  r i n g  o x i d y (As Hydox)
Morpheine 14 10 71.43 28.57
Mptp 19 9 47.37 52.63 N - d e m e t h y l a t i o n y
N-acetylbenzoquinone-imine 5 5 100 0
Naproxen 16 10 62.5 37.5 o - d e m e t h y l a t i o n y
Nicotine 16 9 56.25 43.75 5 ' - o x i d a t i o n y (As Hydox)
Nifedipine 26 14 53.85 46.15
Nimetazepam 15 11 73.33 26.67
Nirvanol 13 9 69.23 30.77
Nitrazepam 11 10 90.91 9.09
Norcordeine 14 10 71.43 28.57
Normopheine 14 10 71.43 28.57
Notriptyline 26 12 46.15 53.85 1 0 - h y d r o x y  l a t i o n y
Oestradiol 20 14 70 30 2 - h y d r o x y l a t i o n y .. .
Omeprazole 25 16 64 36 5 - m e t h l y  h y d r o x y l a t i o n y
Ondanestron 22 13 59.09 40.91 7 - h y d r o x y l a t i o n y
Oxazepam 12 10 83.33 16.67
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Total List I  ex Z pred % poss pred % rxn reduced p a t h caught rxn?
Oxazolam 23 15 65.22 34.78
Oxprenolol 22 12 54.55 45.45
Paracetamol 9 6 66.67 33.33 3 - h y d r o x y  l a t i o n y
Paracetamol-cyteinate 13 8 61.54 38.46
Paracetamol-qlucuronicle 14 11 78.57 21.43
Paracetamoi-mercapturate 16 11 68.75 31.25
Paracetamol-sulfate 9 6 66.67 33.33
Parathion 18 8 44.44 55.56
Paraxanthine-iii 12 6 50 50
Paroxetine 18 13 72.22 27.78
Pentobarbital 21 10 47.62 52.38
Perhexiline 35 17 48.57 51.43
Perphenazine 26 17 65.38 34.62
Phenacetin 16 9 56.25 43.75 0 - d e - e t h y l a t i o n V
Phenformin 15 12 80 20
Phénobarbital 13 10 76.92 23.08
Phenylbutazone 21 15 71.43 28.57
Phenylimidazole 9 6 66.67 33.33
Phenytoin 12 12 100 0 4 ' - h y d r o x y  l a t i o n y
PhIP 14 10 71.43 28.57 N - h y d r o x y l a t i o n y
Pilocarpramine 19 10 52.63 47.37
Pindolol 19 11 57.89 42.11
Piroxicam 11 11 100 0 5 ' - h y d r o x y l a t i o n y
Primidone 15 10 66.67 33.33
Progesterone 32 15 46.88 53.13
Proguanil 18 14 77.78 22.22 i s o p r o p y l  o x i d a t i o n y (As Hydox)
Promethazine 25 14 56 44
Propafenone 27 17 62.96 37.04
Propercyazine 22 14 63.64 36.36
Propranolol 20 13 65 35 4 - h y d r o x y l a t i o n y
Quinidine 20 14 70 30 i n h i b i t i o n n
R-2-hydroxyibu profen 19 9 47.37 52.63
Rapamycin 85 51 60 40
Retinoic acid 31 8 25.81 74.19 4 - h y d r o x y l a t i o n y
Retinol 28 6 21.43 78.57
R-ibuprofen 20 10 50 50 i s o b u t y l  o x i d a t i o n y (As Hydox)
Rifampicin 52 31 59.62 40.38
R-mephobarbital 17 10 58.82 41.18
Rosiglitazone 17 13 76.47 23.53 N - d e m e t h y l a t i o n y
R-R-3-carboxyibuprofen 17 10 58.82 41.18
R-R-3-hydroxyibu profen 19 11 57.89 42.11
R-S-3-carboxyibuprofen 17 9 52.94 47.06
R-S-3-hydroxyibuprofen 19 10 52.63 47.37
Senicione 27 14 51.85 48.15
Skatole 11 7 63.64 36.36
S-mephenytoin 17 11 64.71 35.29 N - d e m e t h y l a t i o n y
Sparteine 26 15 57.69 42.31
Sterigmatocystin 12 10 83.33 16.67
Stilbene epoxide 12 10 83.33 16.67
Sulfaphenazole 25 12 48 52
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Total List I  ex Z pred % poss pred % rxn reduced path caught rxn?
Sulfinpyrazone 20 18 90 10
Sulpiride 27 17 62.96 37.04
Tacrine 14 8 57.14 42.86 7 - h y d r o x y l a t i o n y
Tamoxifen 34 21 61.76 38.24
Taxol 51 38 74.51 25.49 6 a - h y d r o x y ! a t i o n V
Terfenadine 42 27 64.29 35.71
Testosterone 28 15 53.57 46.43 1 6 b - h y d r o x y l a t i o n y
Thebaine 25 14 56 44
Theobromine-iv 12 6 50 50
Theophylline 13 7 53.85 46.15
Theophylline-ii 13 7 53.85 46.15
Thioridazine 27 17 62.96 37.04
Tienilic acid 11 7 63.64 36.36 s - o x i d a t i o n n
Timiperone 24 17 70.83 29.17
Timolol 26 13 50 50
Tolbutamide 20 13 65 35 4 - m e t h y i - h y d r o x y l a t i o n y
Tranylcypromine 11 7 63.64 36.36
T riazolam 12 8 66.67 33.33
Trifluperidol 22 15 68.18 31.82
Trimethidone 13 4 30.77 69.23
Trimethoprim 24 14 58.33 41.67 o - d e m e t h y l a t i o n y
Trimipramine 31 17 54.84 45.16
T ropisetron 22 14 63.64 36.36
Verapamil 48 26 54.17 45.83
Warfarin 17 14 82.35 17.65
Yohimbine 22 14 63.64 36.36
Zopiclone 21 14 66.67 33.33 N - d e m e t h y l a t i o n y
Zotepine 24 16 66.67 33.33
N.B. The columns are: Drug Name, Total number of reactions expected 
(without software), Total number of reactions predicted (with software), the 
percentage of predicted reactions from expected reactions, the percentage of 
reaction reduction, the experimentally obtained path from literature and finally 
if that recorded reaction was caught in the predicted reactions.
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4.5 Template: A Specific Result Example
An example of the program using one example from the test set, caffeine is 
discussed below.
0
\
N
‘CH
N
/
0
Caffeine
Figure 4.4 The molecular structure of caffeine with highlighted site of reaction
An output of the Visual Basic application showing the expected total reactions 
is given in Figure 4.5.
reactions to be flagged?
r  0  d e  éthylation (OC2H5) [o 
r  0  d e  méthylation (0C H 3) (Ô 
r  N d e  éthylation (NC2H5) fô 
[ÿ  N d e  méthylation (NCH3) (3 
r  N Hydroxylation [NH) (Ô~ 
r *  Epoxidation (C=C) [Ô
S? Hydroxylation (CanyC) jg  
f ?  Aromatic Hydroxylation [1 
Methyl hydroxylation ^
c a f f e i n e
E:\from unAtotal 3D structure library\caffeine.mol P R Ê V lj NEXT > I array Num ber p g "
fïo ■’ ^
|Text14
Liptnski's rule of 5
|v  Less than  5  H donors 
S? L ess th an  10  H accep to rs  
iv  W eight under 500 
f ~  r.g P  indei ^
(E;\from uni\total 3D structure library\caffeine.mol Load from Path
array j%g E:\from uniMotal 3D structure library\c^feine.m ol Load From array
Figure 4.5 The GUI (Graphic User Interface) for the Visual Basic application 
used to calculate the number of expected reactions
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The total number of reactions expected to occur is noted at 16. These are 
recorded as  three nitrogen based déméthylation reactions, 9 non-aromatic 
hydroxylation reactions, 1 aromatic hydroxylation reaction and 3 methyl 
hydroxylation reactions.
When caffeine was run through the software, the total number of reactions 
predicted to occur w as given as  7. These are recorded as three nitrogen 
based déméthylation reactions, 3 non-aromatic hydroxylation reactions and 1 
aromatic hydroxylation reaction. The program successfully filtered out those 
reactions (e.g. methyl hydroxylation) that were considered unlikely to occur as 
well as  the surplus non-aromatic reactions.
The three structures resulting from N déméthylation are given below in Figure 
4.6.
H
H
Figure 4.6 The three structures resulting from caffeine N déméthylation
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The original count included each  hydrogen atom as  an individual although the 
environment for each of the three on a  methyl group is the sam e. The 
program recorded just one reaction for each  methyl group thus cutting down 
the structures from nine to three.
Total List ODE prd ODM prd NDE prd NDM prd NH prd Epox prd NAH prd AH prd MH prd
caffeine 3 1 0 9 3 1 1 3 0
Total List total ex total pred % poss pred % rxn reduced Mr CLOGP p a th
caffeine 16 7 43.75 56.25 194.22 -0.262 N -d em eth ylation
The total number of reactions reduced = 9
The percentage reaction number reduction = 56.25%
4.6 Template Conclusion
The raw tem plates drawn up predict that the structure will undergo;
• an oxygen based de-ethylation reaction, the structure m ust p o ssess  
one or more fragments of “OC2H5” and two distances at around 6.5Â 
and 5.25Â;
• an oxygen based de-methylation reaction if the structure p o ssesses  
one or more fragments of “OCH3” and one distance at either around 
6.5Â or 9Â or a m easurem ent to the centre of an aromatic ring at 
5.25Â. If the ring distance is to be included in the template, it shows a 
good correspondence to the oxygen based  de-ethylation template.
• an epoxidation reaction if the structure p o ssesses  one or more 
fragments of “0 =0 ” and two of either the of the three distances at 
around 4.4Â, 3.3Â and 5.25Â, and occurs twice, due to the nature of 
epoxidation of an aromatic or double bond, both carbon atom s 
involved are classed as  site atoms);
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• a nitrogen based de-methylation reaction if the structure p o ssesses  
one or more fragments of “NCH3” and the two distances, one at 
around 2.5Â and a  m easurem ent to the centre of an aromatic ring at 
5.75Â;
• a nitrogen based de-ethylation reaction if the structure p o ssesses  one 
or more fragments of “NC2H5” and the two distances, one a t around 
3.65Â and a  m easurem ent to the centre of an aromatic ring at 6.25Â;
• a nitrogen based hydroxylation reaction if the structure p o ssesses  one 
or more fragments of “NH” and two distances both occurring at around 
2.5Â;
• a methyl hydroxylation reaction if the structure p o ssesses  one or more 
fragments of “CH3” and the two of the three distances around 5Â, 
6.75Â and 9Â.
Because the distances for aromatic and non-aromatic hydroxylation were so  
varied, no template distances could be drawn up. Instead of ignoring these  
reactions a s  they are the most common, all other reactions were searched for 
first, then the structure was then searched for aromatic bonds with a  hydrogen 
atom attached a s  the recognisable fragment for aromatic hydroxylation. Non- 
aromatic hydroxylation reactions were tested for by searching the structure for 
saturated carbon atom s with an attached hydrogen atom. Although this 
m eans non-aromatic hydroxylation reactions would be flagged on the 
fragments such a s  “NCH3” and possibly flagging the sam e reaction for methyl 
hydroxylation, it w as deem ed preferable to be noting the sam e reaction twice 
than not noting it at all. Perhaps the most important feature is that for every 
structure with a  known reaction, the correct known reaction is caught. For 
further verification, structures with known reactions that were not included in 
the test se t should be processed through the program; unfortunately no 
structures with such data are available at the current time.
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By calculating the number of total possible reactions available to a  molecule, 
and then the number of reactions which would occur according to the 
template theory, it can be seen  how the number of possible reaction 
candidates can be reduced by the template program. The structure with the 
most reduced possibilities w as retinol with 6 out of a  possible 26 reactions 
being flagged, a  78.57% reduction of reactions and thus possible outcomes. 
Unfortunately, the program appears to fall down on large multi-fused ring 
structures such a s  benzo(a)pyrene which should undergo epoxidation, but 
owing to the limiting factors of the fragment recognition for noting epoxidation 
reactions, this reaction is not flagged. The possibility of benzo(a)pyrene 
reactions are not totally ignored a s  aromatic reactions would be flagged.
The structures where possibility of reaction outcome reduction did not change 
were for ten members, with total possible reaction outcome ranging from 3 to 
12. Som e of these are due to the repeated;non-aromatic hydroxylation 
reactions a s  noted before. The average reduction in reaction outcome is 
36.10%; with structures expected to have 15 or more reactions having a 
reaction reduction of 40.93%. These positive reductions indicate that physical 
structure is highly important in prediction of reactions.
On considering the results, it has been shown that the template theory has a 
positive effect on removing unlikely reactions from the possible outcom es of 
the initial metabolic pathway of a  structure. Initially, many pharmaceutical 
com panies bought into the “high throughput” methods of drug discovery 
where thousands of potential drugs are screened. Although this seem ed like a 
profitable approach to finding new drugs, “high throughput” is now starting to 
lose appeal a s  a  method, a s  for every one potential drug found, many are 
wasted. Any trends that could be applied to a  structure for the reduction of 
experimental space  are useful in the real experimental world a s  the 
competition for resources is constantly increasing. Scientists are becoming 
more aware of the pressure of ethical and financial issues for reducing w asted 
chemicals, time and other resources utilized in the drug discovery process.
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CHAPTER 5 QSAR
5.1 QSAR Introduction
One definition of a  QSAR (quantitative structure activity relationship) is “a 
mathematical relationship between biological/chemical activity of a compound 
and the predicted or observed properties dependent on its molecular 
structure”'.
The concept of QSAR w as introduced around the 19^  ^century by the work of 
A.F.A. Cros, Hans Horst Meyer, Charles Ernest Overton and later on, Louis 
Hammett". The basic idea is that when a  compound’s structure changes, the 
compound’s properties also change; from which reasoning structure and 
property are inextricably linked. The business of drug discovery often involves 
the use of QSARs to identify chemical structures that could have the desired 
effects on specific targets a s  well a s  identifying features of possible toxicity. 
There is particular interest in the prediction of LogP, which is an important 
feature of a drug used in Lipinski's Rule of Five a s  discussed in the previous 
chapters.
Many QSARs analyse the interactions of a  series of potential drug molecules 
with an enzym e binding site. With this in mind, the obvious and m easurable 
properties of a structure could affect the way a  compound reacts with 
cytochrome P450 and might be predicted via such methods making use of 
IDBS’ predictive software (PredictionBase). A comparative study between the 
derived QSAR of the expressions from the published papers of D. Lewis and 
those generated by PredictionBase w as undertaken.
For the experiment, QSAR expressions were generated to model the binding 
affinities of cytochrome P450 ligands, and specifically looking at those 
involved with CYP1A2. Expressions were generated to predict the binding 
affinity (A G e in d )  and the Michealis constant Km (pM). These expressions were 
modelled using the IDBS PredictionBase software by fragment calculation. As 
a validation and comparison of the data the QSAR expressions were
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compared and contrasted to those generated by Lewis using conventional 
multiple linear regression methods.
The original QSAR expressions were generated to model the binding affinities 
(AGsind, kJ/mol) of cytochrome P450 ligands. Using the exact sam e data set 
from these original models, new expressions were then created using the 
IDBS PredictionBase software (KBase) by fragment calculation. The software 
used was IDBS KBase: a learning system  that creates QSAR models based 
on statistical methods. The models created in KBase could then be used 
further in applications such a s  PharmaExpert to predict biological and 
physicochemical properties of candidate molecules, but owing to time and 
project constraints this further path w as not taken. The created models were 
validated and finally, a s  a comparison, the QSAR expressions were then 
compared and contrasted to those generated by Lewis using conventional 
multiple linear regression m ethods (which estim ate the conditional expected 
value of one variable y given the values of som e other variable (or variables).
PredictionBase: XBase Multiple Regression Models
RCA - Descriptors Contrfcubon j PLS • Descriptors Contribution
Equation Info Comparison Table
MEIQ
WeightDescriptor
Figure 5.1 a screenshot of an example of one of the data interfaces of 
PredictionBase
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Figure 5.2 a screenshot of an example of one of the results interfaces of 
PredictionBase
5.2 QSAR Theory
Computer-aided chemistry is now at a level where much structural and 
chemical data are available and by m eans of quantum and classical physics -  
values such as  three-dimensional space, volume and energies may be 
calculated. The point of a QSAR is to try to identify a relationship between the 
variations in the values of molecular properties and the given biological or 
chemical activity for a series of compounds (known as  a test set) so that the 
model may be applied and used to predict the behaviour of new molecules 
and thusly the likelihood of becoming a new potential drug.
Computer modelling of molecular structures is achieved by many numerical 
models and the calculation of their three dimensional structure and properties 
with known equations of quantum and classical physics. Many programs are 
available to easily generate and present molecular data including three 
dimensional structure and geometries, their energies and associated 
properties with varying degrees of accuracy. A QSAR attem pts to find 
consistent relationships between the variations in the values of molecular
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properties and activity for a  series of structures so  that these expressions or 
“rules” can be used to evaluate new potential drug structures. A QSAR tends 
to be in the form of a  linear equation
(Biological/Chemical activity) = Const + ( C i  P i )  + (C2 P2) + (C3 P3) + ■ ••(C n  P n )
W here the param eters Pi through Pn are either input from experimental data 
or computed for each molecule in the test se t and the coefficients Ci through 
Cn are calculated by fitting variations in the param eters and activity.
The QSAR method of calculation from the paper “A molecular model of 
cyp2d6 constructed by homology with the cyp2c5 crystallographic template: 
investigation of enzyme-substrate interactions” states how the raw model of 
CYP2D6 w as obtained from crystallographic tem plates and then each 
substrate docked into the model using Sybyl software on a Silicon Graphics 
lndigo2 Impact workstation. QSARs were generated by the use of the 
structural characteristics and AGeinci: the latter w as calculated from Kd 
(dissociation constant) data using:
AG bind “ " RT InKd
W here R is the G as constant and T is the absolute tem perature (degrees 
Kelvin) at which Kd w as determined. The empirically-derived QSAR w as 
achieved by linear regression.
5.3 QSAR K B ase -  IDBS Softw are
The experimental part of the comparison w as undertaken with the use of 
IDBS’ QSAR software KBase. KBase is a learning system  that creates 
prediction models based on standard statistical and logico-combinatorial 
m ethods-. The latter are based on the logico-combinatorial algorithm (LCA), 
first developed by Golender and Rozenblit in the early 1980s'''. LCA are 
designed to effectively find and extract the features of chemical com pounds
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responsible for causing a  particular biological response. These activity 
features are represented by:
• structural fragments,
• groups of fragments, and
• se ts  of properties.
Investigation of the retrieved features may provide information on the potential 
drug and its suggest pathway(s) for metabolism. IDBS software has 
contributed the following enhancem ents to the standard LCA:
• the representation of steric information stored in a structure allows one 
to avoid the use of time-consuming geometry optimisation techniques;
• flexible fragmentation processing -  specialist fragments can be drawn 
and then entered into the fragment database  by the user;
• the calculation and inclusion of structure-fragment mappings to take 
into account the “super-fragm ents”;
• implementation of cluster-based LCA analysis. Standard fragment- 
based LCA can eliminate significant but rare fragments and lead to the 
misinterpretation and possible failure to recognize structures containing 
the given fragment. The main advantage of a  cluster-based LCA 
analysis is that the probability and reliability threshold is se t on clusters 
instead of fragments, allowing rare fragments to belong to common 
clusters, thus avoiding their elimination.
5.4 QSAR KBase -  Creating a Model
The creation of a  model is the end result of a  number of processes. Although 
this has no direct relevance towards the main project, understanding the 
model developments and the mathematical logic behind the p rocesses aids 
considerably in the understanding of the direction of the molecular metabolism 
prediction.
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To create a model, the user must first load in a  test se t of data for the model 
to be based on (here, the data w as in the form of a  *.sdf file). Each compound 
in the se t must then undergo several tasks:
Fragmentation: Each compound is fragmented into parts according to the
either the library settings or custom fragments defined by 
the user (creating a  Fragment database  table).
Mapping: The process of counting the number of times each
fragment in the Fragment D atabase Table fits on to each 
structure in the data source (contents of the *.sdf file).
Calculation of Indices: The calculation of, and then viewing of indices and 
descriptor values for structures and fragments, and 
display distances between heteroatom s (heteroatomic 
topological distances) in a  project.
Next is the generation of a  model and the subsequent training and validation. 
Model training in KBase is provided by two well-established MLR methods:
o least squares fitting (LSF) using principal com ponents analysis 
(PCA) where the number of fragment descriptors is determined 
by their % contribution above a  se t threshold;
o Partial least squares (PLS) where number of principal
components are determined by their % contribution being above 
a  se t threshold.
Once the model has been generated, it must be validated. The m ethods in 
use are leave-one-out (LOO) or leave-many-out (LMO), and entail one or 
several of the compounds which are excluded from the original data se t and 
their values recalculated. A comparison is undertaken of the predicted value 
of the compound(s) when it is present in the training se t and when absen t to 
provide an indication of model's quality. Ideally, this validation would be 
repeated for every compound in the set.
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The quality of the model is determined by the following:
r-sq u a re : Multiple correlation coefficient, These coefficients vary from
zero (having no predictive power at all) to unity (representing a 
perfect model, explaining 100% of the response data). It must 
be noted that high values alone for these  coefficients are not 
sufficient to indicate a  valid model. An r^  value of zero would 
indicate no improvement at all, and negative values indicate that 
the current correlations are worse than the previous iteration.
q -sa u a re : The validation coefficient, is defined as  
c f = 1 -  ^ i (  V i - V i f
W here y  are the observed activities, y is the m ean observed activity 
(calculated over the whole data), and the ÿ  is the predicted activity 
value of the compound, calculated from an MLR model generated by 
LOO validation, the compound excluded being the
If the prediction errors are small then ( f  is close to (but less than) unity. 
A poorly fitting model will have a  value of much less than unity, and 
is possibly negative.
Model Instability C oefficients MIC and  MVIC:
The IDBS method determ ines the stability of the model with respect to 
descriptors and calculated values. For a  stable model, the variation of these  
values should be within the confidence interval of the model (set by the user), 
for both instances of all compounds in the se t and the circum stances when 
one or more are excluded. Variation within or outside the confidence interval 
of the model indicates model stability or instability.
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MIC  : The model instability coefficient is defined as:
M I C =  Ï ^ D l C f / N ,
WhereA/o is the number of descriptors used in regression 
DICi is the descriptor instability coefficient (D/C) for descriptor #:
N
DlCi = 100 X / W
W here ACj is the difference between the descriptor contributions with 
th e /^  compound in and out of the training se t
N  is the number of compounds selected for validation
E  is the 95% confidence interval of the normalised descriptor
contributions.
The calculated coefficient is relative to the confidence interval. If the M IC  
value is less than 100% then the model is considered stable, w hereas if it is 
greater than 100% then model is considered to be unstable. The obvious 
observation of those models with a value of less than 50% can be considered 
more reliable than those closer to the 100% value; the actual value is the 
quantitative m easure of the model.
The variation in predicted values with com pounds of the data se t during 
validation can also be recorded. This is defined a s  the model value instability 
coefficient, MVIC:
M 7 C  = 100x f N
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where AVj is the difference between predicted values with the 
compound in and out of the training set;
N  is the total number of compounds selected for validation;
E  is the 95% confidence interval of the predicted activity value with the 
compound in the training set.
The MVIC  is relative to the confidence interval. If MVIC  is < 100% then the 
model is stable. MVIC > 100% indicates model instability. The actual value is 
the quantitative m easure of the model.
MIC and DICmax (DICmax refers to maximum variation) portray the amount 
of difference in the contribution of each  descriptor {i.e., fragm ents or indices) 
to the model, when a  randomly chosen compound is excluded from the data 
se t in a  LOO validation a s  compared to when it is retained. Alternatively, MIC 
and DICmax show the magnitude to which a  model changes when 
compounds are randomly removed, the result of which is given a s  a 
percentage value.
MVIC and MVICmax show the variation in predicted activity when com pounds 
are randomly removed from the data se t in a  LOO validation a s  compared to 
when they are retained. MVICmax refers to the maximum variation in 
prediction within a  se t of compounds.
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Figure 5.3 a Screenshot of the graphical plot of the AG Bind (kJ/mol) original 
against AG Bind (kJ/mol) calculated for the Test Set
5.5 QSAR - Data s e ts  from publications
The Binding affinity, Michealis Km (jjM) and additional Log P data used were 
extracted from various publications by Lewis during 2002-2003''.
The data were then arranged into groups according to Cytochrome, Km and 
activities as  well as  placed into *.sdf files for e a se  of program use. All the 
compounds from the table in S ection  V, which had recorded the cytochrome 
in use, the properties of LogP, AGeind and Km, were used and arranged. 
Copies of these *.sdf files are available in the appendix.
After several attempts at generating models, it w as decided that grouping the 
data by cytochrome families proved to be the best choice. Although models 
were created for all the cytochrome families, only the models generated for 
CYP1A2 are discussed, due to the data se ts  for the other cytochrome being 
too small to yield any conclusive results.
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Examples of som e of the structures for CYP1A2
C H .
CH3
C a f f e i n e T a c r i n e
N H
H . C
O H
. C H .H O
N H
P h e n a c e t i n M e l a t o n i n
C H ,
= /  N ^^N H z 
M e l Q
N := h
7 - e t h o x y r e s o r u f i n
5.6 Extracted QSAR Expressions
There follow the extracted results of QSAR related papers from the selection 
provided by Lewis. For e a se  of reading, an abbreviated title of the paper is 
used, and a  reference will explain full details of the paper in usual form at the 
end of the thesis.
Abbreviations: n = Number of points 
s  = Standard Error 
R = Correlation Coefficient 
F = Variance Ratio
Homoloqv modelling of CYP2A6 based on CYP2C5^':
Substrates modelled that are involved are coumarin, losigamone, cotinine, 
and nicotine.
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Inhibitors modelled that are involved are pilocarpine, nicotine, 4-nitrophenol, 
and tranylcypromine.
D.QSAR Substrate expressions are a s  follows,
n s R F
AGbind = -0.77(±0.19)NHB-0.78(±0.27)logP-4.45 6 0.343 0.97 21.24
AG bind  = -2.77 (± 0 .3 9 )N hb -  0.56(±0.18)logP-  0.017(±0.003) Mr
n s R F
6 0.211 0.99 39.52
QSAR Inhibitor expressions are a s  follows,
pKi = 7.31(+1.11)log P  + 7.26(±1.59)log Mr-5.17(+0.79)log D ja + 0.8 
(±0.15)Nhb‘^
n s R F
-24.128 0.415 0.97 12.36
From these  results it can be seen  that the prediction of binding affinities is 
based on several contributing physical and derived factors from modelling 
interactions. For this instance, the main contributors are number of hydrogen 
bonds, log P, log D7.4 and relative molecular m ass.
Homoloqv modelling of CYP2E1 based on CYP2C5^“:
Substrates modelled that are involved are 4-nitrophenol, Paracetamol, 
dimethylnitrosamine, aniline, benzene, ethanol, chlorzoxazone, butadiene, 
halothane and toluene.
Inhibitors modelled that are involved are primary alcohols (methanol to 
decanol) and carboxylic acids (hexanoic to hexadecanoic)
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D.QSAR Substrate expressions are a s  follows,
n s R F
AGbind = 2.19(±0.39)N f^-^-0.33(+0.33)logP-3.73 9 0.5473 0.94 22.95
AG bind  = 0.41(+0.10)HB  -  2.59(±0.27)N^.^-3.53(+0.53)log Mr-2.13
n s R F
9 0.3269 0.98 42.17
AG bind  = 0.58(±0.09)HB  -  2.33(±0.21)N^-Y^-3.42(±0.36)log M r0.32(± 0.12)N H B  
+1.89
n s R F
9 0.2214 0.99 70.69
AG bind  = 0.33(+0.09)HB  -  2.39f+0.24;/Vn-n-3.48(±0.56)log M r2 .12
n s R F
10 0.3478 0.98 40.86
AG bind  = 0.56(+0.09)HB  -  2.18(+0.17)N^-^-3.37(±0.37)log M r0.36(± 0 .12)N H B  
+ 1.86
n s R F
10 0.2287 0.99 73.08
QSAR Inhibitor expressions are a s  follows,
pK, = 0.983(±0.107)log P  + 0.203(±0.024)log -1.789
n s R F
10 0.2177 0.963 89.4
pKi = 1.047(±0.096)log D 7.4 + 0.244(±0.024)log 07.4^-1.789
n s R F
11 0.1689 0.968 119
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From this it can be seen  that the prediction of binding affinities is based on 
several contributing physical and derived factors from modelling interactions. 
For this case, the main contributors are number of hydrogen bonds, number 
of 77-77 stacking interactions, log P, log D7.4 and relative molecular m ass.
Homoloqv modelling of CYP2C familv based on CYP2C5^'":
Substrates modelled that are involved are for CYP2C8 arachidonic acid, 
carbam azepine, cerivastatin, diclofenac, retinoic acid, retinol, rosiglitazone, 
taxol, trimethoprim and zopiclone.
Substrates modelled which are involved are for CYP2C9 phenytoin, 
tolbutamide, s-ibuprofen, diclofenac, s-warfarin, tienilic acid, 58C80, s- 
naproxen, piroxicam, mefenamic acid.
Substrates modelled that are involved are for CYP2C19 hexobarbital, 
moclobemide, r-mephobarbital, s-mephenytoin, omeprazole, proguanil, 
propanolol, piazepam, r-warfarin, phenytoin and flucanazole.
QSAR CYP2C8 Substrates expressions are as  follows,
n s R  F
AGbind = 2 .0 1 (± 0 .3 3 )N H B -0 .1 2 (+ 0 .0 0 2 )M r-5 .1 0  6  0 .3 3 2  0 .9 7  2 5 .9
AG bind  =  2 .12(± 0 .11)N h b  -  0.013(+0.001)Mr- 0.40(±0.08)N^..^ -5.44
n s R F
6  0 .1 1 2  0 .9 9  1 5 9 .4
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QSAR CYP2C9 Substrates expressions are as  follows,
AGbind = 8.62(+0.82)log D7.4-8.02(+0.79)log P -  6.26(±0.62)pKa 
+ 0 .5 7 (+ 0 .1 9 )H B d  + 42.74
n s R F
8 0.2267 0.99 29.5
QSAR CYP2C19 Substrates expressions are a s  follows,
p K i  =  0 .0 2 9 ( ± 0 .0 0 6 ) M r -  19.13(±2.93)log Mr +0.381 (± 0 .0 4 9 )H B a  -  
0.278(+0.108) H B d +42.094
n s R F
10 0.1720 0.98 38.4
AGbind= 198.94(+34.71)log Mr-0.31(+0.05)Mr-2.39(+0.39)log P -3 9 9 .9 0
n s R F
8 0.2552 0.97 23.5
AGbind = 201.69(+19.87)log M r-0 .3 1  ( + 0 .0 3 ) M r - 2.50(+0.23)log P  +
0.12(+0.04)HBD -405.68
n s R F
8 0.1460 0.99 56.2
From these  results it can be seen  that for the prediction of binding affinities is 
based on several contributing physical and derived factors from modelling 
interactions. For this instance, the main contributors are number of hydrogen 
bonds (donors and acceptors), pKa, log P, log D7.4 and relative molecular 
m ass.
144
Chapter 5: QSAR
Homology modelling of CYP2D6 based on CYP2C5 :
Substrates modelled that are involved are burfuralol, codiene, ondansetron, 
imipramine, desipramine, nortriptyline, amitriptyline, debrisoquine, propanolol, 
dextromethorphan, metoprolol and MDMA.
D.QSAR Substrate expressions are a s  follows,
AG bind  = 492.03(±100.04)log M r-5.076(+ 0.900)N H B  -  3 .755(+ 0.817)N ^.i^  - 
0 .8 8 0 (± 0 .181)M r -9 4 7 .6 8
n s R F
1 0  0 .3 7 2 7  0 .9 4 1  9 .6 1
p K i  = 1.79(+0.21)Nb-0.57(±0.15)Ha -  0 .0 1 4 (± 0 .0 0 2 )M r -  0 .4 8 (± 0 .1 3 )  log P  
- 3 .5 6
n s R F
11 0 .1 8 7 4  0 .9 8  3 5 .1 7
pKi = 0.187(+0.020)logD7.4-1-041 n s R F
7  0 .0 4 7 8  0 .9 8  9 5 .0 9
From these  data it can be seen  that the prediction of binding affinities is based 
on several contributing physical and derived factors from modelling 
interactions. For this instance, the main contributors are number of basic 
nitrogens (NB), number of hydrogen bonds (acceptors), number of t t - t t  
stacking interactions, pKa, log P, log D7.4 and relative molecular m ass.
Homology modelling of CYP1A2 based on CYP2C5^:
Substrates modelled that are involved are caffeine, Phenacetin, IQ, MelQ, 7- 
ethoxyresorufin, melatonin and tacrine. D.QSAR Substrate expressions are a s  
follows,
n s R F  
AGbind = 0 .6 0 1 (+ 0 .0 6 8 )A G p a rt- 4 .8 7 1  7  0 .2 5 9 0  0 .9 7  7 7 .1 7
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From these data it can be seen  that for the prediction of binding affinities is 
based on several contributing physical and derived factors from modelling 
interactions. For this instance, the main contributor is AGpart-
5.7 QSAR -Ravy Data used
The entire data se t for cyp1a2 comprising of the Michealis constant Km (pM), 
the binding affinity A G einci (kJ/mol) and Log P, is shown in Table 5.1.
Table 5.1 Raw data used with Michealis constant, binding affinity and Log P
Drugs Km AGeind Log P
7-Methoxyresorufin 0.21 -9.4577 3.61
7-ethoxyresorufin 1.7 -8.1839 3.15
MelQ 13 -6.9307 2.40
Tacrine 14 -6.8851 2.71
Estradiol 20 -6.6653 2.69
4-aminobiphenyl 30 -6.4156 2.86
Aflatoxin b1 31 -6.2231 2.20
10 33 -6.3568 1.84
Phenacetin 48 -6.126 1.57
PhIP 55 -6.0422 2.23
Melatonin 85.5 -4.7704 1.45
Naproxen 160 -5.3843 3.18
Caffeine 180 -5.3118 0.01
Theophylline 420 -4.7898 1.40
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5.8 QSAR R esu lts
A summary of the results of the model generated by KBase; for a  LSF 
expression for AGsind (kJ/mol) follows:
•  based on Set of 12 structures;
•  4 fragments in regression -  in other words, the model is heavily 
influenced by 4 fragments from either from the standard library or 
custom built by the user;
•  = 0.5833;
•  stability descriptors from One out validation:
MIC = 16.43
Die max = 17.82
MVIC = 32.47
= 0.5487
NOTE: If the MIC  value is less than 100% then the model is considered
stable.
If MVIC  is < 100% then the model is considered stable.
DICmax refers to maximum variation.
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PredictionBase; KBase Validation Results
Results
stru c tu re  ID 1 MVIC Value 1 Exp.Value 1 Calc.Value(In) 1 Cak.Value(Out) J
EWaiin«313S3l
7-ETHOXYRES... 56,13 -8.184 -6.528 -6.006
CAFFEINE 25.05 -5 .312 -5.681 -6.007
ESTRADIOL 50.94 -6.665 -7.014 -7 .823
IQ 3.556 -6.357 -6.265 -6 .229
MEIQ 25.66 -6.931 -6.265 -6 .007
MELATONIN 20.37 -4.77 -5.371 -5.561
NAPROXEN 50.94 -5.384 -5 .733 -6.542
PHENACETIN 13.63 -6.126 -6.528 -6.655
PHIP 8.564 -6.042 -6 .265 -6 .35
TACRINE 40.91 -6.885 -7.421 -7 .975
THEOPHYLLINE 22.12 -4.74 -4.524 -4.198
0
Background
M V IC  VS C on fidence Interval (100%  - y e llo w  line)
Compounds
J
Figure 5.4 Screenshot of the results Interface for LSF expression of AGsinci, 
showing the reliability of the calculated expression according to each member 
of the Test set
A summary of the results of the Km model generated by KBase: for a LSF 
follows:
•  based on Set of 12 structures;
•  5 fragments in regression — in other words, the model is heavily 
influenced by 5 fragments from either the standard library or custom 
built by the user;
•  r^  = 0.8165;
•  Stability descriptors from
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one out validation:
MIC
Die max 
MVIC
= 25.70 
= 30.61 
= 61.69 
= 0.759
NOTE:
stable.
If the MIC  value is less than 100% then the model is considered
If MVIC  is < 100% then the model is considered stable.
DICmax refers to maximum variation.
PredictionBase: KBase Validation Results
s tru ctu re  ID 1 MVIC Value 1 Exp.Value 1 Calc.Value(In) 1 Calc.Value(Out) |
ESJâilJMîlidüJ
7-METHOXYRE.. 95.4 0.21 18.36 64.23
7-ETHOXYRES... 95.4 1.7 -16.45 -62.32
AFLATOXIN B1 95.94 31. 31. -23.49
ESTRADIOL 3.433 20. 25 .4 26.03
IQ 4.828 33 . 25.4 24.52
MEIQ 7.882 13. 25.4 26.85
MELATONIN 33.01 85.5 101. 113.5
NAPROXEN 74.95 160. 126.4 97.42
PHENACETIN 95.4 48. 66.15 112.
PHIP 18.81 55. 25 .4 21.95
TACRINE 7.246 14. 25.4 26.73
0
Background 1^
M V IC  VS C on fidence Interval (100*/o - y e llo w  line)
“*T T
C o m p o u n d s
J
Figure 5.5 Screenshot of the results Interface for LSF expression of Km, 
showing the reliability of the calculated expression according to each member 
of the Test set
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5.9 QSAR Conclusion
The aim of this investigation w as to compare quantatively expressions 
generated from I DBS software to those expressions created by Lewis from his 
publications. To recall, an example expression of a publication “A molecular 
model of cyp2d6 constructed by homology with the cyp2c5 crystallographic 
template: investigation of enzyme-substrate interactions” -
AGBind = 492.03 (±100.04) log M r - 5.076 (±0.900) NHB - 3.755 (±0.817) A/fl- 
n  - 0.880 (±0.181) M r -947.68
n (No. points) 10
s (standard error) 0.3727
r (Correlation Coefficient) 0.941 
F (Variance Ratio) 9.61
It can be seen  from the above expression that the prediction of binding 
affinities (kJ/mol) is based on the following main contributors: number of 
hydrogen bonds, number of t t - t t  stacking interactions and relative molecular 
m ass.
The resulting expression for AGeind LSF from KBase is based on fragm ents 
rather than alternative properties. The molecular fragments and the 
magnitude of their contribution to the expression are described below:
A G =  -1.564 (NMi)
X X
o
+ 0.7911 (NMi) + 1.1568 (NMI)
r = 0.7641
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W here NMi = is Number of times fragment i is mapped
The pyridine ring is of highest influence on the expression, followed by a 
doubly-bonded (sp^) oxygen then a benzene ring. The next fragment, a 
nitrogen atom with two aromatic bonds is also of importance a s  the pyridine 
ring does not cover five membered aromatic rings like the ones found in 
structures like caffeine and MelQ.
OH
HoC
OH
OH
OH
NH
Caffeine MelQ
The resulting expression for Km LSF from KBase is based on fragments rather 
than alternative properties. The molecular fragments and the magnitude of 
their contribution to the expression are described below:
Km = -54.4428 
(NMi)
Q Arm 
O .
.0.
EE SA
Arm
-28.1149 + 40.751 + 75.5688
(NMi) (NMi) (NMi)
+25.4028
(NMi)
r = 0.9036
Where NMi = is Number of times fragment i is mapped
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The first fragment of highest influence on the expression is a  custom fragment 
designed during this work after noticing common structural traits. The second 
influential fragment is a  doubly-bonded (sp^) oxygen and an ethylene (sp^) 
carbon atom. The third fragment is an aromatic (sp^) carbon atom, oxygen 
then saturated (sp^) carbon atom, although the next fragment of influence is 
again an aromatic carbon atom, oxygen atom and then a  specific methyl 
group. Finally, the last fragment is a  phenyl ring.
Although the r value for the LSF AGsind model w as lower than hoped, this w as 
com pensated by the good stability of the model due to thorough validation 
using: LOO validation, LMO validation and Y-Randomization (When the 
values in the data se t are jumbled up and the expression run, in order to 
prove that “nonsense” input data should not yield proper results).
To test the expressions further, an extra molecule, known to react with 
CYP1A2, w as processed with the following results:
Propranolol
[ Exp KBase % error
\ 4  ' L - f  J
km(MM) Ü7 '91.56 5.24
I.................._ I 1 ^
pale AGBind -5 756 '1-5.062 '12.05
There were a  few problems with this experiment that should be noted:
•  Test se ts  are too small -  12 Structures, although sufficient to prove this 
minor experiment, are not enough to base  a solid theory on;
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e Time spent on determining and writing specific fragments for the data 
se t to aid the model creation -  in order to custom make the expression 
more stable, fragments which were not included in the library had to be 
written. However, being able to add in specialist fragments provided 
better models and once drawn, the fragments could be used for the 
generation of other expressions.
As can be seen  from the results, QSAR can provide guidance for drug 
discovery and potential metabolisms. The expressions them selves however 
appear to be finely tuned according to the test se t it was developed from. This 
is adequate for individual cases, but not particularly useful for the chem ists 
hoping to generate a  general “rule” for the reasoning behind metabolism. The 
other overlooked problem with QSAR is random correlation. For one test se t 
an exceptional model may be produced, but on entry of new m em bers to the 
test se t the model can be completely destroyed. Methods for avoiding such 
models (the random correlation) are currently being looked into and 
developed. A suggested idea would the combination of QSAR with a  neural 
network, which could then be “trained” to recognise patterns, which occur, 
with genuine models and those formed from random correlations. However, a 
created expression Is only a s  good a s  the source data from which it w as 
developed. As experimental techniques becom e more refined and results 
improved, so  will the generated QSAR expressions.
With the current situation in chemistry, the obvious direction to take would be 
data sharing between companies. As it is now, many com panies withhold 
much information for fear of competition, and this hinders the developm ent of 
science greatly a s  many researchers simply cannot access  the sheer amount 
of recent chemical data needed to attempt the creation of QSAR and other 
such metabolism prediction methods. For a  significant progression in the 
a reas of predictive metabolism and QSAR, the unification of data and sources 
is a necessity.
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In conclusion, QSAR is an ambitious step in the direction of predictive 
metabolism. As experimental data sources are improved and unified, so will 
the created QSAR expressions becom e more reliable.
* http://en.wikipedia.org/wiki/QSAR Accessed Sept. 2006
“ http://www.netsci.org/Science/Compchem/featurel2.html Accessed June 2006
IDBS PredictionBase: KBase Online Help, Version 2.0, Introduction Accessed August
2005
IDBS PredictionBase: KBase Online Help, Version 2.0, Background to ALGA models in 
PredictionBase Accessed June 2006
 ^ Dave Lewis Paper list:
D. F. V. Lewis, Archives of Biochemistry and Biophysics, Vol. 409 (1), 32-44,2003, “Essential 
requirements for substrate binding affinity and selectivity toward human cyp2 family enzymes”
D. F, V, Lewis, B. G. Lake, M. Dickens, P. S. Goldfarb, Toxicology in Vitro, Vol. 17,179-190,2003, 
“Homology modelling of CYP2A6 based on CYP2C5 crystallographic template: enzyme-substrate 
interactions and QSARs for binding affinity and inhibition”
D. F. V. Lewis, Elizabeth M. J. Gillam, Steven A. Everett, Tsutomu Shimada, Chemico-Biological 
Interactions, Vol. 145,281-295,2003, “Molecular modelling o f human CYPIBI substrate interactions 
and investigation of allelic variant effects on metabolism”
D. F. V. Lewis, B. G. Lake, M. G. Bird, G. D. Loizou, M. Dickens, P. S. Goldfarb, Toxicology in 
Vitro, Vol. 17,93-105,2003, “Homology modelling o f human CYP2E1 based on CYP2C5 crystal 
structure: investigation o f enzyme-substrate and enzyme inhibitor interactions”
D. F. V. Lewis, Brian G. Lake, Maurice Dickens, Peter S. Goldfarb, Drug Metabolism and Drug 
Interactions, Vol. 19 (2), 115-135,2002, “Molecular modelling of CYP2B6 based on homology with 
the CYP2C5 Crystal structure: analysis o f enzyme-substrate interactions”
D. F. V. Lewis, Maurice Dickens, Brian G. Lake, Peter S. Goldfarb, Drug Metabolism and Drug 
Interactions, Vol. 19 (4), 257-285,2003, “Investigation o f enzyme selectivity in the human CYP2C 
subfamily: homology modelling o f CYP2C8, CYP2C9 and CYP2C19 from the CYP2C5 
crystallographic template”
D. F. V. Lewis, Maurice Dickens, Brian G. Lake, Peter S. Goldfarb, Drug Metabolism and Drug 
Interactions, Vol. 19 (3), 189-210,2003,“A molecular model o f CYP2D6 constructed by the 
homology with the CYP2C5 crystallographic template: investigation of enzyme-substrate interactions”
D. F. V. Lewis, B. G. Lake, M. Dickens, Y. -F. Ueng, P. S. Goldfarb, Xenobiotica, Vol. 33 (3), 239-
254,2003, “Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template 
structure”
D. F. V. Lewis, Current Drug Metabolism, Vol. 4,331-340,2003, “On the estimation of binding 
affinity (AGbind) for human P450 substrates (based on K^and Ko Values)
^  D. F. V. Lewis, B. G. Lake, M. Dickens, P. S. Goldfarb, Toxicology in Vitro, Vol. 17,179-190, 
2003, “Homology modelling of CYP2A6 based in the CYP2C5 structure crystallographic template: 
enzyme-substrate interactions and QSARs for binding affinity and inhibition”
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^  D. F. V. Lewis, B, G. Lake, M. G, Bird, G. D. Loizou, M. Dickens, P. S. Goldfarb, Toxicology in 
Vitro, Vol. 17,93-105,2003, “Homology modelling o f Human CYP2E1 based in the CYP2C5 crystal 
structure: investigation of enzyme-substrate and enzyme-inhibitor interactions”
^  D. F. V, Lewis, B. G. Lake, M. Dickens, P. S. Goldfarb, Drug Metabolism and Drug Interactions, 
Vol. 19 (4), 257-285,2003, “Investigation of enzyme selectivity in the human CYP2C subfamily: 
Homology modelling of CYP2C8, CYP2C9 and CYP2C19 from the CYP2C5 crystallographic 
template”
“ D. F. V. Lewis, B. G. Lake, M. Dickens, P. S. Goldfarb, Drug Metabolism and Drug 
Interactions, Vol. 19 (3), 189-210,2003, “A molecular model of CYP2D6 constructed by homology 
with the CYP2C5 crystallographic template: investigation o f enzyme-substrate interactions”
* D. F. V. Lewis, B. G. Lake, Y. -F. Ueng, M. Dickens, P. S. Goldfarb, Xenobiotica, Vol. 33,239-
254,2003, “Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template 
structure ”
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CHAPTER 6 Softw are
6.1 Softw are Introduction
It is my opinion that the simplest form in which chemical predictions can be 
applied and easily viewed is via computational m eans. In order to view and 
access  specific information with certainty, a  simple Visual Basic application 
was created to aid data gathering. This Application w as a tool to complement 
the creation of the Main C++ application MARP (Molecule and Reaction 
Predictor).
Visual Basic6 w as used for the “Helpful Application” as  the easy  visual 
interface worked well for simple and fast linking of ChemlQ2 to a user 
interface. Visual Basic is an object-oriented programming language that uses 
the Microsoft Windows platform. Program s created using Visual Basic look 
and behave like standard Windows programs. Visual Basic provides the tools 
to create windows with standard features such a s  menus, text boxes, 
command buttons, option buttons, list boxes and scroll bars. Although Visual 
Basic is also an Object Orientated programming language, it lacks the 
necessity for detail and complete functionality of C++; a s  unrefined code is 
automatically “corrected” by the compiler -  regardless of the correctness of 
the code.
C++ w as used for MARP with a view for future integration to IDBS software 
since ChemlQ2 itself is programmed in C++. This also allows greater 
functionality and power for object-orientated programming. It allows a 
programmer to get into the workings of a program and adjust it a s  necessary  
for use. C++ also allows programmers control over memory m anagem ent. It is 
also possible to interface C++ with almost any language interpreter or library. 
With the majority of code written in C++, it is an easy  step to selectively “wrap” 
up a  library in COM for easier use in more accessible languages such a s  
Visual Basic. Such C++ programs/ libraries are usually created for "re-use", 
as  well as  hiding the complexity of advanced techniques from users who may
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not understand or, in the case  of som e companies, wish to imitate the 
workings of the library/ program.
6.2.1 Visual Basic Helpful Application Introduction
The “Helpful VB Application” is a  small program, created in Visual Basic 6.0 
for the e a se  of viewing and identifying structural properties of any molecule 
from the Test se t list. The locations of the molecule files in the computer were 
hard-coded into the program for e a se  of scrolling back and forth between 
m em bers in an array.
This small application allowed structural information of various reaction 
fragments used in the Template software program to be gained at a  glance, 
a s  well a s  varying com ponents of Lipinski’s  rule of five, such a s  the number of 
hydrogen bond donors or acceptors. It can load up any molecule from a  path 
input by the user, by an index number for the hard coded array or purely from 
the “Next” and “Previous” buttons. The application can also save  the current 
display molecule a s  “SMILES” code, useful when calculating ClogP from the 
Daylight website'.
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6.2.2 Visual Basic Helpful Application Screenshot
■K. scroll p450
reac tio n s  to  b e  f lagged?
r  0  d e  éthy lation  (OC2H5)
F" 0  d e  m éthylation (0C H 3) [ô~ 
r  N d e  éthylation (NC2H5) [o~ 
R? N d e  m éthylation (NCH3) [3”  
r  N H ydroxylation (NH) jo ”  
r  Epoxidation  (C=C) [ô”
F7 H ydroxylation (CanyC) [§~ 
Iv  A rom atic Hydroxylation [ t~  
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c a f f e i n e
moi to r iîj2
E:\from  uniStotal 3D stru c tu re  libraryScaffeine.mol array N um ber [49”
( iô
f r ë x t Î 4
Lipinski's rule of 5
R? L ess  th a n  5  H donors 
L ess  th a n  1 0  H a c c e p to rs  
R? W eig h t un d e r 5 00
[ ~  Log F  un d e r 5
E :\from  uniMotal 3D stru c tu re  libraryLcaffeine.mol L o ad  from P a th
array E :\from  uniStotal 3D s truc tu re  libraryLcaffeine.mol L oad  From array
Fig. 6.1 Current GUI (Graphical User Interface) of the Visual Basic6 
application used to count possible reactions and structure fragments.
6.2.3 Visual Basic Helpful Application Coding
Load From Path:
Private Sub Command3_Click()
On Error GoTo LoadError
FilePath = Textl.Text 
Label4.Caption = "" 
i = 666
ChemDisplayl.Load (FilePath)
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GetReactions
RefreshAll
Exit Sub
LoadError:
ErrorOnLoad
End Sub
The simplest code: The File path is a s  the user inputs on the form. On Error 
the program calls “ErrorOnLoad” which aborts the rest of the function and 
executes the following.
Private Sub ErrorOnLoad()
Dim strError As String
strError = "Unable to Load File...Check CODE!"
Dim eh As Integer
eh = MsgBox(strError, vbOKOnly)
End Sub
W here a  m essage box is displayed with the se t error string. Error handling 
w as not looked into too deeply a s  this w as a  fairly simple task  purely for 
displaying a  chemical structure.
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Load From Array:
Private Sub Command4_Click()
On Error GoTo LoadError
i = Texts.Text 
GetFilePath
Label4.Caption = FilePath 
Textl.Text = ""
ChemDisplayl.Load (FilePath)
GetReactions 
RefreshAll
Exit Sub 
LoadError:
ErrorOnLoad
End Sub
The simplest code: The array number is a s  the user inputs on the form. On 
Error the program calls "ErrorOnLoad" a s  before.
GetReactions:
This section of the code identifies particular fragm ents for possible reactions. 
For e a se  of explanation, the code will be broken down and explained a s  it is 
viewed:
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Private Sub GetReactions()
CheckAROM.Value = 0 
CheckCanyC.Value = 0 
CheckEPOX.Value = 0 
CheckNC2H5.Value = 0 
CheckNCHS.Value = 0 
CheckNH.Value = 0 
CheckOC2H5.Value = 0 
CheckOCHS.Value = 0 
CheckCHS.Value = 0
Text4.Text = 0
Texts.Text = 0
Text6.Text = 0
Text?.Text = 0
Texts.Text = 0
Text9.Text = 0
TextlO.Text = 0
Textll.Text = 0
Textl2.Text = 0
TextlS.Text = 0
First of all, the fragment counter displays are se t to zero and the check boxes 
cleared of all previous values.
Dim Molecule, NH, 0CH3, OC2H5, NCH3, NC2H5, CH3, CanyC, 
EPOX, CH As Molecule
Dim MolMaps As Mappings
Dim SiteAtom, MolSiteAtom As Atom
Set Molecule = ChemDisplayl.Molecule
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Specific fragments are then declared a s  molecule objects ready for the 
mapping procedure later in the function. Remember, these  are just named 
objects so far; there are no molecule structures associated to the objects as 
yet.
A mappings object a s  well a s  site (on the fragment) and molecule site (on the 
query molecule); atoms are declared.
The query molecule is se t to the loaded molecule in chem displayl (the 
ChemlQ2 window which displays the molecule on the screenshot) from the 
function before, loaded from array or from path.
ChemDisplay2.Load ("C:\\fma\\Fragments\\0CH3.mol") 
Set 0CH3 = ChemDisplay2.Molecule
Set MolMaps = Molecule.CalculateMappings(0CH3, 0) 
If MolMaps.Count > 0 Then CheckOCH3.Value = 1 
Texts.Text = MolMaps.Count
In the Chemdisplay2 (second ChemlQ2 window), the search fragment “OCH3” 
is loaded from a specified location. The loaded molecule is then assigned to 
the OCH3 molecule object declared earlier.
This fragment is then m apped onto the query molecule to se e  how many 
times (if any) this fragment occurs in the query molecule. If the count of 
mappings is greater than zero, a  check is applied to the appropriate OCH3 
check box. The total number of mappings is then displayed in the associated 
text box.
This section of code is repeated for the following fragments:
OC2H5, CH3, NH, NCH3, NC2H5 and finally EPOX (which is a carbon double 
bond carbon)
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Dim Aro_rings As Rings
Dim RingAtom, OppositeAtom As Atom
Dim t, r , s, AromCount, TotalArom As Integer
Set Aro_rings = ChemDisplayl.Molecule.AromaticRings
If Aro rings.Count > 0 Then CheckAROM.Value = 1
A “rings” object is declared (similar to the mappings object) in which to place 
the information about the rings in a molecule. Also two atom s are declared -  
the first is the atom on the ring which is closest to the site atom, the second 
atom is the opposite atom to the first ring atom.
Figure 6.2 A benzene ring indicating the highlighted atoms for calculating the 
ring centre
Various Integers for count and loops are also declared. The number of 
aromatic rings is calculated.
TotalArom = 0
For r = 1 To Aro_rings.Count
For t = 1 To Aro_rings.Item(r).Atoms.Count 
If t <= 6 Then 
Set RingAtom = Aro_rings.Item(r).Atoms.Item(t) 
For s = 1 To RingAtom.Bonds.Count
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Set OppositeAtom =
RingAtom.Bonds.Item(s).GetOppositeAtom(RingAtom)
If OppositeAtom.Symbol = "H" Then 
AromCount = AromCount + 1 
End If 
Next s 
End If 
Next t
Next r
Textll.Text = AromCount
The next piece of code is to find aromatic carbon atom s with a  hydrogen atom 
attached, which would be the site of a  potential reaction.
For each ring, the atom s are counted. For each atom in that ring, get the 
opposite atom. If that opposite atom is a  hydrogen atom, add one to the 
aromatic site count. This loops through for every atom in every ring to check 
for potential aromatic hydroxylation sites.
The total aromatic count is displayed in the appropriate text box on the form.
ChemDisplay2.Load ("C:\\fma\\Fragments\\CH.mol" 
Set CH = ChemDisplay2.Molecule
Dim j, k As Integer
'establishing site atom in fragment 
For j = 1 To CH.Atoms.Count
If CH.Atoms.Item(j).Symbol = "C" Then 
Set MolSiteAtom = CH.Atoms.Item(j)
End If 
Next j
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In the Chemdisplay2 (second ChemlQ2 window), the search fragment “CH” is 
loaded from a specified location. The loaded molecule is then assigned to the 
CH molecule object declared earlier. The carbon atom in the search fragment 
is then identified a s  the site atom.
Dim totalCH As Integer 
totalCH = 0
Set MolMaps = Molecule.CalculateMappings(CH, 0)
If MolMaps.Count > 0 Then
For k = 1 To MolMaps.Count
If
MolMaps.Item(k).GetMappedAtom(MolSiteAtom).Bonds.Count 
4 Then
CheckCanyC.Value = 1 
totalCH = totalCH + 1 
Else
End If
Next k
TextlO.Text = totalCH 
TextlS.Text = MolMaps.Count
End If
This CH fragment is then mapped onto the query molécule to se e  how many 
times (if any) this fragment occurs in the query molecule. If the count of 
mappings is greater than zero, then for each mapping, get the m apped site 
atom and the number of bonds associated with that site atom. If the num ber of 
bonds on that (as it is set) carbon atom is four, then the atom is saturated and
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open to non aromatic hydroxylation. A check is applied to the appropriate CH 
check box and one is added to the non-aromatic aromatic hydroxylation site 
count. The total number of mappings is then displayed in the associated text 
box.
On Error GoTo LoadError 
RefreshAll 
Exit Sub 
LoadError:
ErrorOnLoad 
End Sub
The remaining code is simply error handling as  in the previous load functions, 
and a “RefreshAII” which refreshes the display to output any current 
information just calculated.
Next/Previous:
On use of the “Next” button ;
Private Sub Commandl_Click()
On Error GoTo LoadError
i = i + 1 
GetFilePath
ChemDisplayl.Load (FilePath)
GetReactions 
RefreshAII
Exit Sub
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LoadError:
ErrorOnLoad
End Sub
At the start of the application i = zero, so  each time this button is used the 
value increments by one with each use.
On use of the “Previous” button
Private Sub Command2_Click()
On Error GoTo LoadError 
i = i - 1 
GetFilePath
ChemDisplayl.Load (FilePath)
GetReactions 
RefreshAII
Exit Sub 
LoadError:
ErrorOnLoad
End Sub
At the start of the application i = zero, so each time this button is used the 
value decreases by one with each use. GetFilePath is described next.
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GetFilePath:
Private Sub GetFilePath() 
On Error GoTo LoadError
Dim FilePathArray(500) As String
FilePathArray(0) = "E:\from uni\total 3D 
libraryM, 2, 4 trimethylbenzene .mol" 
FilePathArray(1) = "E:\from uni\total 3D 
library\17a-ethylnyl-estradiol.mol" 
FilePathArray (2 ) = ..
structure
structure
.. FilePathArray (246) = "E:\from uni\total 3D structure 
library\zotepine.mol"
FilePathArray(247) = "E:\from uni\total 3D structure 
library\zoxazolamine.mol"
FilePath = FilePathArray(i)
Exit Sub
LoadError:
ErrorOnLoad
End Sub
Here the path array is declared and populated. The global string variable of 
“FilePath” is se t to the desired array number.
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6.3.1 MARP: Template Program Objectives/ Introduction
MARP is the culmination of all the template theory and other chemical trends 
noted thus far, applied into a  program written in C++ and exploiting the 
features of ChemlQ2.
The first part of the MARP deals with the recognition of the molecular 
structure and its chemical properties such a s  aromatic properties, hydrophilic 
properties and specific functional groups. The drug molecule in question is 
subjected to the following tests. Written a s  separate  functions which can be 
re-used if needed in alternative reincarnations of MARP.
1) Hydrophilic or hydrophobic:
determine whether or not the drug is water-soluble.
2) If the drug has rings, and if these  are Aromatic:
determine the presence of rings, and the possibility of paths relating to 
the structural property e.g. aromatic hydroxylation.
3) Identify functional groups:
determine the possession of relative structural properties e.g. 
carboxylic acid, amine, alcohol, etc.
4) The identity of the atom at the site of reaction for mapping purposes:
the numeric ids of the atom at the site of reaction in both the requested 
search fragment and the query molecule.
5) Distances between the site atom on the query molecule and other points of 
interest on the query molecule:
a) non-Carbon or non-Hydrogen atoms,
b) negative centres of rings.
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Lipinski’s  rule of five is included in the output files, noting the m ass, 
number of hydrogen bond acceptors and donors. LogP is not included.
5a) The application of template theory a s  discussed in chapter 5: 
applying the derived template distances.
6) Cycling of potential resulting structures according to the reaction searched 
for.
7) Additional functions -  such a s  Lipinski’s  rule of five.
The logical path for future work would be after programming in the basic 
testing and template functions, to apply the gained knowledge of metabolic 
pathways in accordance with phase 1 and phase  2 reactions. T hese basic 
ideas can be summarised a s  the following:
A) 1 ) Create a database  of reactions for phase 1.
2) Apply phase 1 to drug molecule.
B) 1 ) Create a database  of reactions for phase 2.
2) Apply phase 2.
Then, after all of the above has been implemented correctly, the calculations 
of PKa and Log P should be attempted. Finally, the program is in a sta te  for 
toxicity and absorption rate to be considered.
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Figure 6.4 Current GUI format for MARP
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6.3.2 MARP: Current Function Coding
To begin with, the basic functions for molecular properties and fragment 
identification are explained and generated:
1) Hydrophilic or hydrophobic:
A Part of the Cldentify class. To test whether a  molecule is hydrophilic. A 
basic interpretation of “hydrophilic” has been used. If the molecule contains 
any highly electronegative atom s such a s  O, N, Cl, F, Br or I, then it can be 
assum ed that the bond it is associated with is polar and therefore the 
molecule may be hydrophilic.
bool Cldentify::TestHydrophilic(CMolecule &Mol)//Pass in 
Query Molecule as Target 
{
m_bIsHydrophilic = false;
for(int i=l;i<= Mol.GetAtoms().GetCount();i++)
{if (Mol.GetAtoms().Getltem(i).GetSymbol() =="0") 
{m_bIsHydrophilic = true;}
if (Mol.GetAtoms().Getltem(i).GetSymbol() 
=="N") {m_blsHydrophilic = true;}
if (Mol.GetAtoms().Getltem(i).GetSymbol() 
=="F") {m_bIsHydrophilic = true;}
if (Mol.GetAtoms().Getltem(i).GetSymbol() 
=="C1") {m_bIsHydrophilic = true;}
if (Mol.GetAtoms() .Getltem(i) .GetSymbol () 
=="Br") {m_bIsHydrophilic = true;}
if (Mol.GetAtoms().Getltem(i).GetSymbol() 
=="!") {m_bIsHydrophilic = true;}
}
return m bIsHydrophilic;}
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Here, all the atoms in the molecule are checked to se e  whether they are any 
of the listed electronegative atoms. If there are any electronegative atom s 
from the list present a  Boolean is returned with the value “True”.
2) If has rings Aromatic or not:
A Part of the Cldentify class. Tests whether a  molecule has aromatic rings, 
using the IDBS ChemlQ method of getting aromatic rings and using the 
molecule property object “ring” which contains information such a s  number of 
members, type of m em bers and if ring is aromatic.
bool Cldentify::TestAromaticRing(CMolecule 
&M0I)//Pass in Query Mol as Target 
{
m_bIsAromatic = false;
CRings Aro_Rings;
CRing Aro_Ring;
Aro_Rings = Mol.GetAromaticRings();
//Has Aromatic Rings?
for(int i =1; i <= Aro_Rings.GetCount(); i++) 
{
m_bIsAromatic = true; 
m_bHasAromaticHeteroAtom =
TestAromaticHeteroAtom(Aro_Rings.Getltem(i));
if (m_bHasAromaticHeteroAtom){m_CurrentHeteroAtom 
GetAromaticHeteroAtom(Aro_Rings.Getltem(i));}
}
return m bIsAromatic; };
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Here, the molecule is checked for possession of aromatic rings using the 
ChemlQ2 method. If there are aromatic rings present, a  Boolean is returned 
with the value “True”. This function w as removed later as  it w as not required 
in its present form in the code.
3) Identify functional G roups:
A Part of the Cldentify class. This is the m ost difficult portion of the code a s  it 
consists of loading a  search fragment a s  a  separate  molecule object and then 
loading the query molecule to be searched through for the fragment. The 
searching is done via the “mapping” abilities of ChemlQ2. Once the fragment 
has been mapped onto the query molecule, the location of the reaction -  the 
site atom -  must be found. This is achieved by knowing which atom in the 
search fragment is the “site” atom, and then finding the relevant m apped atom 
in the query molecule. The function is named “LocateGroup”. A class tree is 
situated further on in the chapter. In order to fully step  through the code, this 
function will be broken into sections. Any sub functions will be h ighlighted 
and discussed at the end of the function.
void Cldentify::LocateGroup(CMolecule &M0I, CString 
&SiteFragmentID)
{
CMappings MolMaps;
//loading fragment from library 
LoadSiteFragment(SiteFragmentID);
The function takes the parameters:
Mol -  the query molecule object 
SiteFragmentId -  the search fragment e.g. “OCH3”
The & at the front of the param eters indicates that these  are references to the 
objects in a  higher class, and saves the need and memory capacity to re­
create these  object. LoadSiteF ragm ent uses the string ID of the fragment to
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be searched for and loads the corresponding molecule from a  hard-coded 
library of molecule fragments created specifically for this searching purpose.
//identifying and creating the fragment site atom... 
m_FragmentSiteAtom =
IdentifySiteFragmentAtom(SiteFragmentID);
Sets the atom object “m_FragmentSiteAtom” by calling the sub-function 
IdentifySiteFragm entA tom  which takes the SiteFragmentID (the fragment 
string e.g. “OCH3”)
if( SiteFragmentID != "Aromatic )
Indicating that the code following is only to be applied to the search fragm ents 
which are not labelled “aromatic”. The list of possible fragments are; OCH3, 
OC2H5, NCH3, NC2H5, NH, aromatic, nonAromatic, epox
MolMaps =
Mol.CalculateMappings(m_SiteFragment,0);
for(int i = 1; i<= MolMaps.GetCount();i++)
{
MolMaps.GetItem(i).GetTargetBonds();
}
The created mappings object is filled with the m aps generated.
//for each mapping found.
if(MolMaps.GetCount() != 0 )
{
for(int i = 1; i<= MolMaps.GetCount();i++)
{
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if (SiteFragmentID != "NonAromatic") 
{
m_Mo1S iteAt om =
MolMaps.GetItem(i).GetMappedAtom(m_FragmentSiteAtom);
m_MolSiteAtom.SetHighlighted(true);
CDistance DistanceClass;
DistanceClass.SetFragmentString(SiteFragmentID); 
DistanceClass.MeasureMolSiteToNonC(Mol, 
m_MolSiteAtom);
//^output*
DistanceClass.SetMoleculeName(m_MoleculeName); 
std::string OutputContent =
DistanceClass.GetFileContent(); 
bool bVerifyRxn
=DistanceClass.VerifyReaction(SiteFragmentID); 
if(bVerifyRxn == 1)
{DistanceClass.WriteDistanceFile(OutputContent);};
} } } }
For each mapping, for which it has already established that it does not have 
the SiteFragmentId of “aromatic”, the fragment site atom is then m apped on to 
the query molecule to get the MolSiteAtom.
An instance of another class is then initiated, C D istanceC lass. In this class 
the distances from the MolSiteAtom to any other points of interest in the query 
molecule are m easured. Finally, the output string is created and written from 
the distance class.
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//...for aromatics 
if(SiteFragmentlD == "Aromatic")
{
//for Each AROMATIC ring found 
for(int j = 1; 
j<=Mol.GetAromaticRings().GetCount(); j++)
{
for(int k = 1; k <=
Mol.GetAromaticRings().Getltem(j).GetAtoms().GetCount(); 
k++)
{ m_MolSiteAtom =
Mol.GetAromaticRings0 .Getltem(j).GetAtoms().Getltem(k);
for(int n =1; n <= 
m_MolSiteAtom.GetBonds().GetCount(); n++)
{
CAtom Opposite = 
m_MolSiteAtom.GetBonds().Getltem(n).GetOppositeAtom(m_Mol 
SiteAtom);
If the SiteFragmentId is “aromatic” then the number of aromatic rings in the 
molecule is counted. If there are more than zero rings, then for each  ring, 
each atom is counted. Each counted atom in the ring it is assum ed to be the 
MolSiteAtom. For each possible MolSiteAtom, the bonds associated with that 
atom are counted. For each of the bonds associated with that atom, the 
opposite atom is identified (it takes two atom s to make a  bond, the 
MolSiteAtom is identified as  one atom, the second is currently unknown).
//and if its a H do the Distance bit
if(Opposite.GetSymbol() == "H")
{
CDistance DistanceClass;
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DistanceClass.SetFragmentString(SiteFragmentlD);
DistanceClass.MeasureMolSiteToNonC(Mol, 
m_MolSiteAtom);
//^output*
DistanceClass.SetMoleculeName(m_MoleculeName);
std::string OutputContent = 
DistanceClass.GetFileContent();
bool bVerifyRxn = 
DistanceClass.VerifyReaction(SiteFragmentlD) ;
if(bVerifyRxn == 1)
{DistanceClass.WriteDistanceFile(OutputContent);};
//de construct?
// DistanceClass.~CDistance0 ; 
}
}
}
}
}//close of aromatic
If the opposing atom to the MolSiteAtom on any given aromatic bond is “H” 
then it is possible that aromatic hydroxylation occurs and the program 
continues a s  before. An instance of another class is then initiated, 
CDistanceClass. In this class the distances from the MolSiteAtom to any other 
points of interest in the query molecule are m easured. Finally, the output 
string is created and written from the distance class.
178
Chapter 6: Software
//...for non aromatic Hydroxylation 
if(SiteFragmentlD == "NonAromatic")
{
if(MolMaps.GetCount() != 0 )
{
for(int i = 1; i<= MolMaps.GetCount();i++)
{
m_MolSiteAtom =
MolMaps.Getltem(i).GetMappedAtom(m_FragmentSiteAtom);
if(m_MolSiteAtom.GetBonds().GetCount() ==
4)
If the SiteFragmentId is “NonAromatic” then for each mapping, the fragment 
site atom is then mapped on to the query molecule to get the MolSiteAtom. 
For each possible MolSiteAtom, the bonds associated with that atom are 
counted. If the number of bonds associated with that atom is equal to four, 
then the atom (identified a s  the correct carbon atom for the site atom) is 
considered saturated and then proceeds with the following code similar to the 
different types of reaction described before.
{CDistance DistanceClass;
DistanceClass.SetFragmentString(SiteFragmentlD); 
DistanceClass.MeasureMolSiteToNonC(Mol, 
m_MolSiteAtom);
//^output*
DistanceClass.SetMoleculeName(m_MoleculeName);
std::string OutputContent = 
DistanceClass.GetFileContent();
bool bVerifyRxn =
DistanceClass.VerifyReaction(SiteFragmentlD);
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if(bVerifyRxn == 1)
{DistanceClass.WriteDistanceFile(OutputContent);};
}}}}//close of function
An instance of another class is then initiated, C D istanceC lass. In this class 
the distances from the MolSiteAtom to any other points of interest in the query 
molecule are m easured. Finally, the output string is created and written from 
the distance class. This concludes the code for LocateG roup.
4) The Identity of th e  atom  a t  th e  s ite  of reaction
L oadSiteP ragm ent is a part of the Identify class. The primary purpose of this 
function is to load the search fragment from purely a  string id obtained from 
the GUI (graphical user interface).
CString Cldentify::LoadSiteFragment(CString 
&SiteFragmentlD)
{
CFragmentLibrary FragLib;
CString GroupPath ;
bool bErroflD = 0;
//set a choice of if statement for 02CH3 etc.. 
if(SiteFragmentlD == "OC2H5")
{GroupPath = FragLib.GetOC2H5(); //O de ethyl
bErrorlD = 1;} 
if(SiteFragmentlD == "0CH3")
{GroupPath = FragLib.GetOCH3(); //O de
emthyl
bErrorlD = 1;} 
if(SiteFragmentlD == "NC2H5")
{GroupPath = FragLib.GetNC2H5(); //N de ethyl
bErrorlD = 1;} 
if(SiteFragmentlD == "NCH3")
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{GroupPath = FragLib.GetNCH3(); // N de
methyl
bErrorlD = 1;} 
if(SiteFragmentlD == "CH3")
{GroupPath = FragLib.GetCH3(); //methyl
hydrox
bErrorlD = 1;} 
if(SiteFragmentlD == "NonAromatic")
{GroupPath = FragLib.GetCH(); //non arom hydrox 
bErrorlD = 1;} 
if(SiteFragmentlD == "Epox")
{GroupPath = FragLib.GetCdbC(); //epox...
bErrorlD = 1;} 
if(SiteFragmentlD == "NH")
{GroupPath = FragLib.GetNH(); // NH 
bErrorlD =1;} 
if(SiteFragmentlD == "Aromatic")
{GroupPath = FragLib.GetCarCH(); //C arom CH
bond
bErrorlD = 1; } 
if(bErrorlD == 0)
GroupPath = FragLib.GetCanyC(); // default to
CanyC
m_SiteFragment.Load(GroupPath); 
return GroupPath;
}
An instance of the class C Fragm entLibrary is created, a s  well a s  an empty 
string for the “GroupPath”, namely the location of the hard-coded fragment 
molecule object exists as  a *.mol file.
Inside CFragm entLibrary, the SiteFragmentId string is required to identify the 
fragment needed to be loaded.
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CString CFragmentLibrary::GetOCHS(){return 0CH3;} //O- 
methyl
W here in the class, the object OCH3 is declared as:
CString 0CH3; //0-methyl
Which is se t previously on the generation of the class as:
void CFragmentLibrary::SetOCH30{ 0CH3 =
"C: \ \fma \ XFragments \ \ 0CH3. mol }  / / 0-methyl
So in the class Cldentify: “GetOCHs’, a string containing the relevant path is 
returned. This string is then loaded via the fragment (a molecular object).
m_SiteFragment.Load(GroupPath);
IdentifySiteFragmentAtom is also a  part of the class Cldentify. Here the 
purpose of the function is to locate the atom in the search fragment.
CAtom Cldentify::IdentifySiteFragmentAtom(CString 
&SiteFragmentlD)
{
CAtom OurSiteAtom;
for(int i =1; i<= 
m_SiteFragment.GetAtoms().GetCount();i++)
An empty atom object is created “OurSiteAtom”, which is to be filled with the 
correct atom information according to the fragment chosen.
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For all of the atom s in the fragment the following is applied:
_
if((SiteFragmentlD == "0CH3") ||
(SiteFragmentlD == "OC2H5"))
{
if(m_SiteFragment.GetAtoms().Getltem(i).GetSymbol()
= = " 0 " )
SetFragmentSiteAtom(m_SiteFragment.GetAtoms().Getlte
m ( i ) ;
OurSiteAtom =
m_FragmentSiteAtom;
}
}
If the fragment string is either of the oxygen based de-alkylation reactions, the 
fragment is searched through for the oxygen atom. Once the oxygen atom is 
found, that particular information is se t to the OurSiteAtom atom object.
if((SiteFragmentlD == "NCH3") ||
(SiteFragmentlD == "NC2H5") |1
(SiteFragmentlD == "NH"))
{
if(m_SiteFragment.GetAtoms().Getltem(i).GetSymbol() 
=="N")
{
SetFragmentSiteAtom(m_SiteFragment.GetAtoms().Getlte 
m ( i ) ) ;
OurSiteAtom =
m FragmentSiteAtom; }}
If the fragment string is either of the nitrogen based de-alkylation reactions 
and the nitrogen hydroxylation, the fragment is searched through for the 
nitrogen atom. Once the nitrogen atom is found, that particular information is 
se t to the OurSiteAtom atom object.
183
Chapter 6: Software
if((SiteFragmentlD == "CH3") ||
(SiteFragmentlD =="Epox") ||
(SiteFragmentlD =="CanyC")|| 
(SiteFragmentlD == "NonAromatic"))
{
if(m_SiteFragment.GetAtoms().Getltem(i).GetSymbol() 
=="C")
{SetFragmentSiteAtom(m_SiteFragment.GetAtoms().Getlt 
em ( i ) ) ;
OurSiteAtom =
m_FragmentSiteAtom;}}
If the fragment string is any of the carbon based hydroxylation reactions; 
methyl hydroxylation, epoxidation and non-aromatic hydroxylation - the 
fragment is searched through for a carbon atom. Once the carbon atom is 
found, that particular information is se t to the OurSiteAtom atom object.
For Aromatic hydroxylation, the method becom es more complex.
if(SiteFragmentlD == "Aromatic" )
{
//if the Atom is C
if(m_SiteFragment.GetAtoms().Getltem(i).GetSymbol ( ) 
=="C")
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For each atom in the fragment, if it is a  Carbon;
{//for number of bonds attached to C 
for(int q = 1; q <= 
m_SiteFragment.GetAtoms().Getltem(i).GetBonds().GetCount(
) ;  q++)
For each bond attached to that carbon atom;
{
//get opposite atom 
CAtom Temp =
m_SiteFragment.GetAtoms{).Getltem(i).GetBonds().Getltem(q 
).GetOppositeAtom(m_SiteFragment.GetAtoms().Getltem(i));
//if that opposite atom is H, we got our
site atom
if(Temp.GetSymbol() == "H") 
{SetFragmentSiteAtom(m_SiteFragment.GetAtoms().Getltem(i)
) ;
OurSiteAtom = m_FragmentSiteAtom; }}}}}
If the opposite atom to the known atom in that bond is a  hydrogen atom, then 
we have our potential aromatic hydroxylation site atom.
return OurSiteAtom;}
The end of the sub-function now returns the correctly filled atom object 
“OurSiteAtom” from the fragment to the LocateGroup function to be m apped 
onto the query molecule.
5) Distances between the site atom on the query molecule and non­
carbon atoms
The Class CDistance is accessed  via the Cldentify class. This is reasonably 
difficult portion of the code a s  it consists of the mapping and measuring of the
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site atom non-Carbon or hydrogen atom s in the query molecule a s  well a s  the 
application of the template theory. The main function is named 
“M easureSitetoNonC” and is programmed into the CDistance class. A class 
tree is situated further on in the chapter. In order to fully step  through the 
code, this function will be broken into sections in the order of the program.
Any sub functions/classes will be highlighted and discussed at the end of the 
function.
void CDistance::MeasureMolSiteToNonC(CMolecule &M0I, 
CAtom &MolSiteAtom)
{
int local_RefSiteAtomNum; 
bool bGot_local_RefSiteAtom;
//initial Setting the distances 
SetFragmentMinMaxDistances();
SetFragmentRangeOfDistances(m_FragmentString); 
SetMolSiteAtom(MolSiteAtom); 
bGot local RefSiteAtom = false;
The template distances are se t in the sub-function of 
SetFragmentMinMaxDistances and SetFragmentRangeOfDistances. The
“MolSiteAtom” is also set.
//TO establish aromatic presence 
bArom_Hydroxylation = TestAromaticRing(Mol);
The molecule is tested for the presence of aromatic rings. MARP uses the 
sam e code as  discussed earlier for the detection of aromatic rings using 
ChemlQ2 functions.
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//^output*
m_strOutFilePath = m_strOutFileSiteNonC;
//set the title of file by total number of 
atoms...for my reference
char Temp[64]; // should be more than enough
sprintf(Temp,"NewFile Total Atoms = %d \n MolSiteAtom 
=  % d " .
Mol.GetAtoms().GetCount(), 
MolSiteAtom.GetNumber());
m_strOutFileContent= std:: string(Temp);
The output text file content is se t to an assigned string variable. The start of 
the contents of the file indicated the count of atom s in the query molecule, 
followed by the numerical value of the identification of the site atom. This is 
followed by the additional values corresponding to Lipinski’s  rule.
//Write Lipinskis rule 5 info just under the title 
(dummy CLogP)
int CLogP = 666;
WriteLipinskiRuleSLine(Mol, CLogP);
In order to retain the m easured distances, an array is created.
//creating atom array 
m_ppDistances = new 
double*[Mol.GetAtoms().GetCount()];
for (int i = 0; i < Mol.GetAtoms().GetCount(); ++i) 
{m_ppDistances[i] = new double 
[Mol.GetAtoms().GetCount()];}
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The current distance to be m easured is done so  by counting all the atom s in 
the molecule which are neither carbon nor hydrogen. Each atom that fulfils 
that specification is then to be m easured against the allocated site atom 
(making sure that the two atom s are not the sam e). The distance is m easured 
using the sub-function D istance.
//for all atoms....
f or ( i=l; K M o l . GetAtoms (). GetCount 0; i++)
{
//...which are NOT carbon...or H!! ! 
if(Mol.GetAtoms().Getltem(i).GetSymbol() != "C"
&& Mol.GetAtoms0 .GetItem(i).GetSymbol0 != "H")
//..measure against SiteAtom 
{int j = MolSiteAtom.GetNumber0 ;
//making sure they're not the same atom
{if(i!=j)
{
double distance =
Distance(Mol.GetAtoms().Getltem(i),Mol.GetAtoms().Getltem
(j) ) ;
if(distance >= Distancel_min && distance 
<=Distancel_max)
{if (bReactionPossible_l ==1){bReactionPossible_2 =
1;}
// for when duplicates turn up which would reinforce the 
template.
bReactionPossible 1 =1;
The portion of the code in blue text is essential to the template theory. 
According to the se t distances (yet to be discussed) if the m easured distance
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is both greater than the minimum se t distance and less than the maximum se t 
distance then the first boolean is flagged indicating that this distance is found. 
Depending on the reaction, several Booleans may need to be flagged in order 
for the complete Boolean linked to that specific reaction to be marked a s  true.
WriteDistanceLine(Mol.GetAtoms().Getltem(i),Mol.GetAtoms(
).Getltem(j));
local_RefSiteAtomNum = j; 
bGot_local_RefSiteAtom =
true; }
If the distance is flagged, then it is written into the output string. The sam e 
process is applied a  maximum of three times as  a maximum of three 
distances were recorded for any one template.
if(distance >= Distance2_min && 
distance <= Distance2_max)
{ bReactionPossible_2 =1;
WriteDistanceLine(Mol.GetAtoms().Getltem(i),Mol.GetA 
toms().Getltem(j));
local_RefSiteAtomNum = j; 
bGot_local_RefSiteAtom =
true;
}
if(distance >= Distance3_min && 
distance <= Distance3_max)
{ bReactionPossible_3 =1;
WriteDistanceLine(Mol.GetAtoms().Getltem(i),Mol.GetA 
toms().Getltem (j ) ) ;
local_RefSiteAtomNum = j; 
bGot local RefSiteAtom = true;}}}}}
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The measuring of the MolSiteAtom to the centre of a ring occurs for only the 
fragments mentioned in the code below. The actual measuring from atom to 
ring is processed in M easureC entreR ingT oSite.
if{in_FraginentString == "0CH3" || "NCH3" I I "NC2H5")
{
if (bGot_local_RefSiteAtom == false)
{local_RefSiteAtomNum =
MolSiteAtom.GetNumber();}
//should catch for Same Site Atom for ring
dists
if(MolSiteAtom.GetNumber() == 
local_RefSiteAtomNum)
{MeasureCentreRingToSite(Mol, MolSiteAtom);}}
Finally, if all the correct booleans are flagged according to the template 
required then a  reaction Boolean is flagged true in F lagTheR ightR eaction -  
a  coding that notes that this reaction is possible.
// if both distances are marked, then flag possible 
reaction
FlagTheRightReaction(bReactionPossible_l, 
bReactionPossible_2 ,bReactionPossible_3, 
m FragmentString);}
5a) The application  of tem plate  theory
SetFragm entM inM axD istances is a part of the CDistance class. It is here 
the minimum and maximum distances discovered for specific reaction 
tem plates are set.
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void CDistance::SetFragmentMinMaxDistances()
{//refer to "all template distances.xls" for guide dists
//O ethyl distances: 
0_Ethyl_Distancel_min = 4.75 
0_Ethyl_Distancel_max = 5.75 
0_Ethyl_Distance2_min = 6.25 
0_Ethyl_Distance2_max = 6.75 
0_Ethyl_Distance3_min = 0.00 
0_Ethyl_Distance3_max = 0.00 
0_Ethyl_RingDistance_min = 0 
O Ethyl RingDistance max = 0
» 6 . 5, 5.25
//not yet
Here, the oxygen de-ethylation reaction tem plate has two marked distances 
for a template. The remaining distances are se t to zero. The two distances 
are:
1) Around 5.25Â min 4.75Â max 5.75À range 1.00Â
2) Around 6.50Â min 6.25Â max 6.75Â range 0.50A
//O methyl distances: »9.0, 6.5
0_Methyl_Distancel_min = 5.85 
0_Methyl_Distancel_max = 7.25 
0_Methyl_Distance2_min = 8.05 
0_Methyl_Distance2_max = 9.95 
0_Methyl_Distance3_min = 0;
0_Methyl_Distance3_max = 0;
0_Methyl_RingDistance_min = 4.25; //rather big 
range 0_Methyl_RingDistance_max = 7.25;
Here, the oxygen déméthylation reaction tem plate has three marked 
distances for a template. The remaining distances are se t to zero. The three 
distances are:
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1) Around 6.50Â min 5.85Â max 7.25Â range 1.40Â
2) Around 9.0Â min 8.05Â max 9.95Â range 1.90Â
Also a ring distance
3) Around 5.75Â min 4.25Â max 7.25Â range 3.00Â
//N ethyl distances: »3.65
N Ethyl Distancel min = 3.45;
N Ethyl Distancel max = 4.00;
N Ethyl Distance2 min = 3.45;
N Ethyl Distance2 max = 4.00; // find same dist
twice
N Ethyl Distance3 min =0;
N Ethyl Distance3 max = 0;
N Ethyl RingDistance min = 5.50;
N Ethyl RingDistance max = 7.00;
Here, the nitrogen de-ethylation reaction template has three marked distances 
for a  template. The remaining distances are se t to zero. The three distances 
are:
1) Around 3.65Â min 3.45Â max 4.00À range 0.55Â
2) Around 3.65Â min 3.45Â max 4.00Â range 0.55Â
Also a  ring distance
3) Around 6.25Â min 5.50Â max 7.00Â range 1.50Â
//N methyl distances: 
N_Methyl_Distancel_min = 1.80 
N_Methyl_Distancel_max = 3.30 
N_Methyl_Distance2_min = 1.80 
N_Methyl_Distance2_max = 3.30 
N_Methyl_Distance3_min = 0; 
N_Methyl_Distance3_max = 0; 
N_Methyl_RingDistance_min = 5.00;
N Methyl RingDistance max = 6.75;
» 2 . 5
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Here, the nitrogen déméthylation reaction template has three marked 
distances for a  template. The remaining distances are se t to zero. The three 
distances are:
1) Around 2.50Â min1.80A max 3.30A range 1.50A
2) Around 2.50A min 1.80A max 3.30A range 1.50A
Also a  ring distance
3) Around 5.85A min S.OOA max 6.75A range 1.75A
//N hydroxyl distances: »2.5
N Hydroxyl Distancel min = 2.20;
N Hydroxyl Distancel max = 2.80;
N Hydroxyl Distance2 min = 2.20;
N Hydroxyl Distance2 max = 2.80;
N Hydroxyl Distance3 min = 0;
N Hydroxyl Distance3 max = 0;
N Hydroxyl RingDistance min = 0;
N Hydroxyl RingDistance max =0; //not yet
Here, the nitrogen hydroxylation reaction template has two marked distances 
for a  template. The remaining distances are se t to zero. The two distances 
are:
1) Around 2.50A min 2 .20k  max 2.80A range 0.60A
2) Around 2.50A min 2.20A max 2.80A range 0.60A
//Epoxidation distances: 
Epoxidation_Distancel_min = 2.75 
Epoxidation_Distancel_max = 3.74 
Epoxidation_Distance2_min = 3.75 
Epoxidation_Distance2_max = 5.25 
Epoxidation_Distance3_min = 2.25 
Epoxidation Distance3 max = 2.74
»4.4, 3.3, 2.5
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Here, the epoxidation reaction template has three marked distances for a 
template. The remaining distances are se t to zero. The three distances are:
1) ca. 2.50Â min 2.25Â max 2.74Â range 0.49Â;
2) ca. 3.30Â min 2.75Â max 3.74Â range 0.99Â;
3) ca. 4.40Â min 3.75Â max 5.35Â range 1.50Â.
//MethylHydroxyl distances: »5, 6.5, 9
Methyl_Hydroxl_Distancel_inin = 4.75 
Methyl_Hydroxl_Distancel_max = 5.25 
Methyl_Hydroxl_Distance2_min = 6.00 
Methyl_Hydroxl_Distance2_niax = 7.50 
Methyl Hydroxl_Distance3_min = 8.40 //large range
Methyl Hydroxl_Distance3_max = 10.70;
Here, the methyl hydroxylation reaction tem plate has three marked distances 
for a template (the remaining distances are se t to zero); the three distances 
are:
1) ca. 5.00Â min 4.75Â max 5.25Â range 0.50Â;
2) ca. 6.50Â min 6.00Â max 7.50Â range 1.50Â;
3) ca. 9.00Â min 8.40Â max 10.70Â range 2.30Â.
//non aromatic hydroxylation varied! »  2.4 -> 10.5 
Non_A_Hydroxyl_Distancel_min = 2.4; 
Non_A_Hydroxyl_Distancel_max = 10.4; 
Non_A_Hydroxyl_Distance2_min = 2.4; 
Non_A_Hydroxyl_Distance2_max = 10.4; 
Non_A_Hydroxyl_Distance3_min = 0;
Non A Hydroxyl Distance3 max = 0;
Here, the non-aromatic reaction tem plate has two marked distances for a 
template (the remaining distances are se t to zero). As the distances used to 
derive this template were so  varied, this is in fact, a rather ineffectual 
template. The two distances are:
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1) min 2.40Â max 10.40Â range 8.00Â;
2) min 2.40Â max 10.40Â range 8.00Â.
//aromatic hydroxylation so very varied! AGAIN »
2.4 -> 9.0
Arom_Hydroxyl_Distancel_min = 2.4 
Arom_Hydroxyl_Distancel_max = 9.0 
Arom_Hydroxyl_Distance2_min = 2.4 
Arom_Hydroxyl_Distance2_max = 9.0 
Arom_Hydroxyl_Distance3_min = 0; 
Arom_Hydroxyl_Distance3_max = 0;
}
Here, the aromatic reaction template has two marked distances for a  template 
(The remaining distances are se t to zero). As the distances used to derive this 
tem plate were so  varied, this is in fact, a  rather ineffectual template. The two 
distances are:
1) min 2.40Â max 9.00Â range 6.60Â ;
2) min 2.40Â max 9.00Â range 6.60Â.
S etF ragm entR angeO fD istances is a part of the CDistance class. It is here 
the minimum and maximum distances discovered for specific reaction 
tem plates are se t to the variables used in the CDistance functions according 
to the reaction for which the data are being searched.
This is a section of the code which identifies an oxygen de-ethylation reaction 
via the “OC2H5” string, and then assigns the correct tem plate to the distance 
variables. This coding is completed for all the other reaction strings:
OC2H5” oxygen de-ethylation
0C H 3” oxygen déméthylation
NC2H5" nitrogen de-ethylation
NCH3" nitrogen déméthylation
NH" nitrogen hydroxylation
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“Nonaromatic” non-aromatic hydroxylation
“Epox” epoxidation
“Aromatic” aromatic hydroxylation
“CHs” methyl hydroxylation
void CDistance::SetFragmentRangeOfDistances(CString 
m_FragmentString)
{
if(m_FragmentString == "OC2H5")
{ Distancel_max = 0_Ethyl_Distancel_max; 
Distancel_min = 0_Ethyl_Distancel_min; 
Distance2_max = 0_Ethyl_Distance2_max; 
Distance2_min = 0_Ethyl_Distance2_min; 
Distance3_max = 0_Ethyl_Distance3_max; 
Distance3_min = 0_Ethyl_Distance3_min; 
RingDistancel_max = 0_Ethyl_RingDistance_max; 
RingDistancel_min = 0_Ethyl_RingDistance_min;
}
D istance is a part of the CDistance class. It is here the distance between the 
two input atoms is calculated. Here the information of the three dimensional 
atomic coordinates is extracted from the atom objects passed  into the 
function.
double CDistance ::Distance(CAtom &Atoml, CAtom
&Atom2)//Pass in Atoms return Distance
{ double xl = Atoml.GetX();
double yl = Atoml.GetY();
double zl = Atoml.Getz();
double x2 = Atom2.GetX();
double y2 = Atom2.GetY();
double z2 = Atom2.Getz();
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For the ea se  of calculation, the x, y and z coordinate portions are generated 
separately from the main equation.
double xpart, ypart, zpart;
xpart = (xl-x2)* (xl-x2) 
ypart = (yl-y2)*(yl-y2) 
zpart = (zl-z2)*(zl-z2)
The distance between two points in three-dimensional space is the square 
root of the sum of the squares of the three parts.
double distance = sqrt((xl-x2)* (xl-x2) + (yl- 
y2)*(yl-y2) + (zl-z2)*(zl-z2));
This information is then put into our generated array (created in CDistance 
earlier). The information inserted into the array is: atom 1, atom 2 and the 
calculated distance between them. Finally, the distance is returned.
m_ppDistances[Atoml.GetNumber()][Atom2.GetNumber()] 
= distance; 
return distance;}
MeasureCentreRingToSite is a part of the CDistance class. It is here the 
distance between the centre of an aromatic ring and the site atom is 
determined. This function takes a molecule object (the molecule being 
investigated) and the mol site atom.
197
Chapter 6: Software
void CDistance::MeasureCentreRingToSite(CMolecule &M0I, 
CAtom SMolSiteAtom)
{ //for each ring found
int j = MolSiteAtom.GetNumber() ;
for (int N = 1 ; N <= Mol.GetRings().GetCount();
N++)
{
First, the number of aromatic rings in the molecule is calculated, then for each 
of these  rings found:
//set these internals to something neutral, but able 
to reset here for each ring 
m_RingCFar =0; 
m_RingCNear = 100;
// for each atom in ring 
for(int i = 1; i <
Mol.GetRings().Getltem(N).GetAtoms().GetCount(); i++)
{
Two distance variables are set; one for the nearest carbon in the ring and one 
for the furthest carbon in the ring.
Then the number of atom s in that specific ring is calculated. For each of the 
atom s in the ring, the distance function is called to m easure the distance 
between the two atoms (the mol site atom and the atom in question in the 
ring):
'  {
double distance =
Distance(Mol.GetRings().Getltem(N).GetAtoms().Getltem(i), 
Mol.GetAtoms().Getltem(j));
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Next, if the distance is greater than the furthest distance (m_RingCFar), then 
the current distance is se t to m_RingCFar a s  the greatest distance.
Next, if the distance is less than the shortest distance (m_RingCNear), then 
the current distance is se t to m_RingCNear a s  the shortest distance.
if (distance >= m_RingCFar){m_RingCFar = distance;} 
if (distance <= m_RingCNear){m_RingCNear = 
distance;}}}
Once this is completed for every atom in the current ring, there are two 
distances recorded, the nearest carbon atom (m_RingCNear) and the furthest 
carbon atom (m_RingCFar). The assum ed centre for the aromatic ring is 
calculated by calling CalculateC entreO fR ing.
//here should be for the centre of each ring
double CentreToSite = CalculateCentreOfRing();
If the distances match the ring variable distances for the current template, 
then a boolean is flagged “True” to note the correct distances. The current 
information is then written to the output file string.
if(CentreToSite>= RingDistancel_min && CentreToSite 
<= RingDistancel_max)
{//flag the ring reaction possible for reaction 
bRingReactionPossible = 1; 
WriteRingDistanceLine(Mol.GetAtoms().Getltem(i),Cent 
reToSite);}}}
C alculateC entreO fR ing is a part of the CDistance class, called by 
M easureC entreR ingToSite. It is here the distance between the two atom s of 
an aromatic ring is calculated.
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double CDistance::CalculateCentreOfRing()
{
double CentreDistance = ((m_RingCFar - 
m_RingCNear)/2) + in_RingCNear; 
return CentreDistance;
}
The assum ed centre of the ring is located by calculating the difference in 
distance between the nearest and the furthest atom, halving that distance and 
then adding that value to the distance for the nearest ring carbon atom.
Figure 6.5 Benzene ring with the highlighted atoms for calculating the centre 
of a hng
FlagTheR ightR eaction is a part of the CDistance class. It is here that all the 
appropriate Booleans, flagged during the measuring and application of 
template distances, are collected. If the correct number of Boolean flags for 
each template are flagged, then the reaction possible Boolean is marked 
“True”.
void CDistance::FlagTheRightReaction(bool 
bReactionPossible_l,
bool bReactionPossible_2, 
bool bReactionPossible_3, 
CString m_FragmentString)
{
200
Chapter 6: Software
Oxygen de-ethylation requires both of the two distances to be present:
//O de ethyl takes 2 of 2 
if(m_FragmentString =="OC2H5")
{
if(bReactionPossible_l == 1 && 
bReactionPossible_2 ==1){bO_EthylationPossible =1;}
}
Oxygen déméthylation requires one of the two distances to be present:
//O de methyl takes 1 of 2 and/or a positive ring 
measurement
if(m_FragmentString =="0CH3")
{
if(bReactionPossible_l == 1 |1 
bReactionPossible_2 ==1 || bRingReactionPossible == 1) 
{bO_MethylationPossible = 1;}
}
Nitrogen de-ethylation requires the one distance to be present:
// N de ethyl takes 1 of 1 
if(m_FragmentString =="NC2H5")
{
if(bReactionPossible_l == 1 1| 
bReactionPossible_2 ==1 && bRingReactionPossible == 1) 
{bN_EthylationPossible =1;}
}
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Nitrogen déméthylation requires either one of the two distances and a ring 
distance to be present:
//N de methyl takes 1 of 1 /or a positive Ring 
measurement...
if(m_FragmentString =="NCH3")
{if(bReactionPossible_l == 1 || bReactionPossible_2 
==1 I I bRingReactionPossible == 1)
{bN_MethylationPossible = 1;}}
Nitrogen hydroxylation requires the one distance to occur twice:
//N Hydroxl takes 2 of 1, as the same distance 
occurs twice
if(m_FragmentString =="NH")
{
if(bReactionPossible_l == 1 && 
bReactionPossible_2 ==1){bN_HydroxylationPossible = 1;}
}
Epoxidation requires two of the three marked distances present:
//Epoxidation takes 2 of 3, 
if(m_FragmentString =="Epox")
{
if(bReactionPossible_l == 1 && bReactionPossible_2
= =  1)
{bEpoxidationPossible = 1;} 
if(bReactionPossible_l == 1 && bReactionPossible_3
== 1)
{bEpoxidationPossible = 1;} 
if(bReactionPossible_2 == 1 && bReactionPossible_3
= =  1 )
{bEpoxidationPossible = 1;}}
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Non-aromatic hydroxylation requires the one distance to occur:
//Non A Hydroxl takes anything
if(m_FragmentString =="NonAromatic" || 
m_FraginentString == "CH")
{
if(bReactionPossible_l ==
1){bNon_A_HydroxylationPossible = 1;}}
Aromatic hydroxylation requires the one distance to occur:
//arom hydrox
if(bArom_Hydroxylation == 1)
{ if(m_FragmentString == "Aromatic")
{
if(bReactionPossible_l ==
1){bArom_HydroxylationPossible =1;}
}}
Methyl hydroxylation requires two of the three marked distances to occur:
// methyl hydroxyl takes 2 of 3 
if(m_FragmentString =="CH3")
{
if(bReactionPossible_l == 1 && bReactionPossible_2
= =  1 )
{bMethylHydroxylationPossible = 1;} 
if(bReactionPossible_l == 1 && bReactionPossible_3
= =  1 )
{bMethylHydroxylationPossible = 1;} 
if(bReactionPossible_2 == 1 && bReactionPossible_3
= =  1 )
{bMethylHydroxylationPossible = 1;}
} }
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6) Cycling of potential re su lt s tru c tu re s
As can be seen  from the previous functions and classes, the possibility of the 
sam e reaction occurring in a molecule more than once is inevitable. In order 
to view the possible resulting structures and if the template theory can be 
applied, the following code w as adapted to preserve the current structure 
being investigated and view the corresponding results at the user’s  leisure.
In the class CMarpDIg (the class which interacts with the GUI), after the user 
has selected a fragment to search for and a molecule to search through, the 
function O nG enerate  is called.
void CMARPDlg::OnGenerate()
{
Generation.Reset_Generate_Instance();
RefreshAllO;
Load();
TotalMapcount =
Generation.Assign_Structures (in_Chemdispl. GetMolecule ( ) ,
m_Cheindisp2 . GetMolecule ( ) ,
m_Chemdisp3.GetMolecule(),
m_Cheindisp4 . GetMolecule ( ) , 
myFilePath);
//setting fragment string in Generation 
Generation.SetGenFragmentStr(m_SearchFragment); 
if(TotalMapcount !=0){CurrentMapcount = 1;}
}
The CG enerate class instance “Generation” created on the compilation of the 
software, is reset to default values in G en era tio n .R ese t_ G en era te_ ln stan ce . 
All the dialogs on the GUI are refreshed.
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Next the number of expected results is calculated and the total count of result 
structures recorded in the variable “TotalMapCount”. This variable is used as  
an index for cycling through the structures, and generated by 
G enera tion .A ssignS truc tu res .
G enera tion .R ese t_G enera te_ lnstance  is a  part of the class CG enerate. The 
purpose of this function is to clear all remaining data which is stored in the 
variables and objects of the G enerate Class.
void CGenerate::Reset_Generate_Instance()
{
GenOriginalMol.Clear() ;
GenChangeMol.Clear 0 ;
GenFragment.Clear() ;
GenAddition_Frag.Clear();
GenMapCount =0;
}
G enera tion .A ssignS truc tu res  is a  part of the class CG enerate. The purpose 
if this function is to se t all the variables and objects used in the Generation 
Class.
int CGenerate::Assign_Structures(CMolecule &OriginalMol,
CMolecule SChangeMol, 
CMolecule &Fragment, 
CMolecule &Addition_Frag, 
CString &FilePath)
{//sets the molecules in the Generation class to be used 
in this class.
SetGenOriginalMol(OriginalMol);
SetGenChangeMol(ChangeMol);
SetGenFragment(Fragment);
SetGenAddition_Frag(Addition_Frag);
SetGenMolFilePath(FilePath);
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Here the array created on the creation of the generation instance is given a 
structure string in order to store the original structure. “GenOriginalMol” is the 
original molecule object to be searched thorough. The “ChangeMol” is the 
result molecule object which changes throughout the function.
ResultStructureStrArray[0] =
GenOriginalMol.GetStructureString(8);//sets original mol 
as 0
ChangeMolStructureString =
ChangeMol.GetStructureString(8);
Next is the calculation of the number of times a  fragment is mapped in the 
molecule. The total number of mappings of that fragment is returned and used 
as  the “TotalMapCount”.
//generates the molmaps 
GenMolMaps =
GenChangeMol.CalculateMappings(GenFragment,0);
GenMapCount = GenMolMaps.GetCount();
return GenMapCount;
On returning to the class CMarpDIg (back to the GUI for input), the user is 
required to cycle through the structures by the “Next” and “Previous” buttons. 
Clicking on the “Next” button calls the function OnNext which claims a result 
string (“Template”) after the application of Generation.TemplateTheory. The 
resulting structure is generated by Generation.GenerateStructure according 
to “TotalMapCount”. This only occurs if the mappings count is greater than 
zero. The data on the GUI is then refreshed.
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void CMARPDlg: :OnNext()
{
CString Template; 
if(CurrentMapcount !=0)
{ if(CurrentMapcount <= TotalMapcount)
{
Template =
Generation.TemplateTheory(m_Chemdispl.GetMolecule(),
m_SearchFragment, 
CurrentMapcount, 
m_FileName);
Generation.GenerateStructure(CurrentMapcount, 
m_SearchFragment);
CurrentMapcount++;
}}
m_Template_output= Template;
UpdateData(FALSE);
//removed as lose 3d coordinates if used 
//m_Chemdispl.GetMolecule().LayoutStructure(); 
//m_Chemdisp2.GetMolecule().LayoutStructure();
UpdateData(FALSE);
RefreshAll();
}
G eneration.T em plateTheory is a part of the class CG enerate. The main 
objective of this function is to access  the class CIdentify in order to carry on 
with the distance measuring and application of the template distances a s  
described before. However in this case, the mapping has already been 
decided and is passed  into the function [D C ase.LocateG roupPerM apping 
via “MapCount”.
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CString CGenerate::TemplateTheory(CMolecule 
&GenChangeMol,
CString
&GenFragmentStr,
int GCurrentMapCount, 
CString &MoleculeName)
{
CString Output;
CString String_result;
CString ReactionName;
ReactionName =
GetReactionName_FromFragStr(GenFragmentStr);
Cldentify IDCase;
IDCase.SetMoleculeName(MoleculeName); 
bool bChosenRxn =
IDCase.LocateGroup_perMapping(GenChangeMol,
GenFragmentStr, 
CurrentMapcount);
As with the previous LocateG roup, LocateG roupPerM apping returns a 
Boolean to flag if a template mapped reaction has been successful. This 
result is then converted into a  legible string for the GUI to display.
String_result = "False";
if(bChosenRxn == true){String_result = "True - Check 
C:\\DISTANCE for Template results!";}
Output = ReactionName + " " + String_result; 
return Output;}
208
Chapter 6: Software
G enera tion .G enera teS truc tu re  creates the resulting structure according to 
the reaction being searched for. For example, an oxygen dééthylation reaction 
will result in the selected “OC2H5” group being cleaved off and replaced with 
an “H”. Hydroxylation type reactions will result in an “H” being removed and 
replaced by “O H ”.
To start, the function has passed  into it the integer “Mapcount” (the current 
mapping index for a  particular fragment) and “FragmentStr” (the string identity 
of that fragment). The first item is to clear any previous incarnations of a result 
structure from the molecule object to be changed by R esetC hangeM ol_Path , 
which simply reloads the path of the original structure into the changing 
molecule object.
void CGenerate::GenerateStructure(int SMapCount, CString 
&FragmentStr)
ResetChangeMol_Path(GenMolFilePath);
The next process involves only those reactions which are cleavage reactions 
(again recognised by fragment strings) and are the only reactions allowed to 
access  the loop.
//start of cleavage and replacement loop
if((FragmentStr == "NCH3")||(FragmentStr == 
"NC2H5") I I (FragmentStr == "NH") | |
(FragmentStr == "0CH3")||(FragmentStr
"0C2H5"))
{
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All the mapped bonds in our fragment are se t to marked. This is a  ChemlQ2 
property which will allow for easier bond removal.
//BONDS
GenMolMaps.GetItem(MapCount).GetTargetBonds().SetAll 
Marked(true);
GenMolMaps.GetItem(MapCount).GetTargetBonds().SetAll 
Highlighted(true);
Then searching through every bond, if the bond is marked, is it removed. This 
is continued until the count of highlighted bonds is equal to zero. The reason 
bonds are removed first is that for a bond to exist, it must be in possession of 
two atoms. If the atom s are deleted first, then when attempting to remove 
bonds, the atom s do not exist and this causes an error.
int i =0; 
do 
{
for(int j= 1; j <=
GenChangeMol.GetBonds().GetCount0 ; j++)
{
if(GenChangeMol.GetBonds().Getltem(j).GetMarked())
{GenChangeMol.RemoveBond(j);}
}
if (j>
GenChangeMol.GetBonds().GetCount()){1=2 ;}
}while(GenChangeMol.GetHighlightedBonds().GetCount ( )
! = 0 ) ;
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Next, all the mapped atom s in our fragment are se t to marked.
//ATOMS
GenMolMaps.GetItem(MapCount).GetTargetAtoms().SetAll 
Marked(true);
GenMolMaps.Getltem(MapCount).GetTargetAtoms().SetAll 
Highlighted(true);
Then searching thorough every atom, if the atom is marked, the symbol of 
that particular atom is checked. If it is NOT “N” or “O” is it removed (rem em ber 
our fragments which undergo cleavage so  far are only N and O based). This 
is continued until the count of highlighted atom s is equal to unity, our site 
atom.
do
{
for(int j= 1; j <=
GenChangeMol.GetAtoms().GetCount(); j ++)
{
if(GenChangeMol.GetAtoms().Getltem(j).GetMarked())
{
CString meh =
GenChangeMol.GetAtoms().Getltem(j).GetSymbol();
if(GenChangeMol.GetAtoms().Getltem(j).GetSymbol() !
"N" )
{if
(GenChangeMol.GetAtoms().Getltem(j).GetSymbol() !=
" 0 " )
{GenChangeMol.RemoveAtom(j);} 
}}}
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}while(GenChangeMol.GetMarkedAtoms().GetCount(
Next, searching thorough every atom, if the atom is marked, the additional 
fragment is joined to the molecule. The additional fragment is previously se t 
during A ssig n S tru c tu res .
for(int j = 1  ; j<=
GenChangeMol.GetAtoms().GetCount(); j ++)
{
if(GenChangeMol.GetAtoms().Getltem(j).GetMarked())
{
if(GenChangeMol.GetAtoms().Getltem(j).GetSymbol() !=
"H")
{
GenChangeMol.Join(GenAddition_Frag, 
GenChangeMol.GetAtoms().Getltem(j),
GenAddition_Frag.GetAtoms().Getltem(1),
1);//single
}}}
}//end of cleavage loop
The next process involves all hydroxylation reactions (or those reactions 
where the replacement of an H atom with OH). All reactions which are non- 
aromatic hydroxylation reactions (again recognised by fragment strings) are 
allowed to access  the loop.
//start of hydroxylation loop
I  !  *************************************************
if((FragmentStr == "CH3")||
(FragmentStr == "NonAromatic"))
{
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A Boolean for saturated atom s is created and se t to “True”. This is followed by 
a count, for each of the marked atom s in the molecule, if that atom is NOT “H” 
and if that atom does NOT have four bonds attached (assuming it is now an 
unsaturated carbon atom) to se t the Boolean for saturated to “False”.
bool bSaturated = true;
for(int q = 1; q<=
GenMolMaps.Getltem(MapCount).GetTargetAtoms().GetCount();
q++)
{
if(GenMolMaps.Getltem(MapCount).GetTargetAtoms().Get 
Item(q).GetSymbol() !="H")
{
if(GenMolMaps.Getltem(MapCount).GetTargetAtoms().Get 
Item(q).GetBonds().GetCount() != 4)
{bSaturated = false;}}}
If the Boolean for saturated carbon atom is still equal to “True”, the 
hydroxylation proceeds by setting all the target bonds to marked a s  before:
if (bSaturated== true)
{
int atoms =
GenChangeMol.GetAtoms().GetCount();
//BONDS
GenMolMaps.Getltem(MapCount).GetTargetBonds().SetAll 
Marked(true) ;
GenMolMaps.Getltem(MapCount).GetTargetBonds().SetAll 
Highlighted(true);
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Also setting all the target atom s to marked.
//ATOMS
GenMolMaps.Getltem(MapCount).GetTargetAtoms().SetAll 
Marked(true);
GenMolMaps.Getltem(MapCount).GetTargetAtoms().SetAll 
Highlighted(true);
For each bond in the molecule, check to se e  if it is marked, if so  it is removed.
for(int j = 1  ; j<=
GenChangeMol.GetBonds() .GetCount(); j ++)
{
if(GenChangeMol.GetBonds().Getltem(j).GetMarked())
{GenChangeMol.RemoveBond(j);}
}
For each atom in the molecule, check to see  if it is marked, if so, and if the 
symbol of this atom is “H”, then the atom is removed.
for(j = 1  ; j<=
GenChangeMol.GetAtoms() .GetCount(); j ++)
{
if(GenChangeMol.GetAtoms().Getltem(j).GetMarked())
{
if(GenChangeMol.GetAtoms().Getltem(j).GetSymbol() ==
"H")
{GenChangeMol.RemoveAtom(j);}
} }
214
Chapter 6: Software
For each every atom in the molecule, check to see  whether it is marked, if so 
and the symbol is "C", then the additional fragment is attached to that atom.
for( j = 1  ; j<= GenChangeMol.GetAtoms().GetCount0 ; j++)
{
if(GenChangeMol.GetAtoms().Getltem(j).GetMarked()
{if(GenChangeMol.GetAtoms().Getltem(j).GetSymbol()
!= "H")
{
GenChangeMol.Join( GenAddition_Frag, 
GenChangeMol.GetAtoms().Getltem(j),
GenAddition_Frag.GetAtoms().Getltem(1), 1);//single
GenChangeMol.SproutHydrogens(GenChangeMol.GetAtoms()
.Getltem(j));
} } } } }
The next process involves the aromatic hydroxylation reactions. All reactions 
which are aromatic hydroxylation reactions (again recognised by fragment 
strings) are allowed to access  the loop. A Boolean for saturated atom s is 
created and se t to “True”. This is followed by a count, for each  of the marked 
atom s in the molecule (if that atom is NOT “H” and if that atom does NOT 
have four bonds attached, assuming it is now an unsaturated carbon atom) to 
se t the Boolean for saturated to “False”.
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if((FragmentStr == "Aromatic")||
(FragmentStr == "Epox"))
{
bool bSaturated = true;
for(int t = 1; t<=
GenMolMaps.Getltem(MapCount).GetTargetAtoms().GetCount(); 
t++)
{
if(GenMolMaps.Getltem(MapCount).GetTargetAtoms().Get 
Item(t).GetSymbol() !="H")
{
if(GenMolMaps.Getltem(MapCount).GetTargetAtoms().Get 
Item(t).GetBonds().GetCount() != 4)
{bSaturated = false;}
}}
If the Boolean for a saturated carbon is “False”, then the following code is 
processed, the hydroxylation proceeds by setting all the target bonds and 
atom s to marked a s  before:
if (bSaturated== false)
{
int atoms =
GenChangeMol.GetAtoms().GetCount();
//BONDS
GenMolMaps.Getltem(MapCount).GetTargetBonds().SetAll 
Marked(true);
GenMolMaps.Getltem(MapCount).GetTargetBonds().SetAll 
Highlighted(true);
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//ATOMS
GenMolMaps.Getltem(MapCount).GetTargetAtoms().SetAll 
Marked(true);
GenMolMaps.Getltem(MapCount).GetTargetAtoms().SetAll 
Highlighted(true);
For each bond in the molecule, check to see  whether it is marked, if so the 
atom s associated to that bond are identified. If an atom is “H”, then the 
opposite atom for that bond is the site atom carbon and therefore the correct 
bond to remove.
for(int j = 1  ; j<=
GenChangeMol.GetBonds() .GetCount(); j ++)
{
if(GenChangeMol.GetBonds().Getltem(j).GetMarked())
{for(int s = 1 ; s<=
GenChangeMol.GetBonds().Getltem(j).GetAtoms().GetCount();
S + + )
{
if(GenChangeMol.GetBonds().Getltem(j).GetAtoms().Get 
Item(s).GetSymbol() == "H")
{GenSiteAtom =
GenChangeMol.GetBonds().Getltem(j).GetOppositeAtom(GenCha 
ngeMol.GetBonds().Getltem(j).GetAtoms().Getltem(s)); 
GenChangeMol.RemoveBond(j);
} } } }
For each atom in the molecule, check to se e  if it is marked, if so, if the symbol 
of that atom is “H”, it is removed.
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for(j = 1 ; j<=
GenChangeMol.GetAtoms().GetCount(); j ++)
{if(GenChangeMol.GetAtoms().Getltem(j).GetMarked())
{
if(GenChangeMol.GetAtoms().Getltem(j).GetSymbol() ==
"H")
{GenChangeMol.RemoveAtom(j);}
} }
For each atom in the molecule, check to see  if it is marked, if so it is the 
remaining site atom. On to that remaining site atom, the additional fragm ent is 
attached.
for( j = 1 ; j<=
GenChangeMol.GetAtoms().GetCount(); j ++)
{
if(GenChangeMol.GetAtoms().Getltem(j).GetMarked())
{if(GenChangeMol.GetAtoms().Getltem(j) ==
GenSiteAtom)
{GenChangeMol.Join(GenAddition_Frag,
GenChangeMol.GetAtoms().Getltem(j),
GenAddition_Frag.GetAtoms().Getltem(1), 1);//single
GenChangeMol.SproutHydrogens(GenChangeMol.GetAtoms()
.Getltem(j));
} } } } }
The current structure is then preserved through the function R eta inS truc tu re .
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RetainStructure(GenChangeMol, MapCount);
}//end of function
RetainStructure takes the changed molecule object and the current mapping 
count "mapcount".
void CGenerate::RetainStructure(CMolecule &GenChangeMol, 
int GGenMapCount)
{
int atoms = GenChangeMol.GetAtoms().GetCount(); 
CString TempStruct;
TempStruct = GenChangeMol.GetStructureString(1); 
ResultStructureStrArray[GenMapCount] = TempStruct;
//8 refers to type..see chemlQ help
}
A temporary string is created to store the structure in string form. This string is 
then put into the created array under the index of “MapCount”.
OnPrev is a  function of CMarpDIg used to cycle through the result structures. 
On clicking the “Previous” button calls OnPrev. If the current map count is 
greater than 1, minus 1 off the map count it calls Generation.LoadPrevious.
void CMARPDlg::OnPrev()
{
if(CurrentMapcount >= 1 )
{CurrentMapcount— ;
Generation.LoadPrevious(CurrentMapcount)
RefreshAll();
} }
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Generation.LoadPrevious belongs to the class CGenerate.
void CGenerate::LoadPrevious(int &MapCount)
{
CString TempStruct =
ResultStructureStrArray[MapCount];
GenChangeMol.SetStructureString(TempStruct);
}
According to the “mapcount”, a  structure string is retrieved from the array and 
the molecule object “GenchangeM ol” is loaded from that string.
7) Additional Functions
The checking of Lipinski’s  rule of five is situated in the class Cldentify, a t the 
end of the functions LocateGroup and LocateGroup_perMapping, called 
by:
//checking Lipinski Rule of 5..
bool Rule_of_Five = CheckLipinskiRuleOf5 (Mol);
Which implements the function CheckLipinskiRuleOfFive.
bool Cldentify::CheckLipinskiRuleOf5 (CMolecule &Mol)
{
bool bRuleOfSLipinskiApply = false;
bool bLessThan5H_Donors = false;
bool bWeightLessThanSOO = false;
bool bLessThanlOH_Acceptors = false;
bool bCLogP_Under5 = false;
int HAcceptors, HDonors, CLogP, Weight;
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Several Booleans and integers are created to aid the following:
HAcceptors = Mol.GetHydrogenBondAcceptorCount();
HDonors = Mol.GetHydrogenBondDonorCount();
Weight = Mol.GetMass();
CLogP = 666;
The count of each property is then applied to the rules accordingly: fewer than 
10 hydrogen acceptors, fewer than 5 hydrogen donors, LogP value of less 
than 5 and relative molecular m ass of under 500 g per mol.
bLessThanlOH_Acceptors = 
CheckLipinskilOH_Acceptors(Mol, bLessThanlOH_Acceptors);
bLessThan5H_Donors =
CheckLipinski5H_Donors(Mol, bLessThan5H_Donors);
bCLogP_Under5 = CheckLipinskiCLogP(Mol,
bCLogP_Under5);
bWeightLessThanSOO = CheckLipinskiWeight(Mol,
bWeightLessThan500) ;
If all of the Booleans are true, then the returned value for Lipinski’s  rule is 
true.
if( bLessThanlOH Acceptors —  true & &
bLessThanSH Donors == true & &
bWeightLessThanSOO == true)
{bRuleOfSLipinskiApply = true;}
}
return bRuleOfSLipinskiApply;
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6.3.3 MARP: U ser guide and  o u tp u t files - FMA
The initial incarnation of MARP was FMA, functional (group) molecular 
analysis. FMA w as used for the initial processing of all the structures for the 
template results by processing large am ounts of drugs from the library via 
hard-coded paths for the user to be able to view each result case  individually. 
FMA is still available and can be used as  the following:
• The user can start the process by entering a fragment by selecting 
one from the “drop down” box. Then entering a file path and drug 
name. To use the default library, just entering a known drug nam e 
from that library will suffice since a default path is hard-coded.
Enter fragment a s Text - 
e  g 0  ethyl a s  OC2H5
C hoose fragment from 
drop box (use up and 
down arrow keys as 
box is not there)
0C 2H 5
OK
Cancel
Enter Path (without File Name) e  g C;\fm a\ don't 
forget DOUBLE backslash. Type in Mol name 
EXACTLY as in filename, but no " mol".
Pathj
Site Atom: jo Name
for all but ch o o se  frag
all frags for all
Find Fragment
Figure 6.5 Initial GUI format for FMA (predecessor of MARP)
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• The user may then either:
o click the far bottom right button “Find Fragment” to find the 
tem plate instances for that one fragment for that one drug; 
o click on the “for all but choose frag”, which p rocesses all the 
drugs hard-coded in the library but for that one fragment; 
o click on the “All frags for all” which processes every drug in 
the library for every fragment listed in the drop-down 
selection.
The results are then saved at the specific location: “C:\DISTANCE_OUTPUT” 
under the correct output file nam e e.g.: 
“OutSiteNonC_caffeine_1_N_DeMethylation.txt”
6.3.4 MARP: U ser gu ide and  o u tp u t files - FMA
The current version of MARP can be used accordingly:
• The user can start the process by entering a  fragment by selecting 
one from the “drop down” box. Then entering a  file path and drug 
name. To use the default library, just entering a  known drug nam e 
from that library will suffice since a  default path is hard-coded.
•  The user must then click the “Load and G enerate” to create the 
generation instance and calculate mappings etc.
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2^2 MARP
| n CH3
2: Enter File Location Directory., double back  
slashs!
3: Enter Filename ONLY, no “.mol
meiq
Load and G enerate
H H H
1 ; Chose fragment from com bo box
Previous Next
N Déméthylation T rue - Check CAD I STAN CE 
for I  em plate results!
xj
H H
resulting
frament looking for
H
replacem ent - m ake 
invisible later
OK
Figure 6.5 Current GUI format for MARP
• The user may then cycle through any possible results using the 
“Previous” and “Next” buttons and view the results of template 
theory in the edit box below. If the template was successful then the 
box will read:
“(current reaction) True- Check C:\DISTANCE_OUTPUT for results”
The results are then saved at the specific location: “C:\DISTANCE_OUTPUT” 
under the correct output file name e.g.: 
“OutSiteNonC_caffeine_1_N_DeMethylation.txt”
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An example output file:
NewFile Total Atoms = 24
MolSiteAtom = 1
H Acceptors = 6,
H Donors = 0,
Weight = 194,
CLogP == Not Calculated Yet
Atoml= N2 Atom2 = N1 Distance = 2.625189
Atoml= 013 Atcm2 = N1 Distance = 2.355302
Atoml= 014 Atcm2 = N1 Distance = 2.357891
6.3.5 MARP Class Tree
Generation
CDialog C Identity C Distance
CGenerate
CMARPQg
The classes have been expanded to show functions and variables belonging 
to that class. They are listed in the order:
CMARPDIg,
CGenerate,
Cldentify,
CDistance.
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CMARPDIg:
B CMARPDIg
1  0  CMARPDIg(CV/nd "pParent = NULL]
i 9 ^  D oD ataE xchange(C D ataE xchange *pDX)
i %  LoadO
i $ 0  OnChangeEditlQ
j 9 ^  OnChangeEdit2()
1 9 ^  OnChangeEdit3[]
1 9 0  OnGenerateO
1 9 ^  OnlnitOialogO
i 9 0  OnNexlO
i 9 0  OnPainlQ
j 9 0  OnPrevO
1 9 0  OnQueryDraglconO
1 9 0  RefreshAIIO
I CurrenlMapcount
1 9(^ Generation
1 9<^ ID C ase
  ^  m_Chemdisp1
  m_Chemdisp2
  m_Chemdisp3
  m_Chemdisp4
  ^  m_FileName
 ^  m_FilePath
1 9 f^  m _hlcon
  m_SearchFragment
  m_T emplate_output
1 9 ^  myFilePath
 ^ 9f^ TolalM apcounl
226
Chapter 6: Software
CGenerate:
B  -®lS CGenerate
  0  Assign_SiteAtom(CAtom ÈtSiteAtom)
  ^  Assign_Structures(CMolecule îtÜriginalMol, CMolecule ÈcChangeMol, CMolecule ^Fragment, CMolecuIe &Addition_Frag, CString îcFilePath)
  0  CGenerateO
  0  "CGenerateO
  0  Find_Addition_Bit{CString îtStrFragment)
  0  GenerateStructure(intî(Mapcount, CString ÈcFragmentStr)
  0  G etG enAddition_FragO
  0  GetGenChangeMolO
  0  GetGenFragmentO
  0  GetGenMapCountO
  0  GetGenOriginalMolQ
  0  G etR eactionN ame_FromFragS tr(CS tring &FragS tr)
  0  LoadPrevious(int &MapCount)
  0  R eset_G eneratej nstanceQ
  0  ResetChangeMol(CS tring &ChangeM olS tructureS tring)
  0  ResetChangeMol_Path(CS tring &FilePath)
  0  RetainStructure(CMo)ecule &GenChangeMol, ini &GenMapCoiint)
  0  SetGenAddition_Frag(CMoIecuIe &Addition_Frag)
  0  SetGenChangeMol(CMolecule îcChangeMoI]
  0  SetGenFragnnent(CMolecule &Fragment)
0  S etG enFragmentS tr(CS tring &FragmentS tr)
  0  SetGenMapCount(intîcMapCount)
  S etG enMolFilePath(CS tring ïcFilePath)
  0  SetGenOriginalMol(CMolecule &OriginalMol)
  ^  TemplateTheory(CMolecuIe 8cGenOriginaIMol, CString îcGenFragmentStr, int &CurrentMapCount, CString ScMoleculeName)
i 9 ^  ChangeMolS tructureS tring
1 9 ^  GenAddition_Frag
j 9 ^  GenChangeMoI
i ^0 GenFragment
i 9 ^  G enFragmentS tr
i 9 ^  G enl nstantS iteAtom
j 9 ^  GenMapCount
i 9 ^  GenMolFilePath
! 9:^ GenMolMaps
1 9 ^  GenOriginalMol
i 9 ^  GenSiteAtom
■ 9s^ Results tructureS trArray
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Cldentify:
là - ‘^ TÏi Cldentify
  ^  AssignMolMapsFromGenfCMappings SfMolMaps]
  0  CheckLipinski10H_Acceptors(CMolecule &M0I, bool bLessThan10H_Acceptors)
  ^  CheckLipinski5H_Donors(CMolecule &M0I, bool bLessThan5H_Donors]
  ^  CheckLipinskiCLogP(CMolecule &M0I, bool bCLogP_Under5)
  ^  CheckLipinskiRule0f5(CMolecule&Mol)
  0  CheckLipinskiWeight(CMolecule &M0I, bool bWeightLessThanSOOJ
  0  CldentifyO
 0  ~Cldentify()
  0  GetFragmentSiteAtomO
  ^  GetMoleculef)
 ^  GetMolSiteAtomO
  0  GetSiteFragmentO
  0  I dentifyS iteFragmentAtom[CS tring &SiteFragmentlD)
  0  Load_or_Fire_up_Default_Mol(CString &lnputName, CString &Path, CString ^Fragmentstring]
  0  Loads iteFragment(CS tring ÈcSiteFragmentlD)
  0  LocateGroup(CMolecule &M0I, CString &SiteFragmentlD]
  0  LocateGroup_perMapping(CMolecule &M0I, CString ScFragmentSitelD, int &CurrenMapCount]
  0  SetAllfCMolecule &M0I, CMolecule &SiteFragment]
  0  SetFragmentSiteAtom(CAtomScFragmentSiteAtom]
  0  SetMolecule(CM olecule &M0I)
  0  S etM oleculeN ame(CS tring &M oleculeN ame)
  0  SetMolSiteAtom(CAtom &MolSiteAtorn)
  0  S etS iteFragment(CM olecule &SiteFragment)
  ^  TestForAIIFragments(CM olecule &M0I]
  0  T estHydrophilic(CM olecule &M0I]
i %  m_bH asAromaticH eteroAtom
i %  m_blsAromatic
I %  m_blsHydrophilic
i %  m_CurrentH eteroAtom
i %  m_FilePath
I %  m_FragmentS iteAtom
! %  m_M olecule
I %  m_M oleculeN ame
I %  m_M olM apsjromG en
: %  m_MolS iteAtom
• %  m_SiteFragment
228
Chapter 6: Software
CDistance:
B  CDistance
  0  CalcuiateCentreOfRingO
  0  CDistanceQ
  0  "CDistanceO
  0  D etectFragmentfCS tring m_FragmentS tring)
  0  Distance(CAtom KAtomt CAtom 8Atom2]
  0  FlagTheRightReaction[bool ReactionPossible_1, bool ReactionPossible_2, bool bReactionPossib!e_3, CString m_FragmentString]
  0  G enerateN a m e j  nternalQ
  0  GetDistanceflong Atom !, long Atom2]
  0  GetFileContentO
  0  GetFiieNameO
  0  GetFileStringO
  0  GetlnFilePathO
  0  GetlnFilePathCompare(]
  0  GetMolSiteAtomO
  0  GetSiteAtomO
  0  GetSiteRxnO
  0  MeasureAII(CM olecule &M0I]
  0  MeasureCentreRingToSite(CM olecule &M0I, CAtom &M0IS iteAtom]
  0  MeasureMolSiteToNonCfCM olecule &M0I, CAtom &M0IS iteAtom]
  0  M easureS iteAII(CM olecule &M0I]
  0  ResetFragmentFlagsO
  0  S etFileN ame(std: : string mJnputName]
  0  SetFileStringfCS tring &FileS tring]
  0  SetFragmentMinMaxDistancesO
  0  S etFragmentR angeO fD istances(CS tring m_FragmentS tring]
  0  S etFragmentS tring(CS tring Fragments tring]
  0  SetlnFilePath(std:: string mJnputPath]
  0  S etM oleculeN ame(CS tring &M oleculeN ame]
  0  SetMolSiteAtomfCAtom &M0IS iteAtom]
  0  SetReactionFlagsO
  0  SetSiteAtomfCAtom &S iteAtom]
  0  SetSiteRxnfstd:: string strReactionJype]
  0  TestAromaticRingfCMolecule &M0I]
  0  T estCurrentB ondE pox(CM olecule &M0I, int i, int j]
  0  VerifyR eaction(CS tring &FragmentS tring]
  0  WriteD istanceFilefstd: : string strOutFileContent]
  0  WriteD istanceLinefCAtom &Atom1, CAtom &Atom2)
  0  WriteLipinskiR uleSLinefCM olecule &M0I, int CLogP]
  0  W riteRingDistanceLinefCAtomSAtomI,double RingDistance]
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0 ^  Arom_Hydroxyl_Distance1_min 
Arom_Hydroxyl_Distance2_max 
Arom_Hydroxyl_Distance2_min 
Arom_Hydroxyl_Distance3_max 
Arom_Hydroxyl_Distance3_min
• hArom_Hydroxylation 
bArom_HydroxyIationPossible
•^ 9 ' bEpoxidationPossible 
bFragmentEpox 
bFragmentMethylHydroxyl 
bFragmentNEthyl 
bFragmentN Hydroxyl 
bFragmentN Methyl 
bFragmentOEthyl 
bFragmentO Methyl 
# 9  bM ethylHydroxylationPossible 
bN_E thylationPossible 
09" bN_HydroxylationPossible 
bN_M ethylationPossible 
bNon_A_HydroxylationPossible 
bO_EthylationPossible 
#9"  bO_M ethylationPossible 
bR eactionPossible_1  
#9^ bR eactionPossib le_2  
bR eactionPossib le_3  
bR eactionPossible_both  
bR ingR eactionPossible  
D istance1_m ax  
Distance1_m in  
-@9' D istance2_m ax  
D istance2_m in  
D istance3_m ax  
D istance3_m in  
EpoxCountI 
EpoxCount2 
EpoxCount3 
# 9 '  Epoxidation_Distance1_m ax  
Epoxidation_Distance1_min  
Epoxidation_Distance2_m ax
• Epoxidation_Distance2_min
■m
 m_;
i.
I...
I..
!..
I.
■ ■ ■ m
-m
■ ■ m
-m
#9
I ê 9  N_Hydroxyl_D istance2_m in
I # 9  N_Hydroxyl_D istance3_m ax
i # 9  N_Hydroxyl_D istance3_m in
i # 9  N_Hydroxyl_R ingD istance_m ax
I # 9  N_Hydroxyl_RingDistance_min
I # 9  N_M ethyl_Distance1_m ax
; (^ 9  N_M ethyl_D ista n ce l _min
Epoxidation_Distance2_min i 0 9  N_M ethyl_Distance2_m ax
Epoxidation_Distance3_m ax | (^9  N lM eth yL D Istan ce£m in
Epoxidation_Distance3_min I...^ 9  N _M ethyLD istance3_m ax
m_FragmentString I...@9 N_M ethyLDistanco3_m in
m_Mol_Site_Atom | (^ 9  N_M ethyLRingDi$tanco_max
rn_ppDistances I ( â 9  N_M olhyl_RingDistanco_min
m_RingCFar j ^ 9  N oi\,A _H ydroxyLD Istancel„m ax
m_RingCNear | ^ 9  N on_A _H ydroxyLD istancel_m in
m_Site_Atom ! ^ 9  N on_A_Hydroxyl_D istance2_m ax
m_strFileS tring |...^ 9  N on_A_Hydroxyl_D istance2_m in
_strlnFilePath |...^ 9  Non_A_H ydroxyl_Distance3_m ax
m_strl nFilePathCompare j...^ 9  Non_A_Hydroxyl_Distance3_m in
m _strM oleculeNam e |...^ 9  0_E thyl_D istance1_m ax
m_strOutFileAII i ^ 9  0_Ethyl_D ista n ce l _min
m_strOutFileCN |...0 9  0_E thyl_D istance2_m ax
m_strOutFileCG i...^ 9  0_E thyl_D istance2_m in
m_strOutFileContent |...^^9  0_E thyl_D istance3_m ax
m_strOutFileName |...^ 9  0_Ethyl_D istance3_m in
m_strOutFilePath |...^ 9  0_Ethyl_R ingD istance_m ax
m_strOutFileSiteAII......................................|...^ 9  0 _ E  thyl_R ingD istance_m in
m_strO utFileS iteN onC |...^ 9  0_M  ethyl_D ista n ce l _m ax
m_strOutTypeText | 0 9  0_M ethyl_D ista n ce l _min
m_strReactionTestingFor | ^ 9  0_M ethyL D istance2_m ax
m_strRxn_Type | ^ 9  0_M ethyFD istance2_m in
m_strSiteNum I...^ 9  0_M ethyL D istance3_m ax
M ethyLHydroxl_Distance1_max }....^ 9  0_M ethyL D istance3_m in
M ethyLHydroxl_Distance1_min 0_M ethyl_R ingD istance_m ax
M ethyl_Hydroxl_Distance2_max ^ 9  0_Motl%'l_RingDistancG_min
M ethyl_Hydroxl_Distance2_min R ingC cnlro_D istancel_m ax
M ethyl_HydroxLDistance3_m ax ^ 9  R in gC en tre lo ista n ce lIm in
MethyLHydroxl_Distance3_min R ingC entre_D istance2_m ax
N_E thyl_D ista n ce l _m ax ; (^ 9  R ingCentre_D istance2_rnax
N_EthyI_D ista n ce l _min | ^ 9  R ingCentre_D istance2_m in
N_Ethyl_Distance2_m ax | ^ 9  R jngC entre_D istance3_m ax
N_Ethyl_Distance2_m in i ^ 9  R ingCentre_Distance3_m in
N_Ethyl_Distance3_m ax • ^ 9  R IngD ista n ce l _m ax
N_Ethyl_Distance3_m in...........................;...^ 9  R ingD istancel_m in
N_Ethyl_RingDistance_m ax.................. |...# 9  R ingD istance2_m ax
N_Ethyl_RingDistance_min....................i...^ 9  R ingD istance2_m in
N_Hydroxyl_Distance1_m ax
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6.4 Software Conclusion
On considering the results in this chapter, the software appears to work well 
alongside ChemlQ2. By utilizing existing functions and creating new specific 
functions for the template use, the recycling of original code and the evolved 
symbiotic software relationship produced a reasonable platform for the 
template theory to be hosted and eventually expanded.
The creation of many small “helper” applications was inevitable for the 
development of MARP. The main minor application being the Visual Basic 
“Helpful App” which noted the number of expected reactions according to 
fragment searches. Visual Basic was an obvious choice for this application as 
it could provide an instant GUI to host ChemIQ2 and then to insert relatively 
simple code to enhance the speed and quality of the results for the number of 
possible reactions. By creating this application, the chance of human error 
influencing the examination of each individual drug molecule for reactions was 
greatly reduced.
The creation of MARP in C++ allowed for a better understanding of the logic 
behind the functions of ChemlQ2 which, in turn, allowed for a better program 
to host the template theory. With a view to expanding MARP in the future, the 
template distances are hard-coded in only one file (ODistance.cpp function 
“SetFragmentMinMaxDistances”) which can allow for easy adjustment in the 
future. Also many fragments were also hard-coded into the program, not just 
those currently being searched for. The entire list of these can be found in the 
FragmentLibrary.cpp.
The structure of MARP was rearranged in order to simplify the process during 
structure cycling so that complicated access to classes and variable passing 
is as minimal as possible.
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Certain functions are kept to certain classes for logical reasons and for ease 
of programming. For example the distances are hard coded in the distance 
class, which is also the only class which calculates the distance between two 
atoms or between the site atom and the centre of a ring. Along the same 
theme, the Identify class is the only class which can identify a fragment from a 
string, the site atom and then the mapping of that site atom to the query 
molecule. All this is done for the ease of future work and the expansion of the 
template theory and the predictive software.
The task set by at the introduction of the project was to create a piece of 
software which is able to predict the most likely pathway for the metabolism of 
drugs. This software was to be based mainly on structure and then supported 
by the confirmation of guidance from other chemical properties such as LogP.
This majority of this task was achieved as the prediction of the first step of 
metabolism structures were created by solely using physical chemical 
structure. Also the most improbable reactions for first step metabolism were 
discarded and their resulting structures and pathways acknowledged but 
removed. The information for the predictions using chemical based knowledge 
and properties such as LogP and pKa were not yet created as not immediate 
trends were apparent enough to be applied to the software. However, the 
software was generated in such a way that it may expand into the area later 
on. The software can be recycled to predict subsequent steps until structure 
appears ready to be excreted, the initial steps of which are implemented in the 
section of the code cycles structures.
This program has the ability to generate every structure that could possibly be 
made, but uses the initiative of template theory to selectively remove those 
structures which are unlikely to be generated. The final program idea for 
predictive metabolism relies upon initial observation of drug metabolism in 
known structures and the observed distances from the estimated site of 
reaction to non-carbon or hydrogen atoms in the molecule. By creating the 
software in such a way, there was not be a need for continual reliance upon a 
large database of drug structures as the template distances give an estimated
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range according to the structure/reaction. Additional information could be 
easily added to the software to improve future metabolism predictions, as the 
intent was to eventually incorporate all chemical properties with structural 
features.
The future of MARP could expand in many possible directions. The obvious 
first choice would be the incorporation of a Log P calculator (or automated 
access to the Daylight ClogP calculator) to fulfil the Lipinski’s Rule portion of 
the code. Secondly, the observation and prediction of pKa and other chemical 
properties could be added in as well. The constant accumulation of data and 
awareness of the molecules chemical properties and structure will eventually 
yield better predictions and software. Once the reactions can be verified and 
adhere to all the guidelines of the “templates” then the next step of the 
reaction could be considered: perhaps a cycling of the existing software on 
the new result structure or even the application of phase 2 reactions with the 
conjugation of larger molecules. Eventually, the theoretical metabolic path 
from administration to excretion could be predicted, and from there, each 
structure in each step analysed for possible toxicity.
Once again, the future work would be heavily entwined with current drug 
development and existing drug research as more information on cytochrome 
P450 itself and the metabolism of drugs becomes available.
6.5 Programmes Used
• The internet for research
•  Arguslab" for 3D modelling
• Viewerpro'" for 3D modelling
• Chemsketch'^ for 2D modelling
• IDBS ChemlQ'' for 3D modelling, file conversion and programming 
basis
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‘ http://www.daylight.com/ Accessed Sept. 2006
“http://www.planaria-soflware.com/ Accessed Sept. 2006
Ayww.accelrys.com/prodncts/dstudio Accessed Sept. 2006
"'http://www.acdlabs.com/products/chem_dsn_lab/chemsketch/ Accessed Sept. 2006
 ^http://www.idbs.com/activitybase/chemistry/ Accessed Sept. 2006
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CHAPTER 7 Conclusion and Further work
7.1 Conclusion Summary
The approach taken in this thesis to the problem of drug metabolism has been 
to initiate an investigation of known drugs and their metabolism along with 
their chemical and structural properties and then to apply that knowledge as a 
guide to software for metabolism prediction. The aim of this work was to 
create a piece of software which was able to predict the most likely pathway 
for the metabolism of drugs, mainly based on structure and supported by 
guidance from other chemical properties such as LogP. The final idea for this 
line of software was to be able to apply known toxicological results or 
fragments to see whether at any of the metabolic stages would show if the 
ensuing structure exhibits toxicity.
The entire idea for the attempt at predictive metabolism relied upon the 
identification of possible trends according to the reactions and the physical 
structure in question. The structural predictions were to be then followed by 
the comparison of known LogP and pKa values.
The majority of this task was achieved as the predictions of the first step of 
possible metabolic structures were created solely by using the three 
dimensional chemical structure. Also the most improbable reactions for first 
step metabolism were discarded and their resulting structures and pathways 
acknowledged but removed. The information for the predictions using 
chemical based knowledge and properties such as LogP and pKa were not yet 
created, as no obvious trends were clear enough to be applied to the software 
produced. However, the software was generated in such a way that it may 
expand into this area later on. The remainder of this chapter is sectioned into 
summaries with respect to the individual chapters throughout the thesis.
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7.2 Conclusion with Reference to Common Trends
The most common reaction for substrates involving cytochrome P450 is 
hydroxylation. This is because hydroxylation is the easiest structural change 
as very little or nothing needs to be cleaved from the structure. The reasons 
for certain selectivities for each reaction are still elusive which indicates that 
there is more scope for continued research. Subsequent trends for the 
selectivity of particular sites for hydroxylation will hopefully emerge through 
research and further examination of individual and multiple sets of 
information.
Examination of the data for reactions linked to molecular mass and identified 
cytochrome yields no obvious immediate trend. By mass alone the reaction 
selection appears to be random, this is not entirely unexpected given the 
diversity of drug structures. On closer examination of the identified 
cytochrome of a reaction, it was noted that:
•  both of the methyl hydroxylation reactions are catalysed by cyp2c9;
• both of the noted epoxidation reactions are catalysed by cyp1 b1 ;
•  two of the nitrogen-based déméthylation reactions and one of the 
oxygen-based déméthylation reactions are catalysed by c28;
•  the remaining oxygen déméthylation is catalysed by 2c9.
Given that these are only a few examples per reaction, and the fact that the 
cytochromes are well known for their ability to exhibit polymorphism, 
assigning reactions according to cytochrome alone is unwise, but this 
information may be used to reinforce another trend in future studies. When 
comparing the mass of the drug in question with cytochrome identification no 
definite trend was apparent. The results for reactions linked to HOMO/LUMO  
and possible site of reaction identification due to specific atomic charge 
showed that the atomic partial charges on the identified carbon atoms for 
oxidation in Ibuprofen do stand apart from the rest of the other potential
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reaction sites; the partial charge value appears to be approximately -0 .40  
electrons (e).
On considering the atomic partial charges on the selected nitrogen atom for 
nitrogen déméthylation in caffeine the exact value of the charge does not 
distinguish itself from the atomic partial charges of the rest of the other 
potential reaction sites. The atomic partial charge value appears to be 
approximately -0 .40e, similar to the other methyl bearing nitrogen atoms 
which each have a partial charge of -0.39e.
The charges on the carbons associated with aromatic hydroxylation of aspirin 
do clearly delineate themselves from the charges of the rest of the other 
potential reaction sites. Their charge value appears to be ca. -0 .0 1 8e. The 
charges on the identified carbons for aromatic hydroxylation of Diclofenac 
also appear somewhat differentiated from the rest of the other immediate 
surrounding potential reaction sites, but when applied to the entire molecule, 
three other potential sites are identified, with carbons of the same type (e.g. 
aromatic) and in similar surroundings. Their charge value appears to be 
approximately -O .l le .  The charges on the identified carbons for aromatic 
hydroxylation of Warfarin do not stand out at all from the rest of the potential 
reaction sites. When the specific charge theory is applied to the entire 
molecule, at least five other potential sites are identified, with the carbons of 
the same type (e.g. aromatic) and in similar surroundings. Their charge value 
appears to be approximately -0.13e. On comparison of the three aromatic 
hydroxylation substrates, none of the identified charges can be used on 
another molecule. The site charges are obviously specific to drug structure, 
and not specific to reaction type. These points of charge in a molecule do not 
aid in the prediction of metabolism in this instance.
The results for reactions linked to Log P, ClogP and identified cytochrome 
yields no obvious immediate trend. By Log P alone, there is no evidence of 
any trend; nor when examining the ClogP results. However, it is believed 
given the influence of Log P in the rule of five, that the values of Log P could
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be used to reinforce an existing prediction method like the template method 
used in this thesis.
On closer inspection of the change in ClogP values of structures both before 
and after reaction it was noted that the change in ClogP values have kept to 
fairly similar values for each reaction. Epoxidation reactions show that a drop 
in ClogP of approximately 1.3 -  2.5 is expected. Furthermore O de-ethylation 
reactions might be expected to show a drop of approximately 1.1 -  1.65 in 
ClogP. Although these show slight trends, it must be noticed that this pattern 
does not apply to N-hydroxylation or N- Déméthylation reactions as the range 
in ClogP differences are just too great.
Examining the results for reactions linked to pKg yields no obvious immediate 
trend. By pKg alone the reaction selection appears to be random, though this 
is not entirely unexpected given the diversity of drug structures.
The cross-referencing of data of reaction type, ClogP, pKg and molecular 
weight still shows no obvious or immediate trend as well as examination of the 
results for reactions linked to the quantities of hydrogen bond acceptors, 
hydrogen bond donors and basic nitrogen atoms in the structure. This leaves 
open a possibility for future studies into the area and suggested courses of 
action could be primarily to incorporate more information into the database as 
bigger populations could show previously hidden trends.
Although all these individual trend attempts appear to be resulting in null 
results, they all form the components of Lipinski’s rule of five which proves 
that united, all these individual components may indicate the properties 
required for a structure to become a successful drug or to avoid poor 
absorption or delay excretion. Bearing this conclusion in mind, it is not 
unreasonable to expect the data from physical and chemical changes in a 
structure to indicate further the reason as to why that specific reaction 
occurred.
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In summary, the most common reactions for inhibitors involving cytochrome 
P450 are again hydroxylation of a methyl group or benzene ring and also 
déméthylation. Once again, the reasons for this selectivity are still being 
investigated and hopefully an emerging trend will occur through studying more 
example structures. Factors that may affect the preference for the site of 
attack may include the nucleophilicity of the site, potential charge, the partial 
charge of potential sites of attack and steric factors. Also the increasing 
importance of Log P and pKg of these molecules with respect to reaction and 
solubility are to be noted as important contributors in the prediction of first 
step metabolism.
7.3 Conclusion with Reference to QSAR
Expressions generated from IDBS software have been compared with those 
expressions created by Lewis from his publications'.
Thus, the prediction of binding affinities is based on the following main 
contributors: number of hydrogen bonds, number of tt - t t  stacking interactions 
and relative molecular mass. Similarly, the resulting expression for AGbind 
using the LSF(Least Square Fit Method) from KBase" is based on fragments 
(i.e. pyridyl, carbonyl, phenyl and aryl nitrogen) rather than alternative 
properties.
Of these fragments, the presence of a pyridine ring has the highest influence 
on the expression, followed by an sp  ^hybridised oxygen and then a benzene 
ring. The aryl nitrogen moiety is also of importance as the pyridyl fragment 
does not cover five membered aromatic rings. Similar result is found for Km 
LSF(Least Square Fit Method) from KBase, although the fragments in 
question are different, and the magnitude of their contribution). In this case 
the phenyl ether. Figure 7.1, is particularly important.
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Figure 7.1 The Custom fragment created for QSAR
Although the r value for the LSF AGbind model was lower than hoped, this was 
compensated by the good stability of the model due to thorough validation 
using: LOO validation, LMO validation and Y-randomization
In conclusion, QSAR can provide guidance for drug discovery and potential 
metabolisms, but the expressions must be finely tuned according to the test 
set from which they were developed. This is adequate for individual cases, but 
not particularly useful for chemists hoping to generate a general “rule” for the 
reasoning behind metabolism.
7.4 Conclusion with Reference to Template Theory
The generation of structural templates involved the measurement of the 
atomic distances from the site of the reaction to other atoms in the molecule 
enabling molecular structure to be related to specific reaction type(s). 
However, because the distances for aromatic and non-aromatic hydroxylation 
were so varied, no template could be drawn up. The non-aromatic 
hydroxylation reactions were tested for, by searching the structure for 
saturated carbon atoms with an attached hydrogen atom. These raw 
templates allow the following general predictions to be made:
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Reaction Type Required
fragment
Dist. 1
(A)
Dist. 2
(A)
Dist. 3
(A)
Dist. to occur in 
structure
0  dééthylation OC2H5 6.5 5.25 1 or more of either 
of the 2 dist.
0  déméthylation OCH3 6.5 5.25 9.0 1 or more of either 
of the 3 dist.
N déméthylation NCHs 2.5 5.?5 1 or more of both 
dist.
N dééthylation NC2H5 3.65 6.25 1 or more of both 
dist.
N hydroxylation NH 2.5 2 or more of the 
marked dist.
Methyl
hydroxylation
CH3 5.0 6.?5 9.0 2 or more of the 3 
dist.
Epoxidation C=C 4.4 3.3 5.25 1 or more of either 
of the 3 dist. and 
occurring twice (for 
the epoxidation site 
could be either 
carbon)
Thus, by calculating both the number of total possible reactions available to a 
molecule, and then the number of reactions which would occur according to 
the template theory, it can be seen how the template program can reduce the 
number of possible reaction candidates.
Overall, by applying this approach the average reduction in reaction outcome 
is 36.10%; with structures expecting to have 15 or more reactions having a 
reaction reduction of 40.93%. These positive reductions indicate that physical 
structure is highly important in metabolism prediction. From these results, it 
has been shown that the template theory has a positive effect on removing
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unlikely reactions from the possible outcomes of a structure's initial metabolic 
pathway.
7.5 Conclusion with Reference to the Generated Software
The software appears to work well alongside ChemlQ2"‘. By utilizing existing 
functions and creating new specific functions for the template use, the 
recycling of original code and the evolved symbiotic software relationship 
produced a reasonable platform for the template theory to be hosted and 
eventually expanded.
The creation of many small “helper” applications was inevitable for the 
development of MARP. The main minor application being the visual basic 
“Helpful App” which noted the number of expected reactions according to 
fragment searches. The creation of this application greatly reduced the 
chances of human error on examining each individual drug molecule for 
reactions.
The creation of MARP in C++ allowed for a better understanding of the logic 
behind the functions of ChemlQ2 which, in turn, allowed for a better program 
to host the template theory. With a view for the expansion of MARP in the 
future, the template distances are hard-coded in only one file (ODistance.cpp 
function “SetFragmentMinMaxDistances”) which can allow for easy 
adjustment.
The task set at the introduction of the project was to create a piece of 
software which is able to predict the most likely pathway for the metabolism of 
drugs. This software was to be mainly based on structure and then supported 
with guidance from other chemical properties such as LogP.
This majority of this task was achieved as the prediction of the first step of 
metabolism structures were created solely by using physico-chemical
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structure. Also the most improbable reactions for first step metabolism were 
discarded and their resulting structures and pathways acknowledged but 
removed. The information for the predictions using chemical based knowledge 
and properties such as LogP and pKa were not yet created as no obvious 
trends were apparent enough to be applied to the software. However, the 
software was generated in such a way that it may expand into this area later 
on. The software can be recycled to predict subsequent steps until the 
structure appears ready to be excreted, the initial steps of which are 
implemented in the section of the code which cycles structures.
This program has the ability to generate every structure that could possibly be 
made, but uses the initiative of template theory to selectively remove those 
structures which are unlikely to be generated. The final idea for the program 
for predictive metabolism relies upon initial observation of drug metabolism in 
known structures and the observed distances from the estimated site of 
reaction to non-carbon or hydrogen atoms in the molecule. By creating the 
software in this way, there was no need for continual reliance upon a large 
database of drug structures as the template distances give an estimated 
range according to the structure/reaction. Additional information could be 
easily added into the software to improve future metabolism predictions, as 
the intent was to eventually incorporate all chemical properties along with the 
structural features.
The future of MARP could expand in many possible directions. The obvious 
first choice would be the incorporation of a Log P calculator (or automated 
access to the Daylight ClogP calculator) to fulfil the Lipinski’s Rule portion of 
the code. Secondly the observation and prediction of PKa and other chemical 
properties could be added in as well. The constant accumulation of data and 
awareness of the molecule’s chemical properties and structure will eventually 
yield better predictions and software. Once the reactions can be verified and 
adhere to all the guidelines of the “templates” then the next step of the 
reaction could be considered. A cycling of the existing software on the new 
resulting structure or even the application of phase 2 reactions with the 
conjugation of larger molecules could be considered. Eventually, the
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theoretical metabolic path from administration to excretion could be predicted, 
and from there, each structure in each step analysed for possible toxicity.
Figure 1.2 Graphical representation of Cytochrome P450, designed by Dr A. Tanczos 
7.6 Future Work
With respect to each of the different areas encountered during this 
investigation, each of the following are possible studies which could be 
pursued. Initially, the common trends could be further investigated and used 
alongside the calculation of log P (ClogP) for predictive means. Also the 
change in the calculated values of log P for the structures before and after the 
reaction (in this instance, the first step metabolism) has taken place could be 
used to reinforce the predicted reaction from applied template theory. The 
cross referencing of properties such as log P, pKa, mass and the identity of 
specific cytochrome catalyst could also be further exploited.
The obvious evolution of the template theory is the application of the common 
trends found, e.g. the reinforcing of the template with log P values and other 
such chemical properties to aid the progression and the accuracy of the
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predictions of the metabolic structures is fruitful direction to consider. Future 
work in this area would be heavily entwined with current drug development 
and existing drug research as more information on cytochrome P450 itself 
and the metabolism of drugs becomes available.
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Percy
I intend to discover, this very afternoon, the secret of alchemy. 
The hidden art of turning base things into... gold.
Blackadder
I see. And the fact that this secret has eluded the most 
intelligent people since the dawn of time doesn't dampen your 
spirits?
Percy
Oh, no. I like a challenge!
Blackadder II, 1985
246
